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Part 1 
 
Introduction 
9 
Chapter 1 
 
General introduction:  
preterm birth and the lung 
10 
Preterm birth 
Epidemiology 
Preterm birth is a major health issue across the globe. In the Western world preterm birth 
accounts for 5-13% of all live births, with important regional differences 1,2. The current 
rate of preterm live birth in the Netherlands is 7.4%, 1% being born before the 32nd week 
of gestation 3,4. The incidence of preterm birth continues to rise steadily, posing society to 
increasing medical and social expenses 1,2. 
Independent general risk factors for preterm delivery include previous preterm deliv-
ery, multiple gestation, short interval between pregnancies, black race, low socioeconomic 
status, low and high maternal ages, and low pre-pregnancy body mass index (BMI) 1,2. 
Conversely, East Asian and Hispanic ethnicity and high BMI are relatively protective 1. 
Specific risk factors are highly associated with different causes of preterm birth, including 
intrauterine infection / inflammation (IUI), premature preterm rupture of membranes 
(PPROM), and maternal preeclampsia / HELLP syndrome (haemolysis, elevated liver en-
zymes, low platelets). Finally, genetic factors play an important role in susceptibility for 
preterm delivery 1,2. 
Consequences 
Worldwide, preterm birth accounts for more than 25% of neonatal mortality 5. In the 
Netherlands 21% of deaths during the first year of life was attributable to preterm birth in 
2005 6. Of infants delivered between 22 and 32 weeks of gestation, a quarter die during 
pregnancy, 13% during delivery or in the delivery room, and 8% in the neonatal intensive 
care unit (NICU) 7. Obviously, the incidences of both perinatal mortality and short-term 
and long-term morbidity are inversely correlated with gestational age at birth 8. Moreover, 
a low gestational age-dependent birth weight percentile increases the risk of adverse 
outcome. The relatively high rate of perinatal mortality after preterm birth in the Nether-
lands is partly explained by a reluctance towards active management of extremely pre-
term infants born before 25 weeks of gestation 7. 
Over the last decades, important advances have been made in the treatment of pre-
term newborns. These include the introduction of antenatal steroid administration and 
exogenous surfactant treatment, both of which have greatly improved outcome after 
preterm birth 9,10. However, due to the consequent increased survival of more extremely 
preterm infants, the overall mortality and morbidity associated with preterm birth are 
improving only gradually 11.  
The major factor limiting viability in extremely preterm infants, is development of the 
lung and associated maturation of its surfactant system12. Because of these being under-
developed, treatment of acute respiratory problems by mechanical ventilation is often 
unavoidable, although acute lung injury and adverse lung development are recognised and 
feared consequences13. These in turn may lead to chronic lung disease of prematurity 
(bronchopulmonary dysplasia; BPD) in an important subset of preterm infants, with im-
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portant long-term consequences14. A more detailed description of the epidemiology, aeti-
ology, and underlying mechanisms for adverse lung development is given in the section 
‘Preterm birth and the lung’. 
Besides having effects on the lung, preterm birth is associated with increased risk for 
serious infections, circulatory disturbances (hypotension, patent ductus arteriosus), necro-
tising enterocolitis (NEC), retinopathy and adverse neurologic outcome, including intra-
ventricular haemorrhage (IVH), periventricular leucomalacia (PVL), and white matter dam-
age (WMD). It is mainly these neurologic disturbances that affect long-term prognosis as 
they may lead to hearing loss, visual impairment, developmental delay, psychological and 
behavioural problems, and cerebral palsy 8,11.  
Aetiology 
Roughly, causes of preterm birth can be divided into two groups: indicated preterm birth, 
and preterm birth preceded by spontaneous preterm labour or PPROM 1,2,15. The former 
group consists mostly of infants delivered by caesarean section for fetal or maternal indi-
cations. These include severe intrauterine growth retardation (IUGR), and maternal pre-
eclampsia and HELLP syndrome 16. Preterm deliveries in the larger group of spontaneous 
preterm labour and PPROM on the other hand are often associated with IUI 17. IUI is 
clearly associated with preterm birth, and its relative contribution to all preterm births 
increases with decreasing gestational age 17-20.  
In addition, multiple gestation is also associated with increased incidences of both 
spontaneous and indicated preterm delivery 2. Less frequent causes of preterm delivery 
include placental abruption and cervical insufficiency 15,21. Although multiple causal factors 
may be involved, an identifiable cause is absent only in a small minority of cases. Distinc-
tion between various causes of preterm birth is imperative not only from an aetiological 
perspective, but also because important associations have been demonstrated between 
the cause of preterm birth and neonatal outcome 22-24.  
Underlying mechanisms 
The mechanisms underlying preterm birth differ for the diverse causes of preterm birth. 
Obviously, in indicated preterm delivery the direct cause is iatrogenic. A decision for indi-
cated preterm delivery is made upon fetal and/or maternal indications. Common fetal 
indications include IUGR, chronic fetal compromise or acute fetal distress. These condi-
tions often result from placental insufficiency and are associated with fetal hypoxia and 
malnutrition and with adverse metabolic consequences in later life 25.  
Maternal indications for preterm delivery are often associated with preeclampsia or 
HELLP syndrome. Features of preeclampsia include hypertension, proteinuria and multi-
system abnormalities in the mother, while the fetus may suffer from IUGR, reduced amni-
otic fluid and intrauterine hypoxia 26. Preeclampsia is a heterogeneous clinical entity, the 
pathogenesis of which is unknown 26. Both vascular mechanisms and the immune system  
seem to play important roles 26,27. A key concept in preeclampsia is maternal-fetal immune 
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maladaptation, mediated by the presence of paternal antigens 26. A feared complication of 
preeclampsia is the HELLP syndrome, occurring in about 15-20% of cases of severe pre-
eclampsia 23. Microangiopathy, haemolytic anaemia, liver injury, and intravascular platelet 
activation and consumption are key characteristics of HELLP 23. The syndrome is often 
progressive in nature and may lead to serious complications in both mother and fetus. 
Therefore, delivery is frequently indicated irrespective of gestational progression 23. 
The subgroup of preterm births preceded by spontaneous preterm labour and PPROM 
most often are associated with IUI 28. Ascending bacterial invasion of the uterine cavity is 
thought to be the most common route of infection 28. Organisms most frequently associ-
ated with chorioamnionitis are bacteria of mainly low virulence, including Ureaplasma 
spp. and Mycoplasma spp. 28,29. Both the maternal and fetal immune system play an im-
portant role in chorioamnionitis, given the demonstrated associations between polymor-
phisms in immunoregulatory genes and risk of chorioamnionitis and preterm labour 30,31. 
The majority of cases of IUI remain clinically silent. These may be diagnosed by culture or 
proteomic profiling of the amniotic fluid 32,33, by microbial culture or footprinting 34,35, or 
by histological examination of the placenta after birth 29,36. More serious cases of IUI may 
become clinically apparent and cause both general (fever, leukocytosis, raised C-reactive 
protein (CRP)) and local symptoms (uterine tenderness, vaginal discharge) 37. Although a 
combination of these symptoms is often given the syndromic description ‘clinical 
chorioamnionitis’, overlap with the histological diagnosis of chorioamnionitis has been 
shown to be only modest 17. The presence of fetal signs of inflammation, such as funisitis 
or elevated cord blood interleukin-6 (IL-6), in chorioamnionitis are though to reflect the 
more serious side of the continuum of IUI 17,29,36,38. 
Less frequent underlying mechanisms of spontaneous preterm labour and PPROM in-
clude uterine overdistention (due to multiple pregnancy, excessive fetal growth or poly-
hydramnios), placental haemorrhage, and psychological stress. These may cause stimula-
tion of the fetal and maternal hypothalamic pituitary axis, increased production of utero-
tonins (most importantly prostaglandins), myometrial activation and uterine extracellular 
matrix degradation, which in turn may lead to premature uterine contractions, cervical 
changes and PPROM 2. Additional mechanisms involved in preterm birth include hormonal 
influences 39,40 and immune modulation at the fetal-maternal interface 41.  
Lung development 
Development and structure 
Underdevelopment of the lung is the major factor limiting viability in extremely preterm 
infants. Below the threshold of viability as determined by gestational age, the preterm 
lung cannot facilitate proper gas exchange necessary for survival in the extrauterine envi-
ronment. Before birth gas exchange is regulated by the placenta, from where oxygen is 
transported to the fetus through the umbilical cord. Although fetal breathing movements 
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are present from the second trimester onwards, their function is to stimulate lung devel-
opment and they do not affect or regulate gas exchange 42. 
Normal human embryonic and fetal lung development can be divided into various 
stages, primarily based on histological appearance. These are: embryonic stage, pseu-
doglandular stage, canalicular stage, saccular stage, and alveolar stage. A graphic repre-
sentation of these overlapping stages of lung development during gestation is shown in 
figure 1.  
 
 
 
Figure 1. Prenatal lung development.  (source: http://www.embryology.ch/anglais/rrespiratory/phasen07.html) 
 
By embryonic day 26 the lung bud develops from the foregut, which will eventually 
develop into the esophagus. The lung bud branches into five saccules, representing the 
foundations of the five lung lobes: two on the left and three on the right 43. Through suc-
cessive stages of branching, 20 generations of airways are formed during the pseudoglan-
dular phase, the name of which is derived from the glandular appearance of the airways at 
this time 43. Simultaneously, the pulmonary vasculature is formed through progressive 
branching from the pulmonary artery 44. Mesenchyme separates the airways from the 
vasculature and orchestrates proper lung development through close communication with 
these tissues 44. 
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During the canalicular phase, the pulmonary acinus develops, capillaries are formed 
and airway epithelial cells start to differentiate 43,44. Epithelium and interstitial thinning 
gradually increase proximity of the airways to the capillaries, allowing for marginal gas 
exchange capacity at some point between 22 and 26 weeks of gestation 43. At this stage, 
peripheral airways begin to form saccules, marking the saccular stage of lung develop-
ment. These saccules are the primary gas-exchange areas, which subsequently develop 
into alveoli through a process of secondary septation 43,44. Alveolarisation commences 
around the 36th week of gestation, just before the normal time of birth, and continues into 
childhood 43,44. Mature alveoli are characterised by a dense structural organisation and an 
extremely thin blood-air barrier, facilitating highly efficient gas-exchange 44. 
A key point during lung development is the initiation of surfactant synthesis and se-
cretion by alveolar type II (ATII) cells. Surfactant is a mixture of 90% lipids and 10% pro-
teins, which is highly effective in reducing alveolar surface tension. Low surface tension is 
essential to prevent alveolar collapse during expiration and facilitate gas exchange 
throughout the respiratory cycle. Along with the primitive lung architecture, surfactant 
deficiency is a key limiting factor for survival after preterm birth.  
Other cell types besides ATII cells that exhibit critical roles in the newborn lung include 
alveolar type I (ATI) cells, fibroblasts, endothelial cells and alveolar macrophages (AMs). 
ATI cells line the majority of the alveolar surface and facilitate gas exchange through their 
extremely flat ultrastructure. Fibroblasts regulate pulmonary cellular and extracellular 
matrix (ECM) homeostasis by producing growth factors and immunomodulators. Endothe-
lial cells reside in close proximity to ATI cells and regulate gas exchange and chemotaxis of 
immune cells. The alveolar space is further inhabited by AMs, with key roles in host de-
fence and surfactant catabolism. 
Molecular regulators of lung development 
Key molecular regulators of the early stages of lung development include members of the 
fibroblast growth factor (FGF) family, the transforming growth factor-β (TGFβ) super-
family, and Sonic hedgehog (Shh) 44. A well-known clinical result of dysregulation during 
this early phase of lung development is congenital diaphragmatic hernia (CDH), which is 
associated with pulmonary hypoplasia. From the developmental perspective of BPD, the 
later process of alveolarisation is critical. While the regulators of the earlier stages of lung 
development are also important during this phase, additional molecules come into play. 
These include transcription factors, growth factors, and ECM proteins 44. 
A wide range of transcription factors have been implicated in both normal and ab-
normal lung development. Transcription factors control the expression of effector mole-
cules through modulation of DNA transcription. GATA-6 regulates alveolar cell differentia-
tion and proliferation from the surrounding mesenchyme and is an upstream regulator of 
several other transcription factors 43,44. Branching of the lung is under close control by 
thyroid transcription factor-1 (TTF1) 43,44. TTF1 also regulates alveolarisation at a later 
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stage, along with Forkhead box (Fox) and other transcription factors such as hypoxia-
inducible factor (HIF) and the vitamin A metabolite retinoic acid 43-45. 
Increasing evidence supports the critical role of growth factors during lung develop-
ment. The importance of TGFβ1, an ubiquitous regulator of embryonic development, in 
early lung development was mentioned earlier. Along with TGFβ1, other growth factors 
come into play during branching morphogenesis, including platelet-derived growth factors 
(PDGFs), epidermal growth factors (EGFs; including TGFα), Wnt growth factors and vascu-
lar endothelial growth factor (VEGF) 43,44. The latter has been shown to be a key regulator 
of both vascularisation and alveolarisation within the lung 46.  
ECM constituents involved in regulation of alveolarisation include collagens, fi-
bronectin, elastin and matrix metalloproteinases (MMPs) 44. Elastin is expressed through-
out the connective tissue in the lung and proper localisation of elastin deposition is essen-
tial for the process of secondary septation 47. MMPs, formerly known as collagenases, 
regulate connective tissue remodelling necessary for development of the highly efficient 
lung architectural structure 44. 
Lastly, both glucocorticoid and thyroid hormones have an impact on the later stages 
of lung development 44. Thyroid hormones stimulate secondary septation, while glucocor-
ticoids accelerate lung maturation through thinning of the alveolar wall and increased 
surfactant synthesis and secretion 44,48. The fact that the regulatory molecules discussed 
comprise only a fraction of the modulators involved in lung development, underlines the 
complexity of this process and the multitude of pathways susceptible for dysregulation. 
Preterm birth and the lung 
Respiratory distress syndrome 
In uncomplicated pregnancies, the uterus provides the optimal environment for normal 
lung development. When the fetus is delivered preterm, this uterine environment is no 
longer available, challenging the adaptive ability of the developing lung. The immature 
stage the lung is in after preterm delivery predisposes the preterm newborn to both acute 
respiratory  distress and long-term adverse effects on lung development. 
Structural lung immaturity and pulmonary surfactant deficiency are the main causes 
for acute respiratory distress after preterm birth, referred to as (infant) respiratory dis-
tress syndrome (RDS) 12. The tight functional relationship with lung immaturity is illus-
trated by the close inverse correlation between RDS incidence and gestational age at 
birth. Infants with RDS may present with tachypoea, expiratory grunting, chest wall retrac-
tions, cyanosis and a typical ‘ground glass’ appearance on chest radiography 49. The intro-
duction of antenatal steroid administration and exogenous surfactant suppletion has sig-
nificantly contributed to the prevention and treatment of RDS over the last decades and 
this has allowed more immature and preterm infants to survive 10. As a result, RDS has 
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become a disease of more immature infants, while its overall incidence has not changed 
much. 
Besides prevention by antenatal steroids and early treatment by postnatal surfactant 
administration, treatment of RDS is mainly supportive 12. Supplemental oxygen admini-
stration is often necessary to prevent hypoxaemia. Ventilation may be supported by non-
invasive methods such as continuous positive airway pressure (CPAP), nasal intermittent 
mandatory ventilation or air flow administered by nasal cannula. More seriously affected 
infants will have to be intubated and mechanically ventilated for a period of time. The use 
of one or more of these treatments often is unavoidable to prevent morbidity and mortal-
ity after preterm birth. On the other hand it is primarily the application of these treat-
ments during a critical phase of lung development that predisposes preterm infants to the 
development of BPD 50-52. 
Bronchopulmonary dysplasia – Background and definition 
Chronic lung disease of prematurity (bronchopulmonary dysplasia; BPD) is a common and 
serious complication of preterm birth. It was initially described by Northway et al. in a 
small group of ventilated moderately preterm infants with relatively high birth weights 
around 2400 grams 53. With increased use of antenatal steroids, surfactant, and non-
invasive modes of ventilation, allowing for increased survival of moderately preterm in-
fants, BPD has become a disease seen primarily in extremely preterm infants. As a conse-
quence, BPD now affects preterm lungs at an earlier stage of lung development, resulting 
in a different pathological picture. Whereas in the initial reports of BPD the lungs of af-
fected infants displayed widespread fibrosis and emphysaema, the current picture of BPD 
is primarily characterised by an arrest in lung development, resulting in alveolar simplifica-
tion. The two phenotypes have often been referred to as ‘old BPD’ and ‘new BPD’, respec-
tively. The main characteristics of both entities are summarised in table 1.  
 
 
Table 1. Characteristics of ‘old’ and ‘new’ BPD. (adapted from Kramer BW, Lievense S, Been JV, Zimmermann LJ; 
Ned Tijdschr Geneeskd 2010)).  
 
Old BPD 
(Northway et al., 1967) 
New BPD 
(Jobe and Bancalari, 2001) 
Gestational age 32 weeks 24-26 weeks 
Birth weight 2000-3000 g 500-1000 g 
Lung maturity (nearly) mature lungs (extremely) immature lungs 
Aiways highly affected minimally affected 
Fibrosis severe minimal 
Alveoli emphysaema / fibrosis simplification 
Primary aetiology secondary injury developmental arrest 
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A key clinical feature of BPD is prolonged dependency on respiratory support, includ-
ing supplemental oxygen and ventilatory support, either non-invasive or invasive. 
Whereas BPD was initially defined as oxygen requirement at 28 days postnatally, addi-
tional definitions emerged over time. In a consensus meeting of the National Institutes of 
Health of the United States in 2000 the current definition was adopted (Table 2) 54. This 
definition allows for subclassification into ‘mild’, ‘moderate’ and ‘severe’ BPD, depending 
on the intensity of respiratory support. Comparison of outcome data in a large cohort of 
preterm infants subsequently showed significant correlations between BPD severity and 
both pulmonary and neurological outcomes at follow-up, confirming the usefulness and 
predictive value of the new definition 55. 
 
 
Table 2. Current diagnostic criteria for bronchopulmonary dysplasia (BPD). (adapted from Jobe AH and Banca-
lari E, Am J Respir Crit Care Med 2001). PMA = postmenstrual age, PPV = positive pressure ventilation, CPAP = 
continuous positive airway pressure. 
 < 32 weeks gestation ≥ 32 weeks gestation 
Time point of assessment 36 weeks PMA 
or at discharge 
28 to 56 days postnatal age 
or at discharge 
Diagnosis Treatment with  > 21% O2 for ≥ 28 days, plus: 
   Mild BPD Breathing room air at 
36 weeks PMA or discharge 
Breathing room air at 
56 days postnatal age or discharge 
   Moderate BPD Need for < 30% O2 at 
36 weeks PMA or discharge 
Need for < 30% O2 at 
56 days postnatal age or discharge 
   Severe BPD Need for ≥ 30% O2 
and/or PPV or CPAP at 
36 weeks PMA or discharge 
Need for ≥ 30% O2 
and/or PPV or CPAP at 
56 days postnatal age or discharge 
 
Bronchopulmonary dysplasia – Epidemiology 
BPD is the most common cause of chronic lung disease in infants 56. A wide range of inci-
dence data for BPD have been reported, mainly depending on the BPD definition used and 
characteristics of the population from which data were derived. Moreover, important 
differences in BPD incidence have been shown to be present between different NICUs 57,58. 
In a large multicentre cohort the incidence ranged from about 7% in infants with birth 
weights between 1250 and 1500 grams to more than 50% in those between 500 and 750 
grams 55.  
Clinical risk factors for BPD development have been extensively studied and are 
widely accepted. They include prematurity, low birth weight, white race, male sex, RDS, 
oxygen supplementation, mechanical ventilation and infection 50,59. Obviously, the contri-
bution of lung immaturity is reflected in the associations between BPD and prematurity, 
low birth weight, and RDS. How white race and male sex contribute to BPD development 
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is less clear, although male sex is recognised as a general risk factor for adverse outcome 
after preterm birth. Oxygen supplementation, mechanical ventilation and infection all 
exert their effects through causing direct injury to the immature lung and affecting lung 
development. In the absence of effective measures to prevent preterm birth, these repre-
sent the majority of potentially preventable contributors to BPD development. Associa-
tions of BPD with other clinical parameters, such as patency of the ductus arteriosus and 
chorioamnionitis have been reported less consistently 57,59,60. 
Bronchopulmonary dysplasia – Consequences 
BPD is a disease with several long-term consequences. Severely affected infants may re-
quire oxygen supplementation for up to several months to years, adversely affecting qual-
ity of life within families 61-63. Many experience respiratory symptoms in childhood such as 
recurrent cough and wheezing, associated with increased use of bronchodilators and ster-
oids 64. Rehospitalisation is frequent in infants with BPD and is most often associated with 
respiratory disorders 65,66. In line with these observations, lung function parameters are 
often abnormal in children with BPD 14,56. Findings in adolescents and young adults are 
similar although these should be interpreted with care since these patients represent 
former infants with ‘old BPD’, a part of the spectrum distinct from that currently observed 
in preterm infants 14,67. Apart from its pulmonary consequences, BPD is associated with 
long term feeding difficulties, growth retardation, osteopenia, nephrocalcinosis, and ad-
verse neurological outcome 68,69.  
Bronchopulmonary dysplasia – Underlying mechanisms 
BPD is a complex and multifactorial disease. A wide range of contributing factors and po-
tential underlying mechanisms have been identified. Although many have contributed to 
our current understanding of abnormal lung development and modulation of lung injury 
and repair, a comprehensive picture of pathways leading to the disease is currently lack-
ing. Several underlying mechanisms will be discussed below, with a focus on human stud-
ies. 
Oxygen toxicity 
One of the first recognised risk factors for BPD was exposure to high levels of oxygen 53. 
Oxygen exposure leads to generation of reactive oxygen species (ROS). Recruited inflam-
matory cells in the lung and increased endogenous levels of free iron may be additional 
sources of ROS 51,70-72. In the lung, ROS lead to cell death, surfactant inactivation, induction 
of pro-inflammatory processes, and increased MMP activity which may lead to ECM deg-
radation 51,73,74. Preterm infants are particularly sensitive to oxygen toxicity due to reduced 
intracellular anti-oxidant capacity 51. A link between oxygen toxicity and BPD is further 
supported by increased levels of carbonyl and peroxidation products in bronchoalveolar 
lavage fluid (BALF) and urine from infants developing BPD. In animals prolonged exposure 
to high levels of oxygen results in pulmonary growth arrest, emhysaema, fibrosis and in-
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flammation, similar to the pathologic picture of BPD seen in human infants 75,76. Despite 
the evidence supporting a role of oxidant stress in BPD, trials evaluating the efficacy of 
anti-oxidants to reduce BPD have rendered disappointing results 51,77.  
Ventilator associated lung injury, inflammation and infection 
Mechanical ventilation in preterm infants is a well known and characterised risk factor for 
BPD. Initiation of mechanical ventilation readily induces cytokine and chemokine expres-
sion in the preterm lung, soon followed by influx and activation of neutrophils from the 
circulation, which further aggravates the inflammatory cascade 78,79. Lung overdistention, 
repetitive alveolar collapse and regional atelectasis have been shown to enhance this 
response 80-82. In addition, primary lung injury may elicit a systemic inflammatory response 
83. Conversely, systemic infections which occur frequently in preterm infants, may en-
hance the local inflammatory response in the lung. 
Increased numbers of neutrophils in tracheal aspirates from preterm infants are asso-
ciated with BPD development 79,84-87. Correspondingly, the expression of several molecular 
mediators of leukocyte adhesion that regulate this influx is elevated in BPD infants 84,87-90. 
Attracted leucocytes elicit an inflammatory response within the lung and produce toxic 
ROS and proteases capable of degrading the pulmonary ECM 50. Additional injury to the 
lung may disrupt the epithelial-endothelial barrier and lead to leakage of fluid and serum 
proteins into the alveolar space, further contributing to local inflammation and surfactant 
inhibition 50,91. 
Numerous reports have shown associations between increased cytokines and 
chemokine concentrations in both blood and lung-derived fluid and development of BPD. 
These include cytokines such as tumour necrosis factor-α (TNFα) 92, interleukin-1β (IL1β) 
90,92,93, IL-6 79,92,94-96, IL-10 97-99, and chemokines including monocyte chemoattractant pro-
teins (MCPs) 78, macrophage inflammatory proteins (MIPs) 78, and CXCL8 (IL-8) 
79,94,95,97,98,100. The latter additionally recruit macrophages into the alveolar space which 
contribute to the inflammatory state. Enhanced expression of many of these mediators 
has also been reported after chorioamnionitis, providing some support for a link between 
intrauterine inflammation and BPD 78,94,97,101-106. Many of these effects are probably medi-
ated by nuclear factor kappa-B (NFκB), an ubiquitous regulator of inflammation. Indeed, 
increased expression of NFκB has been associated with chorioamnionitis 105, prolonged 
mechanical ventilation 105,107, and development of BPD 107.  
Although most of the evidence discussed is derived from human studies, a large body 
of evidence from neonatal animal studies confirms the association between induced lung 
injury, inflammation and subsequent adverse lung development 50. Moreover, animal 
studies have greatly increased our understanding on how antenatal inflammation ad-
versely affects the development of several fetal organs, including the lung 108,109 (figure 2). 
However, results from human studies have not been consistent regarding the association 
between chorioamnionitis and development of BPD, as discussed later 60.  
20 
 
 
Figure 2. Graphic representation of organs known to be affected by prenatal exposure to inflammation. 
(source: Gantert M, Been JV, et al. J Perinatol (in press)). 
Transcription factors 
The transcription factor most extensively studied with regard to BPD is probably vitamin A. 
Through binding of its active metabolite retinoic acid to several nuclear receptors, it regu-
lates the transcription of a wide range of proteins involved in lung development. Infants 
developing BPD have been shown to be vitamin A deficient 110-112, and vitamin A supple-
mentation is one of very few measures that has proven to effectively reduce the incidence 
of BPD 113.  
Other transcription factors implicated in the pathophysiology of BPD include perox-
isome proliferator-activated receptor-γ (PPARγ) and HIFs. PPARγ is a key determinant of 
the lipofibroblast phenotype within the lung. Stimulation of PPARγ prevents transdifferen-
tiation into myofibroblasts, which partly determines the fibrotic picture seen in BPD 114.  
HIFs are widely expressed in the lungs during fetal life, and upregulation of HIF activity in 
animal models improves lung development after injury, corresponding to their function as 
upstream regulators of key modulators of lung development 45,115-117.  
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Growth factors 
Growth factors play a critical role in normal lung development, as discussed previously. 
Several studies have addressed a potential role of individual growth factors in BPD devel-
opment. Low VEGF expression has quite consistently been shown to be associated with 
BPD development 118-120. Alterations in pulmonary concentrations of several other growth 
factors have been described. These include hepatocyte growth factor (HGF; a regulator of 
normal alveolarisation), keratinocyte growth factor (KGF / FGF7; a promotor of epithelial 
repair), TGFβ1 (a regulator of lung development with pro-fibrotic properties), PDGFs (pro-
fibrotic factors also implicated in lung growth), and regulators of angiogenesis such as 
endostatin and angiopoetin-1 121-126. 
Many associations between alterations in growth factor expression in the lung are 
supported by mechanistic evidence from animal studies. Possibly the best example is 
VEGF. VEGF expression is reduced in various animal models of BPD and experimental inhi-
bition of VEGF disrupts both alveolar and pulmonary vascular development 115,127-130. Con-
versely, upregulation of VEGF reduces respiratory distress and mortality both in preterm 
animals and animals exposed to hyperoxia 45,129,131,132. Similar close correlations between 
human findings and animal studies are present for many other growth factors. 
Extracellular matrix constituents and degradants 
During normal lung development, close balancing of pulmonary expression of proteinases 
and their inhibitors is critical. Lungs from children who develop BPD contain increased 
levels of collagen fibres 133-135. Moreover, several reports have shown alterations in ex-
pression patterns of MMPs and tissue inhibitors of MMPs (TIMPs) to be associated with 
BPD, providing a pathophysiological basis for this dysregulation of collagen deposition 136-
140. Prenatal modulation of these mechanisms has been suggested by reports of an asso-
ciation between alterations in pulmonary MMP expression and prior exposure to 
chorioamnionitis 141,142. Other modulators of ECM integrity such as elastase and trypsin-2 
have also been implicated in the pathophysiology of BPD 86,143. Besides controlling ECM 
production and degradation, proteinases may aggravate the inflammatory response 
through stimulation of proteinase-activated receptor-2 (PAR2), the expression of which is 
increased in infants developing BPD 50,144. 
Genetic contributions 
With the recent expansion of research on the genetic basis of disease, evidence support-
ing a genetic component determining BPD susceptibility is emerging. A recent twin study 
even suggests that genetic factors may explain a large majority of the observed variance in 
BPD incidence among preterm infants 145. Polymorphisms in genes encoding for surfactant 
protein-B 146, angiotensin-converting enzyme 147, gluthathione-S-transferase-P1 148, MMP-
16 139 and the inflammatory mediator TNF-α 149 have all been linked to BPD susceptibility 
and may thus explain part of this variation. Additional research using newer techniques 
such as genome-wide association studies carry the potential to reveal novel genetic asso-
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ciations underlying BPD susceptibility. These in turn may lead to increased understanding 
of molecular mechanisms associated with development of the disease 150. 
Changing picture of BPD 
The wide range of mechanisms implicated in the pathophysiology of BPD underlines the 
complexity of this disease process. Adding to this complexity is the apparent change over 
time in both the pathological picture of BPD and the population at risk. Increased use of 
antenatal steroids and postnatal surfactant, less invasive ventilatory strategies and restric-
tive use of supplemental oxygen are among the practice changes that have greatly con-
tributed to this transformation. Without a doubt, pathophysiological mechanisms will 
have changed along both in nature and in magnitude of contribution to the development 
of chronic lung injury. Given the practice changes mentioned and the altered pathological 
picture observed, the relative importance of inflammation, ventilator-induced lung injury 
and oxygen toxicity may well have decreased. On the other hand, the current concept of 
BPD representing a developmental arrest of the lung may well implicate increasing contri-
butions of ECM proteins, alterations in growth factor expression and cellular mechanisms 
in its pathophysiology.  
Conclusion 
Despite the complexity of the aetiology and pathogenesis of BPD, increased knowledge 
about the mechanisms that currently contribute to the disease is highly relevant, given the 
extent of the problem and the paucity of measures available for prevention and treatment 
of the disease 77,151. Thus, ongoing research is vital to increase our understanding and to 
be able to optimise treatment and improve future prospects of preterm infants. 
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Abstract  
Surfactant therapy has significantly changed clinical practice in neonatology over the last 
25 years. Recent trials in infants with respiratory distress syndrome (RDS) have not shown 
superiority of any natural surfactant over another. Advancements in the development of 
synthetic surfactants are promising, yet to date none has been shown to be superior to 
natural preparations. Ideally, surfactant would be administered without requiring  me-
chanical ventilation. An increasing number of studies investigate the roles of alternative 
modes of administration and the use of nasal continuous positive airway pressure to 
minimise the need for mechanical ventilation.  
Whether children with other lung diseases benefit from surfactant therapy is less 
clear. Evidence suggests that infants with meconium aspiration syndrome and children 
with acute lung injury/acute respiratory distress syndrome may benefit, while no positive 
effect of surfactant is seen in infants with congenital diaphragmatic hernia. However, 
more research is needed to establish potential beneficial effects of surfactant administra-
tion in children with lung diseases other than RDS. Furthermore, genetic disorders of sur-
factant metabolism have recently been linked to respiratory diseases of formerly unknown 
origin. It is important to consider these disorders in the differential diagnosis of unex-
plained respiratory distress although no established treatment is yet available besides lung 
transplantation for the most severe cases.  
Conclusion: Research around surfactant is evolving and recent developments include 
further evolution of synthetic surfactants, evaluation of surfactant as a therapeutic option 
in lung diseases other than RDS and the discovery of genetic disorders of surfactant me-
tabolism. Ongoing research is essential to continue to improve therapeutic prospects for 
children with serious respiratory disease involving disturbances in surfactant. 
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Introduction 
Surfactant is a complex mixture of lipids (90%) and proteins (10%) lining the epithelial 
surface of the lung. Four surfactant apoproteins have been described: the hydrophobic 
surfactant protein B (SP-B) and SP-C and the hydrophilic SP-A and SP-D. Surfactant is syn-
thesised by alveolar type II cells, stored in lamellar bodies that are exocytosed and taken 
up into the monolayer lining the alveolar epithelium. Traditionally, surfactant is recog-
nised for its surface tension-lowering properties, by which alveolar collapse is prevented 
and gas exchange is facilitated. More recently, surfactant has been shown to have an im-
portant additional role in innate defence of the lung. Key players in this role are SP-A and 
D, members of the collectin family of proteins. Among their functions are binding, opsoni-
sation and clearance of microbes from the lung and regulation of immune cell activity. 
Several reviews have addressed their role in detail 1,2. Evidence is now accumulating that 
SP-B, SP-C and the surfactant lipids may be involved in modulation of pulmonary inflam-
mation as well 3-8.  
The relevance of surfactant for pulmonary physiology is highlighted by the respiratory 
distress syndrome (RDS) seen in preterm infants, caused by an absolute deficiency of sur-
factant. Affected infants experience respiratory insufficiency often requiring mechanical 
ventilation. The introduction of exogenous surfactant administration for these infants is 
generally regarded as one of the most important advancements in the field of neonatol-
ogy, having significantly decreased neonatal mortality over the last 25 years. Nowadays, 
the potential benefit of surfactant therapy is evaluated in a wide range of respiratory 
disorders in both neonates and paediatric patients. Moreover, several disease entities of 
formerly unknown origin have recently been linked to genetic disorders of surfactant me-
tabolism.  
The purpose of this review is to give an overview of these and other recent develop-
ments in the field of surfactant, focusing on clinically relevant issues in neonatology and 
paediatrics.  
Surfactant in RDS 
In 1959 Avery and Mead established the relationship between surfactant deficiency and 
RDS seen in preterm infants 9. Twenty years later, exogenous surfactant was successfully 
administered to preterm infants with RDS and shown to dramatically improve oxygenation 
in these babies 10. In subsequent clinical trials, reductions in neonatal mortality and inci-
dence of pneumothorax were found after surfactant administration 11. Further trials found 
that early treatment is superior to late treatment 12, multiple doses are better than a sin-
gle dose 13, and prophylactic surfactant is associated with better outcome than is rescue 
treatment 14. Excellent reviews on the history of surfactant are available 15,16.  
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In recent years knowledge of the in vivo surfactant metabolism in RDS patients has in-
creased as a result of metabolic studies. Preterm infants were shown to have a decreased 
surfactant pool size with decreased synthesis but increased recycling of surfactant when 
compared to term infants 17. Furthermore, it was found that both prenatal steroids and 
exogenous surfactant administration after birth stimulate endogenous surfactant synthe-
sis 18,19.  
Recent developments in surfactant treatment for RDS include new comparative trials 
of natural surfactants, exploration of alternative modes of administration and evaluation 
of the use of nasal continuous positive airway pressure (nCPAP) either to decrease the 
need for surfactant or as an adjuvant therapy following surfactant administration. More-
over, much effort is put into the development of synthetic surfactants for treatment of 
respiratory distress. This topic is discussed separately. 
Natural surfactant 
In recent years, several clinical trials have compared the efficacy of different natural sur-
factants in the treatment of RDS. Natural surfactants are generally derived from either 
lung lavage or minced lung of bovine or porcine origin.  
Four studies have compared beractant (Survanta) and poractant-α (Curosurf) 20-23. 
Curosurf was found to have a more rapid onset of action in most studies 21-23. A meta-
analysis of these studies plus one unpublished study suggested a significant decrease in 
neonatal mortality after Curosurf treatment 16. However, three of these studies have 
compared a Curosurf dose of 200 mg/kg with a Survanta dose of 100 mg/kg 21-23. When 
these studies were excluded from analysis, the difference in mortality after treatment 
with comparable doses of both surfactants was not statistically significant 16. Malloy and 
colleagues reported a significant decrease in the incidence of persistent ductus arteriosus 
after Curosurf treatment 21. None of the other studies found such an effect and it is un-
clear whether this difference may be explained by the dosing difference as well.  
Baroutis and colleagues compared the effects of three different surfactant prepara-
tions: Curosurf, Survanta and Alveofact 20. Treatment with either Curosurf or Alveofact 
was associated with a decrease in days on the ventilator, days on oxygen and hospital 
stay, but no significant improvement in morbidity and mortality. A more recent study 
comparing Survanta and Alveofact reported a decrease in chronic lung disease (CLD) with 
Survanta 24. However, CLD was defined as oxygen need at 28 days of age, a definition that 
does not take into account the gestational age of the infant and is generally regarded to 
be imprecise and outdated. There was a decrease in days on the ventilator, days on oxy-
gen and length of hospital stay with Survanta. The need for postnatal steroids was de-
creased in the Survanta group as well; however, their overall use was very high compared 
to current standards.  
Two studies have compared Survanta and Infasurf (calfactant) for the treatment of 
RDS 25,26. The largest study compared the efficacy of the two surfactants for prophylactic 
administration as well as for rescue treatment 26. Infasurf was found to have a more rapid 
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effect, without having an effect on overall incidence of bronchopulmonary dysplasia (BPD) 
or mortality. Subgroup analysis showed a decrease in mortality after prophylactic Survanta 
treatment in infants under 600 g. A more recent, smaller study reported a decrease in 
number of doses required with Infasurf without any differences in outcome 25.  
One small comparative trial was reported on bovine lipid extract surfactant (bLES) and 
Survanta 27. Treatment with bLES was associated with a more rapid improvement in oxy-
genation, yet no effect on short-term outcome was seen.  
In summary, most differences in effectiveness between natural surfactant prepara-
tions are short-lived. On the basis of currently available evidence, no preparation can 
clearly be considered superior to another with regard to morbidity and mortality. More 
data would be needed and future studies should include comparison of long-term out-
come parameters. However, the clinical relevance of these differences is likely to be 
minimal; therefore, future studies should focus on more relevant aspects of surfactant 
therapy.  
Timing of surfactant  
Many studies have investigated the ideal timing of surfactant administration. Systematic 
reviews of earlier studies have found a decrease in the incidence of pneumothorax, pul-
monary interstitial emphysema, CLD and mortality with early (within 2 h after birth) versus 
delayed surfactant administration 12, and a decrease in pneumothorax and mortality with 
prophylactic surfactant administration versus selective rescue therapy 14.  
As stressed by Horbar and colleagues, these trials were conducted at a time when the 
use of antenatal steroid administration was much lower than it is today. Therefore, the 
observed difference between early and delayed surfactant therapy may be smaller in 
current practice 28. A more recent trial still suggests a positive effect of early surfactant 
administration in intubated infants, albeit without any effect on morbidity and mortality 
29. 
Surfactant and nCPAP  
An important issue is the use of nCPAP, either to prevent intubation and surfactant ad-
ministration or to accelerate extubation after surfactant is given. A recent Cochrane re-
view showed that intubation and early administration of surfactant followed by extuba-
tion to nCPAP was associated with decreased ventilator requirement, but an increase in 
number of surfactant administrations when compared to selective surfactant and contin-
ued ventilation 30. No difference in BPD incidence was detected. Dani and colleagues later 
showed that, when intubated and given surfactant, infants may benefit from early extuba-
tion to nCPAP 31. Whether intubation for the purpose of surfactant administration is fa-
vourable for larger preterms with mild to moderate RDS is questioned by a recent study 
showing an increase in median duration of ventilation with elective intubation and surfac-
tant 32.  
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The potential of the initial use of nCPAP to prevent intubation and administration of 
surfactant is the subject of current studies. Potential side effects of intubation and high 
costs of surfactant administration might thus be avoided. Retrospective studies suggest 
that, when compared to early initiation of mechanical ventilation, early nCPAP decreases 
the incidence of intraventricular haemorrhage and  improves survival but may increase 
the risk for necrotising enterocolitis when nCPAP fails 33,34. However, only part of the in-
fants on early mechanical ventilation received surfactant. More recent data from Te Pas 
and colleagues suggest that even if early nCPAP fails, it may still result in a decreased BPD 
risk when compared to infants intubated in the delivery room 35.  
Ideally, avoidance of intubation and subsequent mechanical ventilation would involve 
early initiation of nCPAP in combination with an alternative mode of surfactant admini-
stration. The combined use of early nCPAP and surfactant administration through a thin 
endotracheal catheter was reported to decrease the need for mechanical ventilation in 
very low birth weight infants 36. Other potential alternatives for endotracheal administra-
tion include aerosolisation 37, bronchoscopic administration 38, nasopharyngeal deposition 
39, and administration of surfactant via a laryngeal mask 40,41. Clearly, controlled trials are 
needed to evaluate the safety of alternative modes of surfactant administration and the 
potential of a combined approach with early nCPAP to decrease the subsequent need for 
mechanical ventilation and improve outcome. 
Synthetic surfactant 
A major disadvantage of commercially available natural surfactants is their price. There-
fore much effort has been put into development of synthetic surfactants. The basis of 
these preparations is a highly simplified phospholipid mixture. The lack of surfactant pro-
teins is a disadvantage compared to natural surfactants. Natural surfactant preparations 
contain variable amounts of SP-B and SP-C that enhance surface tension-lowering proper-
ties and long favoured their use above synthetic preparations 42. The potential of several 
additives with surfactant protein-like properties to increase the efficacy of synthetic sur-
factant preparations is currently under evaluation.  
Two synthetic surfactants containing such additives have been tested in clinical trials. 
One is Venticute, which contains recombinant SP-C (rSP-C). However, no trials involving 
Venticute in preterms with RDS have yet been published. The other, lucinactant (Surfaxin), 
is characterised by the addition of KL4 (sinapultide), a non-natural polypeptide that was 
designed to resemble SP-B 43. Two trials comparing prophylactic use of Surfaxin to a natu-
ral surfactant in the treatment of RDS showed no differences in relevant outcome parame-
ters 44,45. However, these trials were designed to show only ‘noninferiority’, and the study 
comparing three surfactant preparations was underpowered to detect a difference be-
tween Surfaxin and  the natural surfactant Survanta 46.  
So although synthetic surfactants, especially those with surfactant protein-like addi-
tives, have theoretical advantages over natural surfactants, to date none has been shown 
to be superior to natural preparations in comparative trials 43. Yet the search for new syn-
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thetic surfactant protein analogues goes on. Recent data from in vitro and animal studies 
are promising regarding efficacy of different SP-B peptides, modified rSP-C with improved 
function and polymyxin B as possible future additives to synthetic surfactants 43. More-
over, a group of additives capable of decreasing surfactant inactivation is under investiga-
tion, showing promising results. These include chitosan 47, hyaluronan 48-50, dextran 51, and 
polymyxin B 52,53. The potential of these additives lies in their use in RDS and meconium 
aspiration syndrome (MAS), where inactivation of surfactant by albumin and meconium 
respectively decreases its efficiency.  
Surfactant in other neonatal lung disease 
Congenital diaphragmatic hernia (CDH)  
CDH is a serious disease associated with a mortality of 25–74%, primarily due to respira-
tory insufficiency 54. Surfactant deficiency and dysfunction have been found in a lamb CDH 
model and respiratory failure in these animals improved after exogenous surfactant ad-
ministration 55. Data on surfactant pool size and function in infants with CDH are inconclu-
sive 56-59. Only one small, randomised trial of surfactant in CDH patients on extracorporal 
membrane oxygenation (ECMO) is available, showing no benefit 60. Incidental reports do 
suggest a beneficial effect 61-63. Recently, the CDH study  group has retrospectively com-
pared the outcomes of CDH infants that did and did not receive exogenous surfactant 
during admission. No difference was observed in term infants 64, while surfactant admini-
stration was associated with increased mortality in preterms 59. However, this difference 
was not statistically significant after adjusting for gestational age and Apgar score. When 
only infants on ECMO were considered, surfactant still did not improve survival 65.  
In conclusion, although surfactant therapy is incorporated in CDH treatment protocols 
in many centres, this strategy is not supported by evidence and is advised to be used only 
in the context of a randomised trial 54,66.  
Meconium aspiration syndrome (MAS) 
Perinatal meconium aspiration affects surfactant function and metabolism in several 
ways. Meconium has an extremely high surface tension 67, inhibits surfactant function 68-71, 
and causes pneumonitis with direct toxicity to alveolar type II cells 72,73. Furthermore, we 
have recently found decreased alveolar surfactant content and synthesis in infants with 
MAS 74.  
Possible treatment options for MAS involving surfactant include bolus surfactant ad-
ministration and lung lavage using either saline or diluted surfactant. Initial case series 
reported temporary improvements in oxygenation and a decreased need for ECMO after 
bolus surfactant treatment 75,76. Two randomised trials of bolus surfactant therapy have 
been published 77,78. A meta-analysis of these studies showed a decreased need for ECMO 
in surfactant-treated infants without any relevant improvement in outcome 79. An impor-
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tant difference between the two studies was the timing of surfactant administration. With 
early treatment (within 6 h after birth), Findlay and colleagues did report additional bene-
ficial effects, such as decreased air leaks and shorter duration of ventilation 77. Based on 
current evidence, Dargaville and Mills advocate early administration of a surfactant known 
to resist meconium inactivation in severely affected infants, with repeated doses when 
needed 80.  
Meconium can be effectively removed from the lung by lavage 81. Most studies report 
a subsequent improvement in oxygenation above pre-lavage baseline, with earlier extuba-
tion and a decrease in pneumothorax incidence 80. Two randomised controlled trials (RCT) 
of lavage therapy in MAS have been reported. Only limited data are available from one 
study, suggesting that surfactant lavage is better than saline lavage 82. No significant dif-
ferences were found between infants lavaged with Surfaxin and nonlavaged infants in the 
other trial 83. However, additional studies are underway 80. Further trials should focus on 
the comparison between bolus surfactant therapy and surfactant lavage.  
In conclusion, infants with MAS seem to benefit from surfactant therapy when started 
early and repeated when necessary. There is insufficient evidence as yet to support the 
use of surfactant lavage therapy for MAS outside the setting of a clinical trial 80. As dis-
cussed earlier, the development of synthetic additives capable of decreasing meconium-
induced surfactant inhibition may help to increase future efficacy of surfactant therapy for 
MAS.  
Other neonatal lung diseases 
Decreases in alveolar surfactant pool size and surfactant recycling have been described in 
chronically ventilated infants progressing to or suffering from BPD 84-86. Therefore, surfac-
tant might be beneficial in treating these infants. Indeed, incidental reports suggest short-
term improvement after surfactant administration in chronically ventilated preterms, 
urging the need for further studies 87-89. Other neonatal pulmonary disorders that may 
benefit from surfactant therapy include haemorrhagic pulmonary oedema 90, and neonatal 
pneumonia 91, yet once again only incidental reports addressing these issues are available.  
Surfactant in paediatrics 
Surfactant has been evaluated as a potential intervention in respiratory diseases beyond 
the neonatal period. Several reports have focused on the use of surfactant in acute respi-
ratory distress syndrome (ARDS) or acute lung injury (ALI). In paediatric ARDS/ALI patients, 
acute improvement of oxygenation is seen with surfactant administration 92-97. No addi-
tional effects on outcome were noted in the first RCT 94. In a more recent RCT in ventilated 
children with respiratory failure and bilateral radiographic abnormalities, treatment with 
Infasurf was associated with a decrease in mortality 96. The mortality effect was greatest in 
the subgroup of infants (age <1 year), yet overall mortality was not significantly different 
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after adjustment for immunocompromised status. Concerns about the study being under-
powered and the increased incidence of hypotension and transient hypoxaemia in the 
treatment group warrant further evaluation before surfactant administration can be rou-
tinely recommended in paediatric ARDS/ALI 98. An important determinant of surfactant 
response seems to be the nature of the lung injury causing the respiratory failure. Patients 
with direct lung injury may benefit more than do patients with indirect lung injury 96. Fu-
ture studies should address differences in ALI aetiology in the patients studied.  
Several studies have investigated a possible role for surfactant in treatment of bron-
chiolitis. A recent systematic review evaluating three trials reported a significant decrease 
in duration of ventilation and of hospital admission with surfactant therapy 99. However, it 
is generally felt that current evidence is insufficient to establish the role of surfactant 
suppletion in bronchiolitis and that additional trials are needed 99-101. Surfactant distur-
bances have been described in a wider range of paediatric lung diseases and recent case 
series suggest a potential beneficial role for surfactant in the treatment of lobar atelecta-
sis 102, intrapulmonary haemorrhage 103, Pneumocystis carinii pneumonia 104, and as an 
adjuvant therapy in ECMO patients 105. Clearly, additional studies are needed to establish 
the safety and potential benefit of surfactant therapy in these disorders as well.  
Genetic disorders of surfactant 
SP-B deficiency 
In recent years, several genetic disorders affecting surfactant metabolism have been iden-
tified. SP-B deficiency, first described in 1993 106, is the most serious of these. It is a rare 
autosomal recessively inherited disease, in the majority of patients caused by the 121ins2 
mutation 107. SP-B is critical for lowering alveolar surface tension. Adding to the surfactant 
dysfunction caused by the deficiency of SP-B is the associated incomplete processing of 
SP-C 108. In almost all cases a total absence of SP-B is present, which is invariably lethal 109. 
Babies present with respiratory failure shortly after birth, only partially and transiently 
being responsive to exogenous surfactant administration. To date, the only therapeutic 
option for these patients is lung transplantation, which should be performed within weeks 
to months 110. Recently, Palomar and colleagues reported that the outcome for lung 
transplantation in SPB- deficient patients is comparable to patients transplanted for other 
reasons 111. However, Hamvas reports that approximately half the families of children 
eligible for lung transplantation decline and another 30% of patients die awaiting trans-
plantation 109.  
SP-C-associated disease 
In recent years, several mutations in the SP-C gene have been identified and connected to 
respiratory disease. The incidence of SP-C-associated disease appears to be considerably 
higher than that of SP-B deficiency 109. This is partly due to the fact that SP-C mutations 
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are inherited in a dominant manner 109. On the other hand, approximately half of the dis-
ease-associated mutations are spontaneous mutations 109. The most common mutation 
I73T, as well as most other mutations, results in production of misfolded SP-C that accu-
mulates within the alveolar type II cell 112-114.  
The presentation and characteristics of respiratory diseases resulting from SP-C muta-
tions are diverse and unpredictable 109. Patients carrying mutations may present anywhere 
between the newborn period and adulthood. In a large cohort of term newborns with 
unexplained respiratory disease, the incidence of SP-C gene mutations was shown to ap-
proach 10% 115. Asymptomatic patients carrying SP-C mutations have also been identified 
116,117. Newborns may present with RDS-like symptoms despite term birth. In paediatric 
patients interstitial lung disease may present with gradual onset of respiratory insuffi-
ciency, hypoxaemia and failure to thrive. Some patients remain stable or even improve, 
while others progress to respiratory insufficiency, eventually requiring lung transplanta-
tion.  
No standard treatment for SP-C-associated disease is available. Some authors have 
seen clinical improvement after treatment with hydroxychloroquine 118,119, or repeated 
lung lavage along with administration of corticosteroids and azathioprine 120, while others 
have not 121,122. Clearly, additional studies are needed to further investigate possible 
treatment options for SP-C-associated disease.  
ABCA3-associated disease 
The most recently discovered genetic disruption of surfactant metabolism is caused by 
mutations in the gene encoding for ABCA3 123. ABCA3 is an ATP-binding cassette (ABC) 
protein localised at the limiting membrane of lamellar bodies 124,125. In vitro studies show 
that depending on the mutation present, the mutant ABCA3 protein is either retained at 
the endoplasmic reticulum or is appropriately localised yet exhibits a decreased capacity 
to hydrolyse ATP 126. The exact role of ABCA3 is unknown; however, other members of the 
ABCA protein family are involved in lipid transport 127. A specific role for ABCA3 in lipid 
metabolism is further supported by the detection of reduced lung levels of phosphatidyl-
glycerol and phosphatidylcholine subtypes in ABCA3 knockout mice, while levels of other 
phospholipids and cholesterol were unaffected 128. Along with other studies, this work 
further suggests a key role for ABCA3 in lamellar body formation 128-130. Abnormal lamellar 
body formation, surfactant deficiency and surfactant dysfunction have indeed been found 
in patients carrying ABCA3 mutations 123,131-133.  
Most patients with ABCA3 mutations described thus far presented in the neonatal pe-
riod with progressive respiratory distress, often being lethal. Hydroxychloroquine and 
corticosteroids have been used in the management of ABCA3-associated disease, yet their 
efficiency in treating the disorder is unclear 132. For these patients, lung transplantation is 
currently the only treatment option 133,134. However, Bullard and colleagues have recently 
stressed the fact that most patients described thus far were derived from highly selected 
populations of infants with unexplained severe respiratory distress 132. The same group 
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has identified ABCA3 mutations in paediatric patients with interstitial lung disease, sug-
gesting that defects in ABCA3 may be involved in a greater range of respiratory diseases 
134. Research on ABCA3-associated respiratory disease is clearly evolving and knowledge 
about the disorder will increase in the near future.  
We wish to underline the importance of considering genetic disorders of surfactant 
metabolism in the differential diagnosis of both unexplained respiratory failure and inter-
stitial lung disease in the newborn period and beyond. When such a disorder is suspected 
in a patient, one should turn to a specialised laboratory for establishment of the diagnosis.  
Surfactant protein polymorphisms and lung disease  
In addition to the mutations described above, more common polymorphisms in surfactant 
proteins have been linked to both increased and decreased risks of developing neonatal 
and paediatric pulmonary disease. Genetic variants of the SP-B gene have been linked to 
increased risks for both respiratory distress 135,136, and BPD 137. Common SP-A alleles, in 
interaction with the SP-B Ile131Thr genotype, have been associated with RDS susceptibil-
ity, while others seem to decrease RDS risk 138,139. Recently, polymorphisms in SP-C genes 
have also been linked to RDS 140. The susceptibility for respiratory syncytial virus (RSV) 
infection is altered by polymorphisms of SP-A and SP-D, known modulators of innate im-
munity. In addition, associations of surfactant protein polymorphisms with extrapulmon-
ary diseases exist, such as recurrent ear infections 141, and meningococcal disease 142.  
The relevance of these associations between surfactant protein haplotypes and neo-
natal and paediatric pulmonary and infectious diseases remains unclear. Associations may 
differ between populations, hence the finding of contrasting risk associations between SP-
B polymorphisms and RDS 136. Larger studies are clearly needed to confirm current find-
ings. Possible future applications include individual risk determination and subsequent 
surfactant protein administration.  
Future directions and conclusion 
As highlighted in this review, substantial progression has been made in recent years con-
sidering the role of surfactant therapy in neonatal and paediatric lung diseases. However, 
many questions remain unanswered. Efforts should be made to investigate the roles of 
nCPAP and alternative administration routes for surfactant in the treatment of preterm 
infants. Further development of synthetic surfactants to enhance their surface tension-
lowering properties and capacity to withstand inactivation may increase future efficacy of 
surfactant therapy. More ideally, one should be able to stimulate endogenous surfactant 
synthesis in preterm infants, preferably antenatally. A potential candidate drug would be 
docosahexaenoic acid, which has been shown to stimulate synthesis of dipalmitoyl phos-
phatidylcholine, the major phospholipid in surfactant, in preterm mice when administered 
to the mother during pregnancy 143. Another promising future application for surfactant is 
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its use as a carrier for drug administration directly into the lung. In this way drugs are 
allowed to act locally with minimisation of unwanted systemic effects. Possible candidate 
drugs include immunosuppressants 144, vasodilators 145, and β-sympathicomimetics 146. 
Investigational drugs that have been administered in animal models using surfactant as a 
carrier include a 5-lipoxygenase inhibitor 147, and recombinant human Clara cell secretory 
protein (rhCC10) 148. Both agents have been shown to decrease experimental lung injury in 
these models. The antiinflammatory and antimicrobial characteristics of SP-A and SP-D 
make them attractive potential therapeutic agents as well. Administration of recombinant 
SP-D fragments in animal models results in enhanced pulmonary clearance of RSV 69, a 
reduced allergic response 149-151, and prevention of endotoxin shock 152. However, SP-A 
and SP-D are very large and complex molecules, making construction of functional recom-
binant whole proteins extremely difficult if not impossible. Much more research is needed 
to evaluate a possible role for surfactant proteins in the treatment of inflammatory dis-
eases. Furthermore, the general evolution of gene therapy involves potential applications 
in the genetic disorders of surfactant metabolism, primarily SP-B deficiency.  
More than 25 years after the introduction of exogenous surfactant therapy, research 
around surfactant is still evolving. Surfactant remains a hallmark in the treatment of RDS, 
especially in very preterm infants. Future research should focus on potential ways to avoid 
intubation and mechanical ventilation and give surfactant via an alternative route. The 
therapeutic role of surfactant in other neonatal and paediatric lung diseases is less clear 
and needs further evaluation. Finally, genetic disorders of surfactant metabolism should 
be taken into account in the differential diagnosis of respiratory distress and interstitial 
lung disease in children.  
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Abstract  
A considerable body of human and animal experimental evidence links antenatal inflam-
mation to both accelerated maturation and adverse development of the lung. Initial re-
ports suggest that in preterm infants histological chorioamnionitis is associated with a 
decreased incidence of respiratory distress syndrome (RDS), while the incidence of bron-
chopulmonary dysplasia (BPD) is increased. Considerable variation exists in the findings of 
subsequent human studies, largely dependent on differences in inclusion and exclusion 
criteria. Taking these differences into account, recent studies generally seem to confirm 
the effect of chorioamnionitis on RDS incidence, while no effect on BPD is seen. The in-
creased use of antenatal steroids and the diminished effects of secondary pro-
inflammatory hits seem to explain part of this change. Additional research is needed to 
explore these complex interactions and their underlying mechanisms, and evaluate the 
long term pulmonary effects of antenatal inflammation.  
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Introduction 
The effects of antenatal inflammation on both short and long term outcome in preterm 
infants have received increasing attention over the last few years. Chorioamnionitis is 
clearly associated with preterm birth and its incidence in preterm infants increases with 
decreasing gestational age 1-3. The primary process in the aetiology of intrauterine in-
flammation is believed to be ascending bacterial invasion from the cervicovaginal tract 4,5, 
although several other routes have been postulated 5. Bacteria may then spread across 
the chorioamniotic membranes and cause chorioamnionitis 4,5. In a subset of patients 
intrauterine inflammation is accompanied by a fetal response, believed to reflect the more 
serious end of the continuum. Initial signs of fetal inflammation in preterm infants are 
seen in the chorionic plate, followed by involvement of the umbilical cord vessels, often 
referred to as “funisitis” 4.  
Both clinical and histopathological definitions of chorioamnionitis have been used as 
indicators of intrauterine inflammation, but numerous studies have shown these to be 
poorly correlated. Clinical indicators of maternal inflammation are unspecific and probably 
mainly identify cases of acute chorioamnionitis. Conversely, histological criteria for 
chorioamnionitis based upon the identification of polymorphonuclear cellular infiltrates, 
are clearly defined, although different grading systems exist. It is generally felt that a 
histological definition of intrauterine inflammation more closely reflects antenatal 
inflammatory exposure than the clinical definition 5.  
Exposure to antenatal inflammation has mainly been associated with alterations in 
brain and lung development. Intrauterine inflammation has quite consistently been shown 
to adversely affect short term neurological outcome by increasing the incidences of 
intraventricular haemorrhage, white matter abnormalities, cystic periventricular 
leucomalacia and cerebral palsy, as reviewed in Dammann et al 6. While several follow-up 
studies show neurodevelopmental outcome to be unaffected 7-11, others have reported 
histological chorioamnionitis to be associated with developmental delay 12,13, abnormal 
neurological outcome 14, speech delay 15, and autism 16. As regards pulmonary outcome, 
Watterberg and colleagues were the first to report a decrease in the incidence of 
respiratory distress syndrome (RDS), while the incidence of chronic lung injury, marked by 
the presence of bronchopulmonary dysplasia (BPD), was increased in infants with 
chorioamnionitis 17. This paradoxical effect of prenatal inflammation on pulmonary 
outcome has been referred to as the “Watterberg effect”. Numerous larger cohort studies 
in preterm infants have since tried to reproduce and explain these findings, yielding 
seemingly inconsistent results. The interpretation of many of these studies is further 
complicated by the fact that important confounders such as gestational age have not been 
adjusted for in the analyses.  
The purpose of this review is to provide a synopsis of the human evidence on 
pulmonary outcome after exposure to intrauterine inflammation defined solely on 
histopathological grounds. Findings of cohort studies will be summarised, with special 
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emphasis on identifying differences and similarities, and exploring potential explanations 
for paradoxical findings among these studies. Separation of the effects of chorioamnionitis 
with and without fetal involvement, and the interaction with antenatal steroid 
administration will receive special attention.  
Respiratory outcome after chorioamnionitis 
In the Watterberg study, 53 mechanically ventilated infants with a birth weight below 
2000 g were divided into two groups based on the presence or absence of RDS 17. None of 
the infants received surfactant or antenatal steroids. The incidence of chorioamnionitis 
was significantly higher in the group without RDS. Conversely, chorioamnionitis-exposed 
patients who survived were more likely to develop BPD. Although infants with chorioam-
nionitis were of significantly lower gestational age, possibly explaining the increased inci-
dence of BPD, the data were not adjusted for this. On the other hand, gestational age 
adjustment would probably have augmented the decreased RDS risk.  
These observations have led many research groups to conduct cohort studies on 
respiratory outcome in preterm newborns exposed to histological chorioamnionitis. The 
general characteristics of these studies are summarised in table 1. Incidences of 
histological chorioamnionitis varied between 33% and 71%, largely depending on variation 
in criteria used for inclusion and exclusion. Two studies comprised patients included in 
randomised controlled trials. One was designed to evaluate the effect of antenatal MgSO4 
on the development of cerebral palsy 18, while the other randomised mechanically 
ventilated infants to either hydrocortisone or placebo to evaluate the effect on BPD 
development 19. While antenatal MgSO4 was shown not to alter respiratory outcome in 
preterm infants 20, the hydrocortisone trial should obviously be interpreted with care.  
The association of chorioamnionitis with relevant respiratory outcome parameters is 
shown in table 2. Chorioamnionitis-exposed patients had either similar 7,21-25, or decreased 
2,3,26,27 RDS incidences in most studies. While Elimian and colleagues reported an increase 
in RDS incidence, the difference disappeared after multivariate analysis 28. Interpretation 
of this study is further complicated by the exclusion of patients with clinical 
chorioamnionitis. Four other large reports adjusted their data for confounding factors, 
invariably showing chorioamnionitis to be associated with significantly decreased RDS risk 
2,3,27,29.  
 
 
Table 1 (next page). Study characteristics of cohort studies reporting short-term pulmonary outcome in preterm 
infants with and without histologic chorioamnionitis (CA). PPROM=premature prolonged rupture of membranes; 
PL=preterm labour; cong=congenital; GA=gestational age; BW=birth weight; PDA=patent ductus arteriosus; 
MV=mechanical ventilation; IUGR=intrauterine growth retardation; AGA=appropriate for gestational age; 
AS=Apgar score; MMP-9=matrix metalloproteinase-9; arandomised controlled trial (RCT) of postnatal hydrocorti-
sone; bpart of RCT of antenatal MgSO4. 
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Author 
Study 
period 
Inclusion 
criteria 
Exclusion 
criteria 
Cohort 
size 
Antenatal
steroids 
Factors in multivariate 
model 
Dexter 
2000 7 
1990- 
1994 
<1250 g + 
PPROM / PL 
>1st born of multiples 
CA+ 164 
CA- 123 
22%  
Elimian 
2000 28 
1990- 
1997 
500-1750 g 
 
Clinical CA 
CA: 527 
CA- 733 
33% ? 
Kosuge 
2000 26 
1993- 
1997 
24-32 w 
Lethal cong 
anomalies 
CA+ 37 
CA- 44 
17%  
Redline 
2002 31 
1995- 
1997 
<32 w + 
<1250 g 
Death <36 w 
CA+ 169 
CA- 202 
65% 
GA; BW Z-score; race; air 
leak; PDA; atherosis; 
sepsis; respiratory dis-
tress 
Ogunyemi 
2003 21 
1992- 
2000 
24-32 w - 
CA+ 254 
CA- 520 
53%  
Kent 
2004 30 
1996- 
2001 
<30 w - 
CA+ 80 
CA- 161 
94% 
(71% 2x) 
GA, BW, sex, surfactant, 
antenatal steroids 
Holcroft  
2004 22 
1999-
2002 
23-34 w Cong anomalies 
CA+ 146 
CA- 208 
?  
Watterberg 
2004a 19 
2001-
2003 
500-999 g  
+ MV 12-48 hrs 
after birth 
Cong anomalies; cong 
sepsis; >twins; postnatal 
steroids 
CA+ 149 
CA- 211 
79%  
de Felice 
2005 23 
? <1250 g Cong anomalies 
CA+ 67 
CA- 49 
?  
Dempsey 
2005 3 
1989- 
1999 
<30 w - 
CA+ 140 
CA- 202 
63% ? 
Mittendorf 
2005b 18 
1995- 
1997 
24-34 w + PL + 
reassuring fetal 
assessment 
Clinical signs of maternal 
infection; preeclampsia 
CA+ 60 
CA- 63 
90%  
Andrews 
2006 29 
1996- 
2001 
23-32 w - 
CA+ 222 
CA- 224 
±87% GA; race; sex 
Mehta 
2006 32 
1999-
2001 
<34 w - 
CA+ 64 
CA- 100 
?  
Richardson 
2006 24 
1995-
2003 
25-34 w + PL / 
suspected CA 
Multiples; cong anoma-
lies 
CA+ 292 
CA- 368 
? 
GA; delivery mode; DM; 
hypertension; abruption; 
IUGR<3% 
Mu  
2008 25 
2000-
2004 
<1250 g Cong anomalies 
CA+ 64 
CA- 55 
45% GA 
Kewitz 
2008 33 
1996-
2000 
<28 w + AGA Cong anomalies 
CA+ 87 
CA- 35 
?  
Lahra  
2009 2 
1991-
2001 
<30 w - 
CA+ 357 
CA- 367 
94% 
(57% 2x) 
GA; 1 min AS<4; multiple 
gestation; hypertension 
Kaukola 
2008 27 
1998-
2002 
<32 w 
Cong anomalies; neona-
tal mortality; general-
ised viral / protozoal 
infection 
CA+ 68 
CA- 99 
86% GA 
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Table 2. Association of histologic chorioamnionitis with respiratory outcome parameters in cohort studies. ↑, 
↓ and = indicate increased, decreased, or unchanged risk after chorioamnionitis, respectively. Abbreviations: 
RDS=respiratory distress syndrome; BPD=bronchopulmonary dysplasia; dexa=postnatal dexamethasone; 
surf=surfactant; MV=mechanical ventilation. aduration of therapy; badjustment for GA and BW Z-score; caddi-
tional adjustment for race, air leak, patent ductus arteriosus, atherosis, sepsis and respiratory distress; dphysi-
ologic BPD definition at 36 w postconceptional age (PCA); ephysiologic BPD definition at 36 w PCA with correction 
for altitude; fBPD defined as O2 at 28 days postnatal age; gBPD definition not mentioned. 
 Outcome (unadjusted) Outcome (adjusted) 
Study 
RD
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Dexter 2000 7 = = =a =a      
Elimian 2000 28 ↑    ↑  =   
Kosuge 2000 26 ↓  =  ↓     
Redline 2002 31  =      ↓b / =c  
Ogunyemi 2003 21 = ↑        
Kent 2004 30  =   = =dexa  =  
Holcroft 2004 22 =         
Watterberg 2004 19  ↑ / =d,e        
de Felice 2005 23 = ↑f ↑ ↑      
Dempsey 2005 3 ↓ =g    ↑pneumonia ↓ =g ↑pneumonia 
Mittendorf 2005 18  ↑f        
Andrews 2006 29       ↓ =  
Mehta 2006 32  ↑        
Richardson 2006 24 = ↑        
Mu 2008 25 = ↑ = / ↑a  ↑  = ↑ =surf / ↑MV 
Kewitz 2008 33  =        
Lahra 2009 2 ↓      ↓   
Kaukola 2009 27 ↓ =     ↓ =  
 
 
Data on the need for respiratory support after chorioamnionitis differ greatly between 
studies. Often parallel to RDS incidence, chorioamnionitis has been reported to increase 
25,28 and decrease 26, as well as not to affect the need for surfactant administration 30. 
Moreover, while some report no effect on the need for mechanical ventilation 25,26, time 
spent on the ventilator 7, and time on additional oxygen supplementation 7, others report 
increased need for ventilatory support or oxygen 23,25.  
The increased incidence of BPD was reproduced in six of the 18 studies 18,21,23-25,32. 
However, gestational age adjustment was performed in only one of these 25. Curiously, the 
risk remained although gestational age was significantly lower in chorioamnionitis infants 
25. Moreover, two of these studies used the old BPD definition of oxygen need at 28 days 
postnatally 18,23. In the remaining reports, multivariate adjustment generally showed no 
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difference in BPD risk or BPD-free survival 3,19,27,29,30, while chorioamnionitis even 
decreased BPD risk in one study 31.  
Incidental reports suggest that chorioamnionitis may be associated with increased 
risks for neonatal pneumonia 3, and severe pulmonary haemorrhage 34. Additional studies 
are needed to investigate these potential associations. 
Respiratory outcome after fetal involvement 
Fetal signs of inflammation accompanying chorioamnionitis are generally felt to reflect a 
more serious inflammatory state. Recent evidence suggests that amnionitis may be an-
other marker of severe intrauterine inflammation, although data linking amnionitis to 
neonatal respiratory outcome are currently lacking 35. Matsuda and colleagues were the 
first to link severe fetal inflammation to BPD development 36. Several studies have since 
addressed the question as to whether fetal inflammation may have additional conse-
quences for neonatal outcome. Reported differences in respiratory outcome parameters 
between chorioamnionitis-exposed patients with and without fetal involvement are 
shown in table 3.  
Fetal inflammation was defined as either chorionic vasculitis 32, umbilical vasculitis 2, 
funisitis 18,22,24,30, “fetal response” 31, or subdivided into polymorphonuclear leukocyte 
(PMN) infiltration of the chorionic plate or the umbilical cord 29. Two studies showed that 
RDS incidence was further decreased in infants with fetal involvement when compared to 
those with only maternal signs of inflammation 2,22, while no additional effect was seen in 
another 24. Multivariate analysis invariably confirmed the association between fetal 
inflammation and decreased RDS incidence 2,24,29, an effect that appears to be additive to 
that of chorioamnionitis alone 2. None of the studies found fetal inflammation to increase 
the risk of developing BPD when compared to only maternal inflammation. Also, no 
overall effect of fetal involvement on BPD risk was seen after adjustment for potential 
confounders 29,31, although in non-white infants severe fetal involvement was associated 
with decreased BPD risk in one study 31.  
Not included in the table is a small case–control study comparing the effects of severe 
acute chorioamnionitis, severe subacute chorioamnionitis (defined by the presence of 
additional mononuclear cells) and subacute necrotising funisitis on neonatal outcome 37. 
Each of these histological states was associated with decreased RDS incidence when com-
pared to matched patients without placental inflammation. Interestingly, BPD incidence 
was greatly increased only in the subacute chorioamnionitis group 37. This suggests that 
both the timing and duration of intrauterine exposure to inflammation may modulate its 
effect on neonatal respiratory outcome. However, the definition of BPD used was not 
mentioned, complicating interpretation of the data. Moreover, others have found no 
association between mononuclear infiltrates and neonatal outcome 29.  
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Table 3. Association of histologic fetal inflammation with respiratory outcome parameters in cohort studies. ↓ 
and = indicate either decreased or unchanged risk after fetal inflammation (CA+F+) versus maternal inflammation 
only (CA+F-). Abbreviations: RDS=respiratory distress syndrome; BPD=bronchopulmonary dysplasia; 
MV=mechanical ventilation; FP=involvement of fetal plate; UC=involvement of umbilical cord. 
 
Outcome  
(unadjusted) 
Outcome (adjusted) 
Study Cohort size RDS BPD Other RDS BPD 
Redline 2002 31 CA+F+ ? 
CA+F- ? 
 =   = 
Kent 2004 30 CA+F+ 40 
CA+F- 40 
 = 
=O2 days    =MV days 
=Surf            =Dexa 
  
Holcroft 2004 22 CA+F+ 87 
CA+F- 59 
↓     
Mittendorf 2005 18 CA+F+ 22 
CA+F- 38 
 =a    
Andrews 2006 29 CA+ 215 
CA+FP+ 178 
CA+UC+ 136 
   
↓ (FP) 
↓ (UC) 
= (FP) 
= (UC) 
Mehta 2006 32 CA+F+ 45 
CA+F- 19 
 =    
Richardson 2006 24 CA+F+178 
CA+F- 114 
= =  ↓  
Lahra 2009 2  CA+F+ 219 
CA+F- 138 
↓   ↓  
Chorioamnionitis and steroids 
Antenatal steroids 
Although chorioamnionitis is an inflammatory state while steroids have an anti-
inflammatory effect, both are capable of enhancing lung maturation, probably partly 
through distinct mechanisms 38,39. Concerns that maternal administration of corticoster-
oids would aggravate the alleged harmful response to intrauterine inflammation have 
initially limited their use in suspected chorioamnionitis. Over recent years, both animal 
experimental studies and clinical studies have provided support for the use of antenatal 
steroids in imminent preterm birth with suspected chorioamnionitis. The human evidence 
is discussed here, while animal experimental evidence has been reviewed recently 38.  
None of the patients reported in the initial Watterberg study received antenatal 
steroids 17. It has been suggested that the inability of many later studies to confirm the 
increased BPD risk, may be attributed to the increased use of antenatal steroids over the 
last 15 years. Several of the aforementioned cohort studies have explored the effect of 
antenatal steroids in patients with histological chorioamnionitis to try to address this 
issue.  
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In line with their established effects in the overall preterm population, antenatal 
steroids also seem to decrease RDS incidence in infants with histological chorioamnionitis. 
Although only Elimian and colleagues found the decrease to be significant 28, a similar 
trend is clearly present in other reports as well 3,40. These observations are supported by 
molecular studies showing increased surfactant protein B in amniotic fluid after antenatal 
steroids in women with intra-amniotic infection 41. In addition, antenatal steroids seem to 
decrease neonatal mortality 3,28 and the incidence of the systemic inflammatory response 
syndrome (SIRS) 40 in chorioamnionitis-exposed infants.  
Despite an apparent reduction in RDS, no significant effect of antenatal steroids on 
BPD incidence has been reported 40. In a logistic regression model to identify risk factors 
for BPD, Kent and Dahlstrom found neither chorioamnionitis nor antenatal steroids to be 
significant predictors 30. On the other hand, all cohort studies with documented antenatal 
steroid exposure rates above 55% have reported either decreased or unchanged 
incidences of RDS and BPD at 36 weeks post-menstrual age (PMA) after chorioamnionitis 
(table 1) 2,3,19,27,29-31. Thus, current high rates of prenatal steroid administration may partly 
explain why the initial observation of an association between chorioamnionitis and BPD is 
no longer reproduced. Taken together, these data further support liberal administration of 
antenatal steroids in case of imminent preterm birth 42, and also when chorioamnionitis is 
present.  
Postnatal steroids 
In light of the association between steroid exposure, chorioamnionitis and respiratory 
outcome, the findings of the hydrocortisone trial are of particular interest. Although hy-
drocortisone did not improve outcome in the general population, subgroup analysis of 
infants with chorioamnionitis showed increased BPD-free survival and decreased mortality 
with postnatal hydrocortisone 19. The effect remained after multivariate analysis and was 
most prominent in infants with fetal signs of inflammation. Thus, anti-inflammatory 
treatment may positively affect pulmonary outcome after antenatal exposure to inflam-
mation. However, the particular study was stopped because of an increased incidence of 
spontaneous gastrointestinal perforations in the treatment group, complicating future 
exploration of this therapeutic option. 
Chorioamnionitis and long term respiratory outcome 
We are aware of only two human studies investigating the association between 
chorioamnionitis and pulmonary outcome beyond the neonatal period. No significant 
differences in the use of supplemental oxygen, bronchodilators and systemic or inhaled 
steroids were reported between patients with and without chorioamnionitis at 18–22 
months’ corrected age in the hydrocortisone trial, irrespective of neonatal hydrocortisone 
treatment 43. A prospective study by Kumar and colleagues was specifically designed to 
60 
investigate the effect of chorioamnionitis on respiratory outcome in early childhood 44. 
Chorioamnionitis and prematurity were shown to have a joint predisposing effect on re-
current wheezing and physician-diagnosed asthma at a mean age of 2.2 years. The effect 
was most prominent in former extremely preterm infants and in African-American chil-
dren. Chorioamnionitis was defined as the presence of either maternal fever or histologi-
cal chorioamnionitis, complicating comparison with studies reporting only histological 
inflammation. Still this study suggests that antenatal inflammation may affect lung devel-
opment beyond the neonatal period and further investigation of the long term pulmonary 
effects of antenatal exposure to inflammation is warranted 45.  
Explaining the inconsistencies 
Reported effects of antenatal inflammation on respiratory outcome differ greatly between 
studies published to date. Figure 1 illustrates how numerous factors complicate interpre-
tation of these associations and may explain at least part of the paradoxical nature of 
findings among different studies. Their potential contributions are discussed in order to 
try to explain the apparent inconsistencies.  
Inclusion and exclusion criteria 
Firstly, inclusion criteria differ greatly between studies. Differences in gestational age and 
the birth weight distributions of the study groups are likely to affect both adverse respira-
tory outcome and its association with chorioamnionitis, since the incidence of both is 
inversely related to gestational age (fig 1). Some studies further selected their cohort by 
including only ventilated infants 17,19, or patients with premature prolonged rupture of 
membranes (PPROM) 7, preterm labour 7,18,24,36, and suspected clinical chorioamnionitis 
24,36. In contrast, cases of clinical chorioamnionitis or suspected maternal infection were 
excluded by others 18,28. The resultant plausible exclusion of more seriously affected 
chorioamnionitis infants 46 may underestimate the effect of chorioamnionitis on RDS re-
duction, since fetal inflammation has been shown to be associated with a more prominent 
reduction in RDS than maternal inflammation alone 2. On the other hand, inclusion of 
mothers based on the presence of preterm labour will preselect mainly patients with his-
tological chorioamnionitis, largely excluding the group of indicated preterm delivery con-
sisting primarily of mothers with preeclampsia, HELLP syndrome (haemolysis, elevated 
liver enzymes and low platelets) and vaginal bleeding. This too is importance since these 
entities have been associated with increased RDS incidence (fig 1) 47-50. Excluding these 
patients may thus underestimate the association between chorioamnionitis and RDS re-
duction and explain why studies doing so have failed to identify this association 7,24. 
The fact that preeclampsia and HELLP syndrome are associated with increased RDS in-
cidence raises another fundamental question. Since these entities and chorioamnionitis 
rarely co-exist, their high incidence in the reference group is an important confounder 
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when assessing the effect of chorioamnionitis on respiratory outcome. It raises the ques-
tion as to whether the decrease in RDS incidence seen after chorioamnionitis may in fact 
reflect an increased risk in patients exposed to preeclampsia or HELLP syndrome. The 
notion that markers of lung maturation are decreased in patients with HELLP syndrome 51, 
while animal studies invariably confirm the lung maturational effects of antenatal inflam-
mation 38,52, suggests that the effect is bidirectional.  
 
 
Figure 1. Diagram showing positive (——) and negative (- - - -) correlations between clinical entities that compli-
cate interpretation of reported associations between chorioamnionitis and neonatal respiratory outcome. 
Abbreviations: HELLP=haemolysis, elevated liver enzymes and low platelets; IUGR=intrauterine growth retarda-
tion; RDS=respiratory distress syndrome; BPD=bronchopulmonary dysplasia.  
 
Disease definitions 
Various histopathological criteria and grading systems for diagnosing chorioamnionitis or 
fetal inflammation exist and likewise, differ importantly between studies. Furthermore, 
the old definition of BPD used by some complicates comparison of this outcome parame-
ter between studies 18,23. Since the incidence of BPD defined as oxygen need at 28 days 
postnatally is more closely related to gestational age than is the more suitable definition 
of BPD at 36 weeks postconceptional age (PCA), the use of the former may account for the 
increased BPD incidence in the chorioamnionitis group through their lower gestational age 
in these studies 23.  
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Confounding factors and covariates 
Since both chorioamnionitis and adverse neonatal outcome are inversely related to gesta-
tional age, adjusting for gestational age differences when exploring associations between 
the two is invaluable. Only a limited number of studies have appreciated this and per-
formed multivariate adjustment to account for this effect 2,3,24,25,27,29-31. Although addi-
tional inclusion of other confounding factors in multivariate models may have increased 
the relevance of the findings in individual studies 2,3,24,29-31, it further complicates compari-
son of the data between them, as does the lack of mentioning the factors included in the 
model 28. Although the fact that gestational age in itself is dependent on many additional 
confounding factors somewhat limits the accuracy of its use in multivariate models 53, the 
magnitude of its confounding nature justifies its use as such.  
Racial differences in chorioamnionitis prevalence and the pulmonary response to 
intrauterine inflammation may account for additional inconsistencies between studies. 
Chorioamnionitis and vaginal bacterial colonisation are more prevalent in non-white 
infants 31,54,55, while white race is a risk factor for BPD 31,56. Redline and colleagues showed 
that in non-white infants, chorioamnionitis was associated with decreased BPD incidence, 
most prominently in infants still ventilated on day 2 31. Conversely, black race augmented 
the increased risk of wheezing and asthma after chorioamnionitis in a follow-up study 44. 
Other important potential confounding variables have been shown to differ importantly 
between white and black mothers and complicate interpretation of the association 
between race, chorioamnionitis prevalence and neonatal outcome 31,55.  
Over the time period the cohort study data have been collected, important changes in 
general practice in neonatal intensive care have taken place. The widespread 
implementation of antenatal steroids is the most obvious and probably the most 
influential example 42. Other practice changes include the increased use of exogenous 
surfactant 57 and non-invasive modes of ventilatory support such as continuous positive 
airway pressure (CPAP) 58. These may reduce secondary lung injury in chorioamnionitis-
exposed infants and partly account for the apparently diminishing association between 
chorioamnionitis and BPD over time 59.  
Exploring the mechanisms 
Sufficient evidence links chorioamnionitis to altered lung maturation and development. In 
animals, antenatal inflammation clearly enhances lung maturation 38,52. The effect has 
been shown to be much greater than that of antenatal steroids, suggesting that at least 
partly distinct mechanisms play a role 39,60. On the other hand, normal lung development 
is disrupted and architectural changes resemble the pathological picture of new BPD cur-
rently seen in preterm infants 38,61-63. Both inflammatory mediators and growth factors 
have been shown to play a role in this process 38,64,65. 
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As for human data two levels of mechanistic evidence may be considered: indirect 
data, investigating associations between covariables and the effect of chorioamnionitis on 
respiratory outcome, and direct data, investigating effects of chorioamnionitis on a 
functional, molecular or cellular level.  
Indirect mechanistic evidence 
Probably the most informative study concerning indirect mechanistic evidence is that 
reported by Van Marter and colleagues 59. In a case–control design, very low birth weight 
infants with BPD were matched with infants without BPD on gestational age, birth weight 
and hospital specific treatment strategies. In these infants chorioamnionitis was associ-
ated with a decreased risk for BPD if infants were ventilated for less than 7 days. However, 
when infants were exposed to mechanical ventilation for more than 7 days or had sepsis, 
chorioamnionitis significantly increased BPD risk, the effect being most prominent in in-
fants with all three risk factors present (fig 1). This suggests that, while antenatal exposure 
to inflammation in itself may reduce BPD risk, it increases the susceptibility of the lung to 
postnatal injurious events. This too may explain part of the Watterberg effect on BPD, 
since only ventilated children were included in their initial study 17. Interestingly, in the 
Watterberg study mean airway pressures needed to ventilate infants were lower initially 
in those exposed to chorioamnionitis but rose above values for non-exposed infants over 
the second week 17. This too is indicative of worsening pulmonary status during mechani-
cal ventilation despite an apparently healthier initial condition.  
Pointing in the same direction is the simple observation that chorioamnionitis 
probably lowers RDS risk without consistently affecting BPD incidence. In other words, 
given the better initial respiratory status reasonably requiring less invasive intervention, 
one would expect BPD risk to diminish as well, since invasive interventional strategies are 
clearly associated with BPD development 66. The notion that this does not happen further 
supports the concept of increased susceptibility of the developing lung to secondary hits 
in the neonatal period following intrauterine exposure to inflammation 67.  
Direct mechanistic evidence 
Not surprisingly, many studies have reported increased levels of pro-inflammatory cyto-
kines, chemokines and other markers of inflammation in cord blood, fetal placental capil-
laries and lung-derived specimens in patients with histological evidence of intrauterine 
inflammation 14,17,18,27,36,68-72. Chorioamnionitis and funisitis have also been associated with 
increased numbers of macrophages and lymphocytes in the lung 73-75. Moreover, both 
maternal and fetal polymorphisms of immunoregulatory genes have been associated with 
both histological chorioamnionitis 76-82 and neonatal sepsis 81, while no association with 
neonatal pulmonary outcome was found 81.  
A considerable body of evidence links Ureaplasma urealyticum to chorioamnionitis, 
preterm birth and the development of chronic lung disease 83,84, as reviewed elsewhere 
85,86. Awareness of the role of Ureaplasma species is invaluable, since its in vitro cultivation 
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needs specific and complex nutritional requirements and regular culture techniques will 
often miss the organism. Molecular techniques may improve the detection of 
chorioamnionitis-associated pathogens including Ureaplasma 87,88. The ability of Urea-
plasma species to induce both lung maturation and injury has been confirmed in animal 
models 89,90. However, antibiotic treatment aimed at eradicating Ureaplasma does not 
seem to improve respiratory outcome in preterm infants 91. Worryingly, in women in 
threatened preterm labour antibiotic treatment is associated with an increased risk of 
cerebral palsy 92. No difference in outcome is seen in a similar trial in women with PPROM 
93.  
In preterm infants not exposed to antenatal steroids, Watterberg and colleagues 
showed that chorioamnionitis was associated with increased serum cortisol levels 94. Since 
corticoids are known stimulants of surfactant synthesis and lung maturation, this could 
partly account for the reduction in respiratory distress in these infants 94, although animal 
data do not support this concept 39.  
In a pathological study in stillborn fetuses, those with chorioamnionitis had decreased 
pulmonary expression of serum and glucocorticoid-inducible kinase (SGK1), a known 
regulator of epithelial Na+ channel (EnaC) and Na+-K+-ATPase 73. The authors suggest that 
this may decrease pulmonary fluid clearance and consequently affect gas exchange, 
predisposing infants to increased ventilatory support. The same group showed that 
proliferation of epithelial cells, endothelial cells and fibroblasts was decreased while 
apoptosis of distal lung epithelial cells was increased in fetuses with chorioamnionitis 95. 
This provides a potential human link between chorioamnionitis and adverse lung 
development. Matrix metalloproteinase-8 and -9, neutrophil products capable of cleaving 
important matrix components, may also play a role in this process. Increased levels in cord 
blood and lung-derived fluid have been linked to both chorioamnionitis 27,96,97 and the 
development of BPD 97-101. Taken together, human studies on mechanistic evidence are 
scarce when compared to animal experimental studies. Additional human data are 
indispensable in exploring the underlying mechanisms of pulmonary developmental 
changes after chorioamnionitis.  
Conclusions 
Evidence is increasing that intrauterine inflammation decreases RDS risk in preterm in-
fants through stimulation of lung maturation. Despite a reduction in RDS, the incidence of 
BPD is unchanged, while recent data suggest the susceptibility for subsequent asthma 
development to be increased. Both altered lung development and enhanced susceptibility 
to secondary injury may account for this effect. Antenatal steroids further decrease the 
incidence of RDS and possibly also that of BPD in chorioamnionitis-exposed infants.  
Although current treatment strategies seem to diminish the adverse effects 
chorioamnionitis has on neonatal outcome in preterm infants, its impact on adverse 
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outcome obviously remains substantial through its causal relationship with preterm birth 
itself. Future research should focus on the mechanisms of inflammation-induced lung 
injury, long term follow-up of pulmonary outcome after chorioamnionitis and ways to 
reduce its adverse effects on lung development and injury repair.  
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Aims of the thesis 
 
As highlighted, the phenotype of BPD seems to be shifting. However, the underlying 
mechanisms are largely unclear, and human data on this issue are scarce. The current 
thesis aims to investigate perinatal factors that contribute to (adverse) lung development 
after preterm birth. Increased knowledge of the contribution of these early factors is im-
portant as it may facilitate better identification of the population at risk, as well as offer 
new possibilities for development of future preventive and therapeutic interventions. 
Given its modulatory role in lung maturation and high prevalence in preterm infants, 
chorioamnionitis will receive special attention. More specifically, the following aims apply 
to this thesis: 
 
 
1. Determine the relative contributions of pulmonary inflammatory mediators 
(Chapter 4), growth factors (Chapter 6), and DNA damage (Chapter 8) in the early 
phase of BPD. 
 
2. Investigate the effects of antenatal factors on prenatal lung development (Chap-
ter 7) and postnatal epithelial repair potential (Chapter 5). 
 
3. Evaluate the association between chorioamnionitis and neonatal (pulmonary) 
outcome (Chapter 9-12), with additional focus on the modulatory effect of ante-
natal steroids (Chapter 9-10).  
 
4. Determine the role of the surfactant response and ‘secondary hits’ in the associa-
tion between chorioamnionitis and BPD (Chapter 11-12). 
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Laboratory and translational observations 
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Abstract 
Background. Early pulmonary inflammation is historically regarded a key element in the 
pathophysiology of bronchopulmonary dysplasia (BPD). We sought to determine the fea-
sibility of quantifying 32 inflammatory mediators in bronchoalveolar lavage fluid (BALF) 
and identify their associations with clinical variables in ventilated preterm infants during 
the first postnatal week.  
Methods. BALF was performed in ventilated infants born before 32 weeks gestation at 
postnatal days 0, 1, 3 and 7. Cytokine and chemokine levels were determined in 50μl of 
BALF using multiplex immunoassay. Associations between clinical variables and growth 
factor levels, normalised by log-transformation, were tested using Student’s t-test. 
Results. 93 BALF samples were obtained from 59 infants. Levels were within the de-
tection range of the assay for the vast majority of mediators. Chorioamnionitis was highly 
associated with increased inflammatory mediator levels at several time points. IL-10, IL-
1β, TNF-α and IL-1α had the highest predictive ability for chorioamnionitis (area under 
ROC curve = 0.94, 0.92, 0.92, and 0.91, respectively; all p<0.01). Surprisingly, increased 
cytokine or chemokine levels did not predict the development of bronchopulmonary dys-
plasia (BPD). Instead, several chemokines were decreased in infants developing BPD. 
Conclusions. Using multiplex immunoassay it is feasible to quantify a wide range of in-
flammatory mediators in small amounts of BALF from preterm infants. Prior exposure to 
chorioamnionitis was the main determinant of postnatal pulmonary inflammation. The 
latter was not predictive of BPD, in line with the concept of ‘new BPD’ being a lung devel-
opmental disease rather than being due to secondary injury. 
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Introduction 
Chronic lung disease of prematurity (bronchopulmonary dysplasia; BPD) has been recog-
nised as a serious pulmonary consequence of preterm birth for over 40 years. Important 
risk factors include mechanical ventilation, oxygen exposure, and infection. These and 
other factors such as antenatal exposure to chorioamnionitis may lead to pulmonary in-
flammation, historically considered a hallmark of BPD development 1,2. In the late nineties, 
it was first recognised that the BPD phenotype may be shifting 3. Whereas secondary lung 
injury was a hallmark of ‘old’ BPD, the current ‘new’ BPD appears to be characterised 
mainly by a developmental arrest of the lung 3. Increased survival of smaller and more 
immature infants, and the increased use of protective treatment strategies for respiratory 
distress after preterm birth, seem important modulators of this change 4,5. 
In line with the recognised role of inflammation in BPD development, numerous stud-
ies have shown associations between increased pulmonary levels of inflammatory markers 
and subsequent BPD development, as reviewed elsewhere 2. Several factors complicate 
interpretation of these studies. In spite of the complexity of pulmonary inflammation and 
BPD pathophysiology, most studies have focused on either a single mediator or a small 
group of markers. In addition, associations between individual mediators and BPD often 
are not in agreement between studies. Finally, most studies of lung-derived fluid have 
primarily sampled the larger airways, whereas BPD is considered a disorder affecting the 
distant lung areas involved in gas-exchange. 
Over recent years, newer techniques have allowed simultaneous detection of an in-
creasing number of markers in small samples. Multiplex immunoassay (MIA) is an example 
of such a technique, which has been used to quantify inflammatory markers in several 
body fluids. Using this technique, others have shown associations between cytokine levels 
in blood and subsequent BPD development 6-8. In the current study we simultaneously 
detected 32 inflammatory markers in BALF from ventilated preterm infants over the first 
postnatal week using MIA. Our aims were to determine the feasibility of this approach and 
relate the measurements to selected clinical variables (chorioamnionitis, antenatal and 
postnatal steroid and caffeine supplementation, sepsis, high frequency ventilation, devel-
opment of BPD, and mortality) in a temporal fashion. 
Methods 
Infant enrolment and characteristics 
Ventilated preterm infants born before 32 weeks gestational age were enrolled in the 
NICUs of the University Hospitals in Maastricht and Leuven. The Medical Ethical Commit-
tees of both hospitals approved the study and written parental consent was obtained. 
Histological chorioamnionitis was diagnosed when >10 neutrophils per high power field 
were present in the chorion or amnion. Betamethasone (2x 12 mg i.m. 24 hrs apart) was 
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administered to the mother in case of imminent preterm delivery. Postnatal hydrocorti-
sone (1.25 mg/kg i.v. once every 6 hrs) was administered when persistent hypotension 
was present despite fluid administration and use of inotropics. High frequency ventilation 
(HFV) was generally used as a rescue ventilatory treatment. Caffeine base was given when 
extubation was anticipated (loading dose 10 mg/kg i.v., initial daily dose 2.5 mg/kg i.v.). 
Clinical sepsis was diagnosed when elevated C-reactive protein and clinical symptoms 
were present, with or without a positive blood culture. Patients were considered to have 
BPD when they were on supplemental oxygen, continuous positive airway pressure (CPAP) 
or mechanical ventilation at 36 weeks postmenstrual age (PMA). 
BALF collection and processing 
BAL was performed at postnatal days 0 (within 24 hrs after birth), 1, 3, and 7 as described 
earlier 9,10. Obviously, no BALF was obtained when infants were not yet on or already off 
the ventilator, thus explaining ‘missing’ values. Briefly, after turning the infant’s head to 
the left, a suction catheter was inserted through a side port of the Trachcare® suctioning 
system until slight resistance was felt. One ml per kg birth weight of sterile isotonic saline 
was gently infused and suctioning was performed while slowly retracting the catheter. The 
procedure was repeated once and the collected fluid was pooled and placed on ice. After 
centrifugation for 10 minutes at 4°C and 300 × g, the supernatant was aliquoted and 
stored at -80°C until analysis. 
Multiplex analysis 
Various inflammatory mediators were measured in BALF using a multiplex immunoassay 
as described previously 11,12. Measurements and data analysis of all assays were per-
formed using the Bio-Plex system in combination with the Bio-Plex Manager software 
version 4.1 using five parametric curve fitting (Bio-Rad Laboratories, Hercules CA, USA). In 
house quality control acquisition was performed as described elsewhere 13. Mediator 
levels were expressed per ml BALF retrieved, according to European Respiratory Society 
task force guidelines 14. Undetectable levels were assigned the value ‘0’, while levels 
above the upper limit of detection were assigned the highest value on the standard curve. 
Statistics 
Continuous variables are expressed as mean ± SD, or median (IQR) in case of non-
normality. Between-group differences were assessed by ANOVA or Kruskall-Wallis test, 
respectively. Dichotomous variables are expressed as n/N (%) and tested using χ2-test. For 
statistical testing of inflammatory mediator levels, these were transformed using the for-
mula [Ln (mediator level + 1)] to account both for non-normality and non-detectable lev-
els. For graphical display, mean transformed subgroup levels were transformed back into 
pg/ml and assigned a color according to a semi-logarithmic color grading scale. ROC curves 
(area under the curve (AUC)) were computed using transformed mediator levels to inves-
tigate the predictive ability of individual mediator levels for certain clinical variables. Mul-
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tivariable models were not computed due to the high number of variables relative to the 
sample size. A two-tailed alpha level of .05 was applied in all analyses. Statistics were 
computed using SPSS 15.0 software. 
Results 
General characteristics 
Ninety-three BALF samples obtained from 59 infants were included. General patient char-
acteristics are shown in Table 1. Significant differences in FiO2, and treatment with hydro-
cortisone and caffeine were present between distinct postnatal days.  
 
 
Table 1. Population characteristics per postnatal day. Postnatal hydrocortisone, caffeine, sepsis, and high fre-
quency ventilation were considered positive when present on that particular day. Continuous variables are 
expressed as mean ± SD, or median (IQR) for skewed data. Dichotomous data are expressed as n/N (%). Overall 
p-values for between-day differences are presented (ANOVA, Kruskall-Wallis test or χ2-test, respectively). Abbre-
viations: FiO2=fraction of inspired oxygen; MAP=mean airway pressure. 
 
 Day 0 (n=27) Day 1 (n=21) Day 3 (n=31) Day 7 (n=14) P value 
Gestational age (wks) 28.0 ± 1.9 28.2 ± 2.0 28.7 ± 1.9 27.4 ± 2.0 .21 
Birth weight (g) 1059 ± 206 1084 ± 237 1073 ± 258 934 ± 262 .27 
Histological chorioamnionitis 5/22 (23) 2/15 (13) 5/23 (22) 3/11 (27) .84 
Antenatal betamethasone 19/27 (70) 15/21 (71) 28/31 (90) 12/14 (86) .19 
Last betamethasone   
(days before birth) 
1 (0-5) 2 (0-8) 5 (1-8) 3 (1-8) .11 
Postnatal hydrocortisone 2/24 (8) 3/21 (14) 9/29 (31) 7/13 (54) .01 
Caffeine 0/23 (0) 1/21 (5) 6/29 (21) 0/13 (0) .02 
Clinical sepsis 1/24 (4) 4/21 (19) 2/29 (7) 1/13 (8) .34 
High frequency ventilation 8/27 (30) 7/21 (33) 6/28 (21) 5/13 (39) .68 
Mean FiO2 0-6 hrs before BAL 
(%) 
41 ± 22 29 ± 11 25 ± 6 26 ± 5 <.001 
Mean MAP 0-6 hrs before BAL 
(cmH2O) 
8.7 ± 2.3 8.6 ± 2.6 7.8 ± 2.1 8.1 ± 1.7 .47 
Bronchopulmonary dysplasia 5/24 (21) 8/20 (40) 10/29 (35) 4/14 (29) .55 
Mortality 6/27 (22) 1/21 (5) 3/31 (10) 1/14 (7) .24 
 
BALF inflammatory mediator levels: detectability 
The levels of each individual mediator were within the detection range of the assay in the 
majority of BALF samples. Undetectable levels were present only for IL-4 (4% and 7% on 
days 0 and 7, respectively), IL-13 (11%, 10%, 19%, and 7% on days 0, 1, 3, and 7, respec-
tively), and CXCL12 (7%, 52%, 13%, and 14% on days 0, 1, 3, and 7, respectively). In con-
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trast, some mediators had levels above the upper detection limit: IL-6 (5% on day 1), CCL2 
(7%, 5%, and 10% on days 0, 1, and 3 respectively), CCL3 (3% on day 3), CCL18 (4%, 10%, 
74%, and 93% on days 0, 1, 3, and 7, respectively), and CXCL8 (11% and 19% on days 0 and 
3, respectively). 
BALF inflammatory mediator levels: general profiles 
Inflammatory mediator profiles in BALF obtained at different postnatal days are shown in 
Table 2 and visualised in Figure 1. When significant differences over time were present, 
essentially three distinct patterns could be identified: a general increase over time (CCL2, 
CCL18, CCL22), a U-shaped pattern with high initial values, followed by a temporary de-
crease and subsequent increase (IL1-α, IL-1β, IL-7, IL-10, IL-17, IL-18, TNF-α, OSM, CCL3), 
and a biphasic pattern with high levels on days 0 and 3 and lower levels on days 1 and 7 
(IL-2, IL-15, IL-22, IL-23, MIF, CCL11, CXCL8, CXCL9, CXCL12). 
 
 
Figure 1. Bronchoalveolar lavage fluid inflammatory mediator profile in total population. Colors represent 
mean log-transformed levels, back transformed into pg/ml for visual display of time-dependent profile. Abbrevia-
tions: IL=interleukin; TNF=tumour necrosis factor; IFN=interferon; OSM=oncostatin M; MIF=macrophage migra-
tion inhibitory factor; OPG=osteoprotegerin. 
 
BALF inflammatory mediator levels: clinical associations 
Associations between BALF levels of inflammatory mediators and various clinical variables 
are shown in Table 3. It is important to note the low number of infants in several group 
comparisons. Despite this, significant and clinically plausible associations between several 
clinical variables and BALF inflammatory mediator levels were observed. Most promi-
nently, histological chorioamnionitis was associated with increased levels of several me-
diators on day 0 (IL-1α, IL-1β, IL-2, IL-5, IL-7, IL-10, IL-12p70, IL17, IL23, TNF-α, IFN-γ, OSM, 
CCL3, CCL5, CCL11, CCL19), and to a lesser extent on days 1 (CXCL12) and 3 (IL-2, IL-7, IL-
12p70, IL-22, IFN-γ, CCL5, CCL11, CXCL10; Table 3; Figure 2). As shown in Figure 3, BALF 
levels of several mediators carry substantial diagnostic potential for histological 
chorioamnionitis within 24 hours after birth. Increased levels were also found in infants 
with sepsis (IL-6 and IL-17), although IL-4 was decreased on day 3 (Table 3). Conversely, 
both antenatal and postnatal steroid exposure were associated with decreased inflamma-
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tory mediator levels on day 7 predominantly. HFV and caffeine treatment showed little 
association with BALF inflammatory mediator levels. 
 
Table 2. Bronchoalveolar lavage fluid inflammatory mediator levels per postnatal day. Levels are presented as 
median (IQR). Overall p-values for between-day differences are presented (Kruskall-Wallis test). Abbreviations: 
IL=interleukin; TNF=tumour necrosis factor; IFN=interferon; OSM=oncostatin M; MIF=macrophage migration 
inhibitory factor; OPG=osteoprotegerin. 
 
 Concentration (pg/ml) 
 Day 0 (n=27) Day 1 (n=21) Day 3 (n=31) Day 7 (n=14) 
P 
value 
IL-1α 36 (15-115) 17 (12-24) 52 (20-117) 128 (19-442) .001 
IL-1β 8 (4-16) 4 (3-8) 9 (5-21) 112 (6-508) .001 
IL-2 64 (34-104) 34 (30-44) 38 (29-62) 38 (30-67) .03 
IL-4 8 (6-11) 7 (6-8) 6 (4-8) 6 (5-7) .14 
IL-5 11 (7-26) 8 (5-11) 10 (7-18) 11 (7-25) .23 
IL-6 279 (99-727) 115 (32-242) 170 (71-551) 528 (62-1105) .07 
IL-7 16 (7-35) 8 (6-10) 13 (7-22) 10 (7-28) .03 
IL-10 21 (15-28) 14 (13-17) 19 (14-23) 20 (14-43) .002 
IL-12p70 306 (222-483) 226 (192-251) 239 (176-338) 212 (159-312) .06 
IL-13 1.3 (0.8-2.8) 0.8 (0.7-1.3) 0.8 (0.3-1.7) 0.9 (0.5-1.5) .14 
IL-15 9 (5-18) 4 (2-5) 8 (4-15) 5 (4-8) <.001 
IL-17 210 (80-407) 73 (52-149) 227 (159-467) 209 (172-314) .001 
IL-18 37 (25-65) 26 (18-34) 65 (35-131) 125 (60-207) <.001 
IL-22 15 (8-21) 7 (6-10) 10 (8-14) 8 (6-10) .002 
IL-23 323 (132-673) 124 (109-155) 258 (124-550) 187 (116-498) .005 
TNF-α 13 (6-41) 6 (5-10) 15 (7-36) 32 (6-229) .003 
IFN-γ 294 (165-577) 192 (150-209) 206 (142-343) 177 (144-556) .15 
OSM 40 (21-107) 16 (15-22) 40 (19-107) 105 (20-625) <.001 
MIF 9254 (6793-14737) 6409 (3894-9802) 12668 (8514-16630) 11226 (9690-12727) <.001 
CCL2 1459 (602-3644) 1479 (837-2246) 3930 (2076-8741) 4945 (1841-7777) <.001 
CCL3 302 (166-770) 151 (135-195) 257 (143-512) 629 (131-2960) .02 
CCL5 72 (57-120) 57 (56-66) 60 (52-77) 56 (45-141) .14 
CCL11 232 (124-444) 101 (89-122) 207 (113-292) 159 (103-253) <.001 
CCL17 20 (13-43) 61 (22-83) 28 (14-76) 18 (9-38) .09 
CCL18 552 (112-1295) 711 (196-1525) 4500 (4493-4500) 4500 (4500-4500) <.001 
CCL19 42 (12-90) 18 (15-26) 21 (12-49) 19 (15-39) .82 
CCL22 62 (21-150) 76 (42-133) 197 (53-372) 137 (64-252) .01 
CXCL8 120 (53-1894) 85 (68-110) 109 (78-1739) 73 (56-80) .006 
CXCL9 30 (24-45) 16 (14-24) 19 (14-34) 16 (13-25) <.001 
CXCL10 98 (75-477) 183 (125-321) 236 (109-735) 307 (144-655) .21 
CXCL12 882 (263-1687) 0 (0-199) 646 (298-953) 314 (60-1023) <.001 
OPG 2079 (1105-2741) 1496 (1045-2133) 1871 (1242-3453) 2140 (1208-2733) .48 
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Table 3. Associations of bronchoalveolar lavage fluid inflammatory mediator levels with clinical variables. 
‘None’ indicates no association, ‘-‘ indicates no statistical testing due to presence of the clinical variable in < 2 
infants. ↑/↓=p<.05 ; ↑↑/↓↓=p<.01; ↑↑↑/↓↓↓=p<.001. AbbreviaƟons: IL=interleukin; TNF=tumour 
necrosis factor; IFN=interferon; OSM=oncostatin M; MIF=macrophage migration inhibitory factor; HFV=high 
frequency ventilation (as opposed to conventional ventilation). 
 Day 0 Day 1 Day 3 Day 7 
Histological 
chorioamnionitis 
IL-1α ↑↑    
IL-1β ↑ 
IL-2 ↑   
IL-5 ↑ 
IL-7 ↑ 
IL-10 ↑ 
IL-12p70 ↑  
IL-17 ↑↑ 
IL-23 ↑ 
TNF-α ↑↑
IFN-γ ↑ 
OSM ↑↑ 
CCL3 ↑↑ 
CCL5 ↑ 
CCL11 ↑ 
CCL19 ↑↑
IL-2 ↑ 
IL-7 ↑ 
IL-12p70 ↑ 
IL-22 ↑ 
IFN-γ ↑ 
CCL5 ↑ 
CCL11 ↑ 
CXCL10 ↑↑ 
None 
Antenatal  
betamethasone 
 
None 
 
None CCL18 ↓ IL5 ↓ 
IFNγ ↓ 
CCL3 ↓ 
Postnatal  
hydrocortisone 
IL12p70 ↓ 
IFN-γ ↓ 
CCL22 ↑↑ 
IL-2 ↓ 
IL-6 ↑ 
CXCL12 ↑↑↑ 
MIF ↑ IL-2 ↓ 
IL-10 ↓ 
IL-12p70 ↓ 
IL-13 ↓ 
IFNγ ↓ 
CCL11 ↓ 
Caffeine - - CCL18 ↑ - 
Sepsis - IL-6 ↑ 
IL-17 ↑↑ 
IL-4 ↓ - 
HFV CXCL9 ↓ None None CXCL10 ↓ 
Bronchopulmo- 
nary dysplasia 
CCL19 ↓↓↓ 
CCL22 ↓ 
CXCL8 ↓ 
None CCL19 ↓ 
MIF ↓ 
CXCL8 ↓ 
CCL5 ↓ 
Mortality None - IL-4 ↓↓ 
IL-5 ↓ 
IL-12p70 ↓
CCL5 ↓↓ 
CCL18 ↑ 
CXCL8 ↑↑↑
CXCL10 ↓↓ 
- 
 
 
Surprisingly, development of BPD was not preceded by increased BALF levels of inflamma-
tory mediators (Table 3; Figure 4). Instead, BPD was associated with decreased levels of 
several factors on distinct postnatal days (day 0: CCL19, CCL22, CXCL8; day 3: CCL19, MIF, 
CXCL8; day 7: CCL5). Likewise, decreased levels of several mediators on day 3 were associ-
ated with neonatal mortality (IL-4, IL-5, IL-12p70, CCL5, CXCL10), although CCL18 and 
CXCL8 were elevated in these infants. 
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Figure 2. Bronchoalveolar lavage fluid inflammatory mediator profile according to chorioamnionitis exposure. 
Colors represent mean log-transformed subgroup levels, back transformed into pg/ml for visual display of time-
dependent profiles. Abbreviations: chorio=chorioamnionitis; IL=interleukin; TNF=tumour necrosis factor; 
IFN=interferon; OSM=oncostatin M; MIF=macrophage migration inhibitory factor; OPG=osteoprotegerin. 
 
 
 
 
Figure 3. Predictive ability of day 0 bronchoalveolar lavage fluid inflammatory mediators for histological 
chorioamnionitis. Bars represent area under the curve (AUC) of ROC curves for chorioamnionitis prediction for 
each individual mediator. *p<.05; **p<.01. Abbreviations: chorio=chorioamnionitis; IL=interleukin; TNF=tumour 
necrosis factor; IFN=interferon; OSM=oncostatin M; MIF=macrophage migration inhibitory factor; 
OPG=osteoprotegerin. 
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Figure 3. Bronchoalveolar lavage fluid inflammatory mediator profile according to development of bron-
chopulmonary dysplasia. Colors represent mean log-transformed subgroup levels, back transformed into pg/ml 
for visual display of time-dependent profiles. Abbreviations: BPD=bronchopulmonary dysplasia; IL=interleukin; 
TNF=tumour necrosis factor; IFN=interferon; OSM=oncostatin M; MIF=macrophage migration inhibitory factor; 
OPG=osteoprotegerin. 
Discussion 
Using MIA, it is feasible to detect 32 inflammatory mediators in small samples of BALF 
obtained from ventilated preterm infants. Levels were outside the detection range of the 
assay for very few markers, and in only a small number of samples. Further analyses sug-
gest important correlations of BALF inflammatory mediator levels with several clinical 
variables, most prominently so with histological chorioamnionitis. Development of BPD 
was preceded by decreased rather than increased pulmonary chemokine levels. 
 Previous studies of inflammatory mediators in lung-derived fluid samples from pre-
term infants have analysed individual markers or at best small groups of markers. Over 
recent years new analysis techniques have become available allowing for detection of an 
increasing number of factors in increasingly small samples. MIA has proven a powerful 
tool to simultaneously quantify individual levels of up to a hundred protein markers in 
both human and animal-derived samples 15. To our knowledge, the current study is the 
first to investigate the feasibility of MIA in lung-derived fluid from preterm infants. We 
demonstrate very good detectability of almost all inflammatory mediators studied in as 
little as 50 μl of BALF. Using this technique we were able to adequately quantify mediators 
previously reported undetectable in lung derived specimens for preterm infants 16,17. 
BALF inflammatory mediator levels were shown to be of clinical relevance, that is, im-
portant correlations were present between their levels and several clinical variables. An-
tenatal exposure to chorioamnionitis resulted in a clear inflammatory pulmonary profile, 
involving both cytokines and chemokines. This is in accordance with earlier human reports 
and animal experimental evidence 1,18. The effect was most prominent directly after birth 
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and was still present three days later. It is interesting to note that IL-10, classically re-
garded an anti-inflammatory cytokine, was the most discriminative determinant of 
chorioamnionitis. This suggests a strong anti-inflammatory response to chorioamnionitis-
induced pulmonary inflammation, despite earlier suggestions of defective anti-
inflammatory mechanisms in preterm infants 19. Importantly, the observed profile after 
chorioamnionitis also involved IL-1, a key modulator of the pulmonary maturational re-
sponse after intrauterine inflammation 20.  
Relative to the prominent inflammatory profile observed after chorioamnionitis, very 
little association between BALF inflammatory mediator levels and sepsis was observed. 
Possible explanations include primarily pulmonary versus systemic inflammation in 
chorioamnionitis versus sepsis, and small group numbers in the sepsis comparisons. Con-
versely, anti-inflammatory effects probably account for the associations between both 
antenatal and postnatal steroid exposure and decreased inflammatory mediator levels in 
BALF. The early association between increased inflammatory markers and postnatal hy-
drocortisone probably represents the particular need for blood pressure support (e.g. 
hydrocortisone) in sicker infants with more pronounced inflammation. We were able to 
confirm a previously reported association between decreased pulmonary levels of IL-
12p70 and neonatal mortality 21. This intriguing link warrants further study. 
Possibly the most striking observation is the absence of any association between in-
creased BALF levels of inflammatory markers and subsequent BPD development. We be-
lieve this is in accordance with the current concept that the pathophysiology of BPD is 
shifting 3. Pulmonary inflammation, along with secondary lung injury, was clearly a hall-
mark of the ‘old’ BPD phenotype 3. In accordance, many early studies have reported asso-
ciations between increased markers of lung inflammation and subsequent development of 
BPD, as reviewed elsewhere 2. As noted earlier, treatment changes have accounted for 
increased survival of more immature infants and a more gentle approach towards treat-
ment of their respiratory problems. These factors contributed to development of ‘new’ 
BPD, thought to represent an arrest in lung development rather than secondary lung in-
jury 3. In accordance, we previously demonstrated significant associations between pul-
monary expression of several growth factors with essential roles in lung development, and 
subsequent BPD development 10. The findings of the current study, involving the same 
cohort, further support a role for lung developmental changes rather than early lung in-
flammation in the pathophysiology of BPD.  
Several studies have identified chorioamnionitis as an important risk factor for BPD 
development. However, in general findings regarding this association are contradictory 1. 
More recent studies support a ‘second hit’ hypothesis, suggesting that prolonged me-
chanical ventilation, postnatal sepsis and decreased surfactant efficacy all modulate the 
association between chorioamnionitis and BPD 22-25. The current finding of early postnatal 
inflammation being associated with chorioamnionitis but not with BPD, further adds to 
the increasing evidence for postnatal modulation of this association rather than it being a 
direct mechanism. 
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While cytokine levels had no relationship whatsoever with BPD, several chemokines 
showed a negative rather than positive correlation with BPD on several postnatal days. 
Although due to the low number of infants no firm conclusions can be made, these obser-
vations appeal for speculation. Decreased levels on days 0 and 3 of both CCL19 and CXCL8 
were associated with BPD. CCL19 is a developmental regulator of lymphoid tissue. De-
creased pulmonary CCL19 has been associated with allergic airway inflammation in mice 
26, and post-transplantation bronchiolitis obliterans in humans 27, supporting a potential 
role of CCL19 deficiency in adverse pulmonary outcome. Paradoxically, CXCL8 has previ-
ously been reported to be positively associated with the BPD phenotype 28,29. However, 
more recent reports have not been able to reproduce this 30-32. Other chemokines nega-
tively associated with development of BPD were CCL5, CCL22 and MIF. Decreased MIF 
expression may indicate a decreased potential for alveolar epithelial repair 33, while  
chemokines such as CXCL8 and the CC chemokines, have been implicated in the regulation 
of angiogenesis 34. Proper angiogenesis is invaluable for normal lung development and has 
been implicated in the pathophysiology of new BPD 35. The association between decreased 
chemokine expression and subsequent BPD development may thus reflect modulation of 
pulmonary angiogenesis, although additional research is needed to investigate this. 
The current study has several limitations. Although considerable in size in its sort, the 
presented cohort is too small to draw firm conclusions with regard to most associations 
between mediator levels and clinical variables. For the same reason no attempt was made 
to perform multivariable analyses by adjusting for potential confounders, or combining 
levels of different mediators in predictive models. Thus, we cannot exclude confounding 
effects in our results. However, as a feasibility study it may guide future research on the 
topic. A second limitation is that BALF can only be derived from ventilated infants, intro-
ducing bias. Others have shown the feasibility of detection of inflammatory markers using 
MIA in exhaled breath condensate 36. Future studies should evaluate the feasibility of 
marker detection in lung-derived fluid obtained by non-invasive techniques, allowing the 
evaluation of cytokine and chemokine profiles in healthier, non-ventilated neonates. 
In conclusion, we have demonstrated the feasibility of quantifying individual levels of 
up to 32 molecular markers in as little as 50 μl of BALF. Given the low yield of BAL from 
ventilated preterm infants, and the evolving potential of collecting lung-derived specimens 
in a less invasive manner, these results are promising. Chorioamnionitis was found to be 
associated with upregulation of a wide range of pulmonary inflammatory mediators 
shortly after birth. We were unable to detect any association between pulmonary inflam-
mation and BPD, whereas BPD was preceded by alterations in pulmonary growth factor 
profiles in the same cohort. These observations are in line with the current concept of a 
shifting pathophysiology of BPD. 
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Abstract  
Background: Preterm infants are highly susceptible to lung injury. While both chorioam-
nionitis and antenatal steroids induce lung maturation, chorioamnionitis is also associated 
with adverse lung development. We investigated the ability of bronchoalveolar lavage 
fluid (BALF) from ventilated preterm infants to restore alveolar epithelial integrity after 
injury in vitro, depending on whether or not they were exposed to chorioamnionitis or 
antenatal steroids. For this purpose, a translational model for alveolar epithelial repair 
was developed and characterised. 
Methods: BALF was added to mechanically wounded monolayers of A549 cells. 
Wound closure was quantified over time and compared between preterm infants (gesta-
tional age < 32 wks) exposed or not exposed to chorioamnionitis and antenatal steroids (≥ 
1 dose). Furthermore, keratinocyte growth factor (KGF) and vascular endothelial growth 
factor (VEGF) were quantified in BALF, and their ability to induce alveolar epithelial repair 
was evaluated in the model. 
Results: On day 0/1, BALF from infants exposed to antenatal steroids significantly in-
creased epithelial repair (40.3 ± 35.5 vs. -6.3 ± 75.0% above control/mg protein), while 
chorioamnionitis decreased woundhealing capacity of BALF (-2.9 ± 87.1 vs. 40.2 ± 36.9% 
above control/mg protein). BALF from patients with chorioamnionitis contained less KGF 
(11 (0-27) vs. 0 (0-4) pg/ml) and less detectable VEGF (66 vs. 95%) on day 0. BALF levels of 
VEGF and KGF correlated with its ability to induce wound repair. Moreover, KGF stimu-
lated epithelial repair dose-dependently, although the low levels in BALF suggest KGF is 
not a major modulator of BALF-induced wound repair. VEGF also stimulated alveolar 
epithelial repair, an effect that was blocked by addition of soluble VEGF receptor-1 
(sVEGFr1/Flt-1). However, BALF-induced wound repair was not significantly affected by 
addition of sVEGFr1. 
Conclusion: Antenatal steroids improve the ability of BALF derived from preterm in-
fants to stimulate alveolar epithelial repair in vitro. Conversely, chorioamnionitis is associ-
ated with decreased wound-healing capacity of BALF. A definite role for KGF and VEGF in 
either process could not be established. Decreased ability to induce alveolar epithelial 
repair after injury may contribute to the association between chorioamnionitis and ad-
verse lung development in mechanically ventilated preterm infants. 
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Background 
Antenatal steroid administration and intrauterine inflammation are two important factors 
capable of promoting lung maturation before birth. Maternal administration of corticos-
teroids in case of anticipated preterm delivery enhances structural lung maturation and 
stimulates surfactant secretion in the fetus, and has become standard of care in current 
obstetric practice 1,2. Intrauterine inflammation, represented histopathologically by 
chorioamnionitis, stimulates lung maturation and decreases the incidence of the respira-
tory distress syndrome (RDS) 3-6.  
Although both chorioamnionitis and antenatal steroids induce lung maturation, a sin-
gle course of antenatal steroids does not seem to affect longer term lung development 
while chorioamnionitis does 1,3,4. Several studies have shown an association between 
chorioamnionitis and subsequent development of chronic lung disease of prematurity 
(bronchopulmonary dysplasia; BPD) 3. Experimental chorioamnionitis in animals, besides 
inducing lung maturation, also results in a pathological picture of alveolar simplification 
similar to that of BPD currently seen in preterm infants 4. This suggests that, although the 
short term effect appears similar, both entities induce different responses affecting sub-
sequent lung development. The notion that antenatal steroid administration further re-
duces RDS incidence in preterm infants exposed to intrauterine inflammation, also sug-
gests that both processes exert their effects at least partially through distinct mechanisms 
3. 
The mechanisms by which the differential effects of antenatal exposure to steroids 
and inflammation induce lung maturation and affect lung development are incompletely 
understood. Different effects of both antecedents on pulmonary growth factor expression 
have been demonstrated 2,4,7. However, lung development is a dynamic, complex and 
tightly regulated process involving multiple cell types, effector molecules and interactions. 
By quantifying biological activity of human lung-derived specimens, all potential modula-
tors present are allowed to conduct their effects. An available model for this purpose is 
the epithelial wound healing model. After induction of a mechanical defect in cultured 
epithelial cells, the effect of a modulator on the ability of the epithelium to restore its 
integrity is evaluated. A translational approach can be made by evaluating the effect of 
human lung-derived fluid obtained in vivo on alveolar wound healing capacity in vitro 8. 
Using this approach relevant differences between distinct patient groups have been re-
ported 9,10.  
This model has not been applied in neonatal pulmonary medicine, while it offers com-
parison of biological activity of lung-derived fluid between patients that were or were not 
exposed to either antenatal steroids or chorioamnionitis to evaluate their effects on the 
ability to restore alveolar epithelial injury. This is of particular interest for chorioamnioni-
tis, since the relationship between chorioamnionitis and adverse lung development has 
been shown to be predominantly modulated by postnatal injury. Clinical data suggest that 
chorioamnionitis in itself is not a risk factor for adverse lung development and may actu-
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ally even be protective, while subsequent postnatal exposure to either sepsis, mechanical 
ventilation or both highly increases BPD risk 11-14.  
We hypothesised that chorioamnionitis reduces the ability of lung-derived fluid to re-
store alveolar epithelial integrity after injury, while antenatal steroids would have a stimu-
latory effect. To test this hypothesis, we developed a translational in vivo-in vitro model 
for alveolar epithelial repair. By collecting bronchoalveolar lavage fluid (BALF) at consecu-
tive postnatal time points, we evaluated the time-dependent postnatal effect of both 
antenatal modulators on BALF biological activity. We further investigated a potential un-
derlying role of two growth factors in the BALF-modulated repair process. Vascular endo-
thelial growth factor (VEGF) is invaluable for normal lung development and is decreased in 
lung-derived fluid from infants developing BPD 15-18, and in sheep lungs after experimental 
chorioamnionitis 7. Keratinocyte growth factor (KGF) is a potent stimulant of alveolar re-
pair after lung injury 19-25 and high KGF in tracheal aspirate fluid (TAF) has been associated 
with absence of BPD 26. Importantly, both growth factors have been shown to enhance in 
vitro alveolar epithelial wound healing 27-29.  
Methods  
Patient characteristics and enrolment 
Patients were eligible for the study when born before 32 weeks gestational age and venti-
lated for RDS. Patients were enrolled in the NICUs in the University Hospitals of Maastricht 
and Leuven. The Medical Ethical Committees of both hospitals approved the study and 
written parental consent was obtained. Chorioamnionitis was diagnosed histologically 
when >10 neutrophils per high-power field were present in the chorion or amnion. Ster-
oids were administered to the mother in case of anticipated preterm delivery by giving 
two intramuscular doses of betamethasone acetate 12 mg 24 hrs apart. 
BALF collection and processing 
BALF was performed at postnatal days 0-1, 3-4, and 7 according to a standard procedure. 
After turning the infant's head to the left, a 6 French suction catheter was inserted 
through a side port of the Trachcare® closed suctioning system until slight resistance was 
felt. Then, one ml per kg birth weight of sterile isotonic saline solution was gently infused 
into the lung. After five seconds, suctioning was performed while slowly retracting the 
catheter. The procedure was repeated once after which the collected fluid was pooled and 
placed on ice. After centrifugation for 10 minutes at 4°C and 300 × g, the supernatant was 
collected, aliquoted and stored at -80°C until analysis. 
In vitro alveolar epithelial wound healing assay 
A549 cells (Sigma-Aldrich, St. Louis, MO, USA) were seeded in 24-well plates (BD, Franklin 
Lakes NJ, USA; approximately 200.000 cells per well) and grown to confluence at 37°C and 
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a 5% CO2-95% air atmosphere in RPMI 1640 medium (Dutch modification; Invitrogen, 
Carlsbad CA, USA) supplied with 10% (v/v) fetal bovine serum (FBS; Greiner Bio-One, 
Kremsmünster, Austria), 200 μM L-glutamine (L-glut; Invitrogen, Carslbad CA, USA) and 10 
U penicillin + 10 μg streptomycin per ml (P/S; Invitrogen, Carslbad CA, USA). A black grid 
printed on a plastic sheet was attached to the bottom of each plate, positioning a 2 × 2 
mm square underneath the centre of each well. Between the lines of each square a rec-
tangular wound was created by gently scratching the monolayer with a sterile 1 ml pipette 
tip. By visualisation, scratches of poor quality were excluded from further analysis before 
start of the experiment. After wounding, each well was washed with 1 ml of phosphate-
buffered saline (PBS (pH 7.4); Invitrogen, Carslbad CA, USA) to remove cellular debris. 
For model validation experiments, effects of FBS and albumin on wound healing were 
evaluated by adding various concentrations of FBS to RPMI 1640 medium + L-glut + P/S or 
human serum albumin (A1887, Sigma-Aldrich, St. Louis MO, USA) to control medium 
(RPMI 1640 + 0.1% (v/v) FBS + L-glut + P/S), using 300 μl medium per well. Various concen-
trations of BALF diluted in control medium were added to wounded monolayers, using 
300 μl medium per well, to evaluate the effect of BALF dilution on wound healing. For this 
purpose, BALF was obtained from a term newborn ventilated for non-pulmonary reasons. 
Effect of BALF, KGF and VEGF on in vitro alveolar epithelial wound healing 
For BALF experiments, BALF was diluted 1:10 in control medium and each well was sup-
plied with 300 μl of this mixture from one BALF specimen after wounding. Control wells 
were supplied with isotonic saline 1:10 in control medium. All experiments were per-
formed in triplicate and each 24-well plate contained three controls. Moreover, each plate 
included one positive control containing 10% (v/v) FBS. In additional experiments, various 
concentrations of human KGF (R&D systems, Minneapolis MN, USA) diluted in control 
medium were added to wounded monolayers in 24-well plates. VEGF (10 pg/ml; R&D 
systems, Minneapolis MN, USA), soluble VEGF receptor 1 (sVEGFr1/Flt1; R&D systems, 
Minneapolis MN, USA) (6 ng/ml) and BALF (1:10 (v/v)) diluted in control medium were 
added in distinct experiments, both solitary and combined, to evaluate their effects on 
alveolar epithelial wound repair. For this purpose BALF from several patients was pooled 
to obtain a large and uniform sample. Each plate contained three controls and quadrupli-
cates for each growth factor/receptor concentration.  
Assessment of wound healing 
Using a Leica DC 300 F camera coupled to a Leica MZ FL III stereomicroscope, each wound 
was photographed at a magnification of 3.15× directly after scratching (t = 0) and at sub-
sequent time points (6 and 24 hours for BALF experiments). Each well was repeatedly 
photographed within the central square of the grid to ensure wound surface measure-
ments were performed at a fixed position.  
The wounded surface was quantified by tracing the wound edge and calculating the 
denuded surface area using Image J software. The assessor was blinded for the experi-
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mental condition of the photograph. Wound healing was assessed by subtracting the 
wound area at a given time point from the wound area at time point zero and expressed 
as the percentage of wound healing of each BALF specimen above the wound healing of 
the control wells (containing 0.1% FBS (v/v)) on the same culture plate. 
Quantification of total protein, KGF, VEGF, sVEGFr1, and M30 
Total protein in BALF was quantified using the NanoOrange® protein quantitation kit (Mo-
lecular Probes, Eugene, OR, USA) according to the manufacturer's instructions. KGF, VEGF 
and sVEGFr1 in BALF were quantified by ELISA (R&D systems, Minneapolis MN) according 
to the manufacturer's instructions, in half-area 96-well ELISA plates (Greiner Bio-One, 
Kremsmünster, Austria). To assess the effect of BALF on induction of apoptosis in A549 
cells, M30 (CK18Asp396-NE; a soluble marker of epithelial cell apoptosis) was quantified in 
the cell culture supernatant at the end of the wound healing experiment (t = 24) using 
ELISA (Peviva AB, Bromma, Sweden). For this purpose, triplicates from the culture experi-
ments were pooled to represent a single patient sample. 
Statistics 
Continuous data are expressed as mean ± standard deviation if normally distributed, and 
median plus interquartile range otherwise. Differences between groups were tested using 
student t-test and ANOVA with post-hoc Bonferroni correction for comparison of two or 
three groups, respectively. Mann-Whitney U test was used for comparison of non-
parametric data and dichotomous variables were tested using χ2-test. Correlations were 
determined using Pearson's correlation coefficient. A test result of p < 0.05 was consid-
ered significant (two-tailed). All analyses were performed using SPSS 15.0 software. 
Results 
FBS stimulates in vitro alveolar epithelial wound healing 
The effect on wound healing of addition of increasing FBS concentrations to culture me-
dium was evaluated in order to validate the model (Figure 1A). Addition of FBS concentra-
tion-dependently stimulated wound closure. A large number of cells detached from the 
culture plate during incubation without FBS over 24 hours, while cell attachment was 
conserved and partial wound closure occurred during incubation in 0.1% FBS. Thus, this 
concentration was used as the optimal concentration to preserve cell viability and deter-
mine the effect of subsequent addition of BALF. 
Wound closure rate 
To evaluate wound closure rate, wounded monolayers were incubated in control medium 
(0.1% FBS (v/v)) and positive control medium (10% FBS (v/v)) with serial photographs 
taken over a 24-hour period (Figure 1B). In control medium, wound closure rate decreased 
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over time, stabilising between four and six hours of incubation. A more gradual decrease 
was observed during incubation with positive control medium. 
 
 
 
Figure 1. Characterisation of the alveolar epithelial wound repair model. A. Effect of addition of various concen-
trations of fetal bovine serum (FBS) to culture medium on in vitro alveolar epithelial wound healing (A; t = 24 
hours). Bars represent mean wound closure + SEM (number of pixels ×1000) of triplicate experiments (*p < 0.05; 
***p < 0.001 vs. control). B. Differences in wound closure rate over time between incubation in control medium 
(0.1% FBS) and positive control medium (10% FBS). Points represent mean wound closure rate + SEM of triplicate 
experiments (**p < 0.01; ***p < 0.001 vs control). C. Effect of addition of various concentrations of bronchoal-
veolar lavage fluid (BALF) from a term newborn diluted in control medium (0.1% FBS) on in vitro alveolar epithe-
lial wound healing (t = 24 hours). Bars represent mean wound closure + SEM (% of control) of triplicate experi-
ments (*p < 0.05; **p < 0.01 vs. control). D. Effects of various concentrations of albumin and BALF (diluted 1:10) 
from a term newborn (total protein in the original BALF specimen was 1.7 mg/ml). Bars represent mean wound 
closure + SEM relative to control medium of triplicate experiments (***p < 0.001 vs. control). 
 
BALF has a concentration-dependent effect on wound closure 
To evaluate the optimal dilution factor for BALF addition to the model, and evaluate the 
concentration dependency of the BALF effect on wound healing, BALF obtained from a 
term newborn was added in various concentrations to the model (Figure 1C). Addition of 
BALF to control medium had a concentration-dependent stimulatory effect on wound 
closure. For further experiments BALF was diluted 1:10. 
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Albumin does not affect wound closure 
Albumin is the most abundant protein in BALF and may be increased in serious lung injury 
as a result of distortion of the blood-air barrier. We evaluated the effect of addition of 
albumin to control medium on wound closure in order to determine whether this would 
affect our model (Figure 1D). Albumin did not significantly affect wound closure, while 
wound closure was significantly enhanced by addition of BALF, which contained less pro-
tein than the highest albumin concentration used in the experiment. 
BALF characteristics and wound healing 
74 BALF specimens were collected from 45 ventilated preterm infants. There was no sig-
nificant difference in total protein or wound closure between different postnatal days 
when all patients were considered (not shown). No significant differences in gestational 
age or birth weight were present between the different patient groups (Table 1). Patients 
with chorioamnionitis had significantly increased BALF total protein at day 7 when com-
pared to patients without chorioamnionitis. No other differences in total protein were 
observed at any postnatal day. Wound closure correlated significantly with BALF total 
protein content (R2 = 0.44; p < 0.001) and wound closure data are corrected for total BALF 
protein content in further analyses. Neither wound closure nor BALF total protein corre-
lated with either gestational age or birth weight. There was a close correlation between 
wound closure at t = 6 and t = 24 (R2 = 0.80; p < 0.001), yet the majority of the effect was 
reached within 6 hours after wound induction. Further analyses were performed only at t 
= 6. 
 
To evaluate the effects of chorioamnionitis and antenatal steroids, the capacity of BALF to 
stimulate alveolar epithelial repair in vitro was compared between infants with and with-
out chorioamnionitis and infants that had and had not received antenatal steroids. 
Chorioamnionitis decreases wound healing capacity of BALF 
BALF obtained from infants with histological chorioamnionitis demonstrated a significantly 
decreased capacity to stimulate in vitro wound healing when compared to BALF from 
infants without histological chorioamnionitis at day 0/1 (Figure 2A). No significant differ-
ences were observed between infants with and without chorioamnionitis on postnatal 
days 3/4 and 7. 
Prenatal steroids stimulate wound healing capacity of BALF 
BALF from infants exposed to antenatal steroids demonstrated a significantly increased 
capacity to stimulate wound healing at day 0/1 when compared to BALF from non-
exposed infants (Figure 2B). No significant differences were observed after day 0/1, al-
though it should be noted that at these time points the no steroids group comprised only 
two patients. 
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Table 1. General characteristics of different patient groups included in the cell culture experiments and the 
total population (including VEGF and KGF quantification). *p < 0.05 vs no chorioamnionitis day 7. Abbreviations: 
chorio = chorioamnionitis; IQR = interquartile range; SD = standard deviation. 
Wound healing  
experimental group 
Chorio 
(n=7) 
No chorio 
(n=30) 
Steroids 
(n=35) 
No steroids 
(n=10) 
Gestational age in weeks 
(median (IQR)) 
26.9  
(25.6-28.7) 
28.6  
(27.0-39.3) 
28.6  
(26.9-29.4) 
27.5  
(26.2-29.7) 
Birth weight in grams  
(mean ± SD) 
1027 ± 246 1069 ± 221 1091 ± 223 1028 ± 268 
BALF total protein day 0/1  
in mg/ml (mean ± SD) 
0.75 ± 0.49 
(n=7) 
0.76 ± 0.47 
(n=28) 
0.82 ± 0.57 
(n=32) 
0.62 ± 0.46 
(n=9) 
BALF total protein day 3/4  
in mg/ml (mean ± SD) 
1.47 ± 2.38 
(n=5) 
1.25 ± 1.34 
(n=14) 
1.09 ± 1.22 
(n=19) 
3.21 ± 3.53 
(n=2) 
BALF total protein day 7  
in mg/ml (mean ± SD) 
0.84 ± 0.39* 
(n=3) 
0.44 ± 0.18 
(n=7) 
0.51 ± 0.28 
(n=9) 
0.95 ± 0.03 
(n=2) 
Total population 
Chorio 
(n=8) 
No chorio 
(n=37) 
Steroids 
(n=51) 
No steroids 
(n=11) 
Gestational age in weeks 
(median (IQR)) 
26.5  
(25.7-28.4) 
28.4  
(26.8-29.4) 
28.6  
(26.9-29.4) 
27.6  
(26.3-29.7) 
Birth weight in grams  
(mean ± SD) 
1014 ± 231 1045 ± 228 1079 ± 236 1045 ± 260 
 
 
To further investigate the possible mechanisms of the effects of chorioamnionitis and 
antenatal steroids on the ability of BALF to repair alveolar epithelial injury in vitro, we 
focused on BALF-induced apoptosis and possible roles for KGF and VEGF, known modula-
tors of lung development and lung injury repair. KGF and VEGF were quantified in BALF 
and added to the model in various concentrations. 
BALF-induced apoptosis is not influenced by chorioamnionitis or antenatal steroids  
To investigate whether the effects of chorioamnionitis and antenatal steroids on day 0/1 
could be explained by differential effects on BALF-induced apoptosis in A549 cells, we 
quantified M30, a soluble marker of epithelial apoptosis, in the cell culture supernatant at 
the end of the wound healing experiment. No significant differences were observed be-
tween culture supernatants of day 0/1 experiments from infants with or without 
chorioamnionitis (841 ± 338 vs. 1085 ± 316 U/L, p = 0.08; Figure 3A), and from infants 
exposed or not exposed to antenatal betamethasone (1028 ± 314 vs. 1041 ± 389 U/L, p = 
0.42; Figure 3B). 
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Figure 2. Effects of chorioamnionitis and antenatal steroids on bronchoalveolar lavage fluid (BALF) wound 
healing capacity. Effect of BALF obtained at different postnatal days from patients with and without chorioam-
nionitis (A), and from patients with and without antenatal steroid exposure (B) on in vitro alveolar epithelial 
wound healing. Bars represent mean wound closure +/- SEM (% above control/mg total protein in BALF) of 
triplicate experiments (*p < 0.05). 
 
 
 
 
Figure 3. M30 detected in culture supernatant after day 0/1 wound healing experiment according to chorioam-
nionitis or betamethasone exposure. Bars represent mean wound closure + SEM per group. No significant 
differences between groups were present. 
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Chorioamnionitis is associated with decreased KGF and less detectable VEGF in BALF 
KGF and VEGF were quantified in 121 BALF specimens from 62 patients, including all BALF 
specimens tested in the in vitro wound healing experiments. KGF was detected in 63%, 
53%, 71% and 56% of BALF specimens obtained on day 0, 1, 3/4 and 7, respectively. KGF in 
BALF correlated positively with gestational age on day 0, but not thereafter (R2 = 0.17, p < 
0.05). VEGF was detected in 88%, 97%, 94% and 100% of BALF specimens obtained on day 
0, 1, 3/4 and 7, respectively. 
KGF concentrations in BALF obtained on day 0 from patients with chorioamnionitis 
were significantly lower than those in BALF from patients without chorioamnionitis (0 (0-
5) vs. 11 (0-27), p < .05; Figure 4A). Furthermore, no KGF was detectable in chorioamnioni-
tis-exposed infants at day 7, while 75% of non-exposed infants had detectable KGF (p < 
0.05). BALF from infants with chorioamnionitis was significantly less likely to contain de-
tectable levels of VEGF on day 0 when compared to BALF from infants without chorioam-
nionitis (67% versus 95%, p < 0.05). Absolute VEGF concentrations were not significantly 
different between infants with or without chorioamnionitis on day 0 (9 (0-17) vs. 17 (7-
29), p = 0.14), or on any other day (Figure 4B). 
 
 
Figure 4. Keratinocyte growth factor (KGF) and vascular endothelial growth factor (VEGF) levels in bronchoal-
veolar lavage fluid (BALF). KGF (A) and VEGF (B) levels in bronchoalveolar lavage fluid (BALF) obtained at differ-
ent postnatal days from patients with and without chorioamnionitis. Points represent individual BALF growth 
factor concentrations, horizontal lines represent medians (*p < 0.05). 
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Concentrations of both KGF and VEGF in BALF correlated significantly with the ability of 
BALF to stimulate alveolar epithelial repair in vitro albeit with low R2 values (R2 = 0.08, p < 
0.05; and R2 = 0.10, p < 0.01, respectively). This illustrates that small part of the decreased 
ability of BALF obtained from patients with chorioamnionitis to stimulate alveolar epithe-
lial repair may result from the decreased availability of these growth factors. No significant 
differences in BALF VEGF or KGF concentrations were detected on any day between pa-
tients that had or had not received antenatal steroids. 
KGF, VEGF and in vitro wound healing 
Remaining BALF was pooled for further experiments aimed at evaluating the roles of KGF 
and VEGF in BALF on wound repair. The pooled BALF contained 40 pg/ml VEGF, but unde-
tectable levels of KGF. In the absence of BALF, VEGF stimulated alveolar epithelial repair, 
an effect that was blocked by addition of sVEGFr1 (Figure 5A). However, addition of the 
same concentrations of sVEGFr1, VEGF, or a combination of both to BALF did not signifi-
cantly alter its effect on wound healing (Figure 5A). To evaluate whether natural abun-
dance of sVEGFr1 in BALF could explain the inability to detect a VEGF-mediated effect on 
BALF-induced alveolar epithelial wound repair, we quantified sVEGFr1 in a subset of re-
maining BALF samples (n = 10). sVEGFr1 was present in significant amounts in all evalu-
ated samples (median [range] = 5.39 [1.28; >10] ng/l). 
Given the undetectable levels of KGF in the BALF pool, no attempts to antagonise the 
effect of KGF in BALF were made. Nevertheless, KGF was shown to have a concentration 
dependent stimulatory effect on wound healing (Figure 5B). 
 
 
 
Figure 5. Vascular endothelial growth factor (VEGF) and keratinocyte growth factor (KGF) effects on alveolar 
epithelial wound repair. Effect of addition of different combinations of bronchoalveolar lavage fluid (BALF), 
VEGF (10 pg/ml), and soluble VEGF-receptor 1 (sVEGFr1; 6 ng/ml) (A), or various concentrations of KGF (B) on in 
vitro alveolar epithelial wound healing. Bars represent mean wound closure + SEM (% of control) of triplicate 
experiments (*p < 0.05, and **p < 0.01 vs control). No significant differences are present between BALF alone 
and BALF with any addition. Significant differences between VEGF, and both sVEGFr1 and VEGF + sVEGFr1 are 
present (both p < .05). 
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Discussion 
We report the development and characterisation of a translational in vivo/in vitro model 
for alveolar epithelial repair. Wound repair was quantified after mechanical wounding of a 
monolayer of A549 cells. FBS and BALF stimulated alveolar epithelial wound healing in this 
model in a concentration-dependent manner. Physiological concentrations of albumin, the 
most abundant protein in BALF, did not affect wound repair indicating that the effect of 
BALF results from actions of specific mediators rather than a general protein or dilutional 
effect. BALF from patients with chorioamnionitis had a significantly reduced capacity to 
induce alveolar epithelial wound healing, while exposure to antenatal steroids was associ-
ated with increased wound healing capacity of BALF shortly after birth. These effects were 
not attributable to alterations in BALF-induced apoptosis. BALF from patients exposed to 
chorioamnionitis contained lower levels of KGF and less detectable VEGF on postnatal day 
0. BALF wound healing capacity correlated with levels of both of these and addition of 
these factors to our model resulted in stimulation of alveolar epithelial repair. However, 
results from subsequent experiments suggest that, at the concentrations present, their 
contribution to BALF-induced wound repair is at best around 10%, although significant 
effects could not be demonstrated.  
Evaluation of epithelial wound healing in vitro is an established model for epithelial 
repair after injury and has been applied and characterised for many different epithelial 
types, including the alveolar epithelium 8. Many investigators have used primary cultures 
of alveolar type II cells isolated from animal lungs in epithelial repair models since A549 
cells do not hold all characteristics of type II cells and freshly isolated human type II cells 
are not readily available 8,27,28. Still, of all human cell-lines available A549 cells share most 
characteristics with alveolar type II cells and are most widely used in human in vitro mod-
els of alveolar physiology. More importantly, in testing the biological activity of human 
BALF, we refrained from using animal-derived type II cells because of concerns regarding 
loss or modulation of biological signal due to species difference, in accordance with previ-
ous reports 9,10. 
We are aware of only two earlier reports evaluating the effect of human lung-derived 
fluid on alveolar epithelial repair in vitro 9,10. Perkins et al. recently showed that in patients 
ventilated for acute respiratory distress syndrome (ARDS), treatment with salbutamol, a 
β2-agonist, significantly increased the ability of BALF to stimulate wound healing in A549-
cells 10. Interestingly, BALF derived from salbutamol-treated patients also contained higher 
levels of VEGF, although the authors show evidence that in their study interleukin-1β (IL-
1β) and not VEGF was the main contributor to epithelial repair 10. In an earlier report, 
pulmonary edema fluid from ventilated adult patients with acute lung injury (ALI)/ARDS 
enhanced wound repair when compared to plasma or edema fluid from ventilated pa-
tients with hydrostatic edema 9. Additional experiments suggested that IL-1β accounted 
for part of this effect, although edema fluid IL-1β concentrations were not reported. IL-1β 
was not evaluated in our model since BALF levels were increased rather than decreased 
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after chorioamnionitis in our cohort (unpublished observations), arguing against its con-
tribution to the decreased wound healing ability of BALF. IL-1 receptor antagonist (IL-1ra) 
induced by BALF in A549 cells or present in the alveolar space may further modulate the 
effects of IL-1β, complicating assessment of its contribution to our findings. Considering 
the inflammatory nature of both ALI/ARDS and chorioamnionitis, one might expect that 
these conditions have similar effects on wound repair. However, chorioamnionitis was 
associated with decreased wound healing in our model whereas BALF from ALI/ARDS 
patients increased wound repair 9. Total protein concentrations in edema fluid from 
ALI/ARDS patients were also significantly higher 9, possibly explaining part of its increased 
wound healing potential. Furthermore age-related differences, differences in specimen 
used (BALF versus edema fluid) and growth factor patterns may partly account for differ-
ences.  
A unique aspect of our study is the evaluation of the differential effect of BALF col-
lected consecutively within distinct patient groups. We observed clear effects of the ante-
natal antecedents studied on wound healing capacity of BALF early after birth, whereas no 
significant effects were present later on. Thus, the effects of modulators of wound healing 
present in BALF on epithelial repair appear to vary over time. Multiple studies have shown 
that short term exposure to injury may induce important and sustained lung damage 30,31. 
Therefore, modulation of lung injury repair by antenatal events seen in our study is likely 
to be of clinical importance, even though the effects are only observed shortly after birth. 
A larger time window between the antecedent and its effect, and possible interference of 
other factors influencing repair capacity may explain disappearance of the association 
over time 32.  
The decreased capacity of BALF from patients previously exposed to chorioamnionitis 
to restore epithelial integrity provides a novel link between antenatal inflammation and 
adverse lung development 3,4,33. Our model is unique in comparing biological activity of 
human BALF between patients with and without chorioamnionitis. The data suggest that 
prenatal exposure to inflammation results in BALF that is less efficient in repairing lung 
injury. This may explain why chorioamnionitis alone may not predispose to adverse lung 
development, while additional exposure to postnatal injurious factors such as mechanical 
ventilation and sepsis highly augments its association with chronic lung disease 11,12. Ex-
perimental chorioamnionitis in preterm sheep increases the inflammatory response to 
postnatal mechanical ventilation, suggesting that inflammatory factors play a role 34. 
Paradoxically, classic inflammatory  cytokines known to be upregulated in chorioamnioni-
tis have previously been shown to stimulate wound repair 8,9. The finding of decreased 
epithelial repair after chorioamnionitis in our model suggests an additional role for other 
modulators. Although our initial experiments suggest that decreased levels of VEGF and 
KGF after chorioamnionitis may explain part of the decreased ability of BALF to induce 
alveolar epithelial repair, a definite contribution of neither factor could be established. We 
were able confirm earlier reports of stimulatory effects of VEGF and KGF on in vitro alveo-
lar epithelial wound healing 27-29, and decreased availability of VEGF after chorioamnionitis 
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7. Moreover, both KGF and VEGF levels in BALF are linked to development of BPD in previ-
ous reports 15-17,26, as well as in our sample 18. A considerable amount of animal experi-
mental data further supports a pivotal role of both factors in lung development and repair 
19-25,27,28,35. Thus, the early decrease in BALF levels of KGF and VEGF is likely to contribute 
to adverse lung development seen after chorioamnionitis, although our experiments sug-
gest that their effects are primarily exerted through mechanisms other than BALF-induced 
alveolar epithelial repair. The overall low levels of VEGF and KGF as compared to adult 
studies may reflect developmental regulation as well as differences in BAL technique (e.g. 
non-bronchoscopic versus bronchoscopic). Furthermore, the potential role of the appar-
ent abundance of sVEGFr1 in the alveolar space in decreasing VEGF bioavailability war-
rants further investigation 36.  
Although antenatal steroids reduce RDS incidence, enhance structural maturity of the 
lung and improve lung function 1,2,37, BPD incidence seems unaffected 1. However, when 
only studies using betamethasone are considered, BPD is significantly reduced 1. By dem-
onstrating an association between antenatal betamethasone and enhanced alveolar 
epithelial repair, our data provide a potential link between betamethasone exposure and 
improved lung development.  
An earlier study found no effect of corticosteroids on airway epithelial repair 38, while 
another showed dexamethasone to inhibit wound repair initially, while inducing extended 
subsequent wound-healing potential in bronchial epithelial cells 39. Thus, the direct effect 
induced by corticosteriods seems to differ from the longer term changes that affect the 
cellular response to injury. In sheep, maternal betamethasone acetate administration 
results in peak fetal plasma concentrations after 3 hours, dropping below the detection 
limit within 8 hours 40. Since infants in our study were exposed to maternal steroids hours 
to weeks before birth, indirect mechanisms most likely explain the increased BALF wound 
healing capacity seen in our model. We were unable to detect betamethasone effects on 
BALF-induced apoptosis, and VEGF or KGF levels, suggesting that other factors play a role 
in this process.  
Our model obviously is a simplified representation of the in vivo situation, since the 
alveolar space consist of a combination of different cell types. Communication between 
these cells cannot be investigated in our current model. Still we feel this model is an im-
portant first step in the identification of risk factors and protective factors in lung injury 
repair and of the underlying mechanisms at a molecular level. Larger patient groups are 
needed to further evaluate possible other modulating factors, such as oxygen exposure, 
mechanical ventilation characteristics and the combined effects of chorioamnionitis and 
antenatal steroids 3,41. 
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Conclusion 
A translational in vivo/in vitro model for alveolar epithelial repair using BALF as a reflection 
of the in vivo pulmonary environment, was characterised and applied. The evaluation of 
alveolar epithelial repair capacity of BALF serially collected in distinct patient groups pro-
vides a unique means by which biological activity of human specimens can be linked to 
clinical parameters over time. BALF obtained shortly after birth from preterm infants ex-
posed to chorioamnionitis had a significantly decreased ability to restore alveolar epithe-
lial integrity in vitro, providing a biological link between chorioamnionitis and adverse lung 
development. Our data suggest that the contribution of VEGF and KGF in BALF to this 
effect is probably small, although their decrease after chorioamnionitis may well modulate 
the susceptibility for adverse lung development. Conversely, prenatal steroid administra-
tion was shown to significantly increase wound-healing capacity of BALF in preterm in-
fants. Additional research is needed to study the underlying mechanisms of modulation of 
alveolar epithelial repair by chorioamnionitis and antenatal steroids. Further evaluation of 
biological activity of human specimens in translational models like the one presented here 
carries great potential to study mechanisms underlying disease associations. 
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Abstract  
Chronic lung disease of prematurity (bronchopulmonary dysplasia; BPD) is characterized 
by an arrest in lung development. We hypothesized that early alterations in pulmonary 
expression of growth factors important for normal lung development would precede de-
velopment of BPD.  
Bronchoalveolar lavage fluid (BALF) was obtained from ventilated preterm infants (n = 
62) on postnatal d 0, 1, 3, and 7 and analyzed for total phospholipids (PL), VEGF, PDGF-BB, 
TGF-α and -β1, granulocyte macrophage colony stimulating factor (GM-CSF), and kerati-
nocyte growth factor (KGF). Levels (Ln transformed) were compared between infants 
developing BPD and BPD-free survivors, adjusted for potential confounders.  
BPD was associated with higher overall GM-CSF (β (95% CI) = 0.69 (0.13;1.25); p < 
0.05), lower overall latent TGF-β1 (β (95% CI)= –1.19 (–1.87, –0.39); p < 0.01) and total PL 
(β (95% CI) = –0.64 (–1.23, –0.05); p < 0.05), and lower d 0 and 3 levels of VEGF (mean 
difference (95% CI) = –1.75 (–2.72, –0.77), p < 0.001; and –1.18 (–2.30, –0.06), p < 0.05, 
respectively) and TGF-α (mean difference (95% CI) = –0.73 (–1.42, –0.04), p < 0.05; and –
1.01 (–1.64, –0.38), p < 0.01, respectively). Day 0 VEGF levels had the highest predictive 
value for BPD (area under receiver operating characteristic curve = 0.87; p < 0.01).  
In conclusion, substantial alterations in BALF growth factor levels are present in in-
fants developing BPD. An early imbalance in pulmonary growth factors may contribute to 
the developmental arrest of the lung seen in BPD. 
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Introduction 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease seen in preterm infants, af-
fecting around 35% of extremely low-birth weight infants. BPD is associated with recur-
rent respiratory infections, frequent rehospitalization, and adverse neurodevelopmental 
outcome. The classical BPD picture of emphysema, inflammation, and fibrosis, as originally 
described by Northway et al. 1, has been replaced by one best characterized as an arrest in 
lung development 2. This shift coincided with the introduction of surfactant replacement 
therapy and antenatal steroid administration, which have allowed smaller and less mature 
infants to survive.  
The pathophysiology of BPD is complex and is an interplay between iatrogenic injury 
due to both mechanical ventilation and oxygen supplementation and other factors such as 
genetic predisposition and inflammation 3. The latter has been shown to predispose the 
infant to BPD already before birth, as indicated by the relationship between chorioamnio-
nitis and adverse lung development 4,5. In recent years, accumulating evidence indicates 
that growth factors play an important role in the developmental arrest of the lung seen in 
“new BPD” 3,6. However, much of this evidence is derived from experimental animal data. 
Studies on pulmonary growth factor concentrations and indicators of lung maturation in 
preterm infants are scarce. Most of them report on analyses on tracheal aspirate fluid 
(TAF), retrieving epithelial lining fluid of more proximal origin than bronchoalveolar lavage 
(BAL) 7. Moreover, very few studies have investigated concurrent coexpression of various 
growth factors in human specimens.  
The objective of this study was to simultaneously quantify concentrations of several 
growth factors in BAL fluid (BALF) obtained from ventilated preterm infants during the 
first week after birth. Growth factors were selected based on their previously demon-
strated roles in lung development and chronic lung injury. VEGF is a known stimulant of 
alveolarization and vascularization and is invaluable for normal lung development 3,8. 
Keratinocyte growth factor (KGF) is an epithelial mitogen with an important role in lung 
injury repair 9, while PDGF-BB has been linked to compensatory lung growth 10, in addition 
to adverse lung development and fibrosis 11. The hematopoietic cytokine granulocyte 
macrophage colony stimulating factor (GM-CSF) is up-regulated by inflammation 12 and 
plays an important role in surfactant homeostasis 13. TGF-α disrupts lung morphogenesis 
in mice 14 and has been implicated in the pathogenesis of BPD 15. Finally, TGF-β1 is a cyto-
kine essential for normal lung development 16, although its overexpression decreases 
alveolarization in animal models 17. It was hypothesized that early differences in BALF 
expression patterns of these growth factors would be present between infants who even-
tually developed BPD and those who did not. In addition, we quantified BALF total phos-
pholipids (PL) as a general measure of lung maturation. 
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Materials and methods 
Patient characteristics and enrolment 
Patients were eligible for the study if they were born before 32-wk gestational age and 
ventilated for respiratory distress syndrome (RDS). Patients were enrolled in the NICUs of 
the University Hospitals in Maastricht and Leuven. The Medical Ethical Committees of 
both hospitals have approved the study and written parental consent was obtained. BPD 
was diagnosed according to Jobe and Bancalari 18. Chorioamnionitis was diagnosed his-
tologically when >10 neutrophils per high power field were present in the chorion or am-
nion. Betamethasone (2 × 12 mg i.m., 24 h apart) was administered to the mother in case 
of imminent preterm delivery.  
BALF collection and processing 
BAL was performed at postnatal d 0 (within 24 h after birth), 1, 3–4, and 7 according to a 
standard procedure. After turning the infant’s head to the left, a 6F suction catheter was 
inserted through a side port of the Trachcare closed suctioning system until slight resis-
tance was felt. Then, 1 mL/kg birth weight of sterile isotonic saline was gently infused into 
the lung. After 5 s, suctioning was performed while slowly retracting the catheter. The 
procedure was repeated once after which the collected fluid was pooled and placed on 
ice. After centrifugation for 10 min at 4°C and 300 × g, the supernatant was collected, 
aliquoted, and stored at –80°C until analysis.  
Quantification of growth factors and total PL in BALF 
VEGF, KGF, PDGF-BB, GM-CSF, TGF-α, and TGF-β1 and were quantified by ELISA (R&D 
systems, Minneapolis, MN) according to the manufacturer’s instructions, in half-area 96-
well ELISA plates (Greiner Bio-one, Alphen a/d Rijn, The Netherlands). Both active and 
total (latent + active) TGF-β1 were quantified. The concentration of latent TGF-β1 was 
obtained by subtracting the amount of active TGF-β1 from the total TGF-β1, quantified 
after acid activation of each individual sample. As a general measure of BALF surfactant 
content, total PL were quantified according to Stewart 19, with minor modifications to 
analyze small quantities. Briefly, fluid was evaporated from 15 μL of BALF by heating at 
50°C under continuous nitrogen gas flow. The dried material was reconstituted in 100 μL 
of chloroform and vortexed. Then, 50 μL of ammonium ferrothiocyanate was added, and 
the mixture was vortexed thoroughly for 30 s. The organic phase (containing the stained 
PL) was separated from the inorganic phase by centrifugation (10 min, 2000 rpm). Then, 
75 μL of the organic phase of each sample was transferred into a 96-well glass-coated 
microtiter plate (Instrument Solutions, Nieuwegein, The Netherlands), and extinction was 
measured at 488 nm in a Spectra Max M2 photospectrometer using a phosphatidylcholine 
standard curve (range, 0–200 μg/mL). Growth factor and PL concentrations were consid-
ered detectable when they were above background levels of their respective assays. All 
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concentrations are expressed per milliliter of BALF retrieved according to European Respi-
ratory Society task force guidelines 20.  
Univariable analyses 
Data are expressed as mean ± SD or median with interquartile range (IQR) where appro-
priate. Correspondingly, differences between groups were tested using either t test or 
Mann-Whitney U test. Dichotomous variables were tested using χ2 test. Correlations be-
tween variables were determined using Spearman’s ρ correlation coefficient.  
Multivariable analyses—the marginal model 
To obtain a more symmetric distribution of the positively skewed growth factor levels 
while appreciating undetectable levels (which were entered as “0”), concentrations were 
transformed using the following formula: Ln ([growth factor] + 1). Marginal models were 
fitted to evaluate average changes in transformed growth factor concentrations over time 
between infants with or without BPD, adjusting for other potential confounders (21). Indi-
vidual infants were taken as random factor and time (categorized) as well as the other 
explanatory variables constituted the model’s fixed effect part. A top down procedure was 
handled for variable selection, except for BPD and gestational age, which were always 
kept in the model. Model parameters were estimated via the restricted maximum likeli-
hood method. The final variance-covariance matrix was selected via likelihood ratio tests. 
Based on the estimated mean transformed growth factor values, Bonferroni post hoc 
analysis was applied for multiple pairwise comparisons between groups and time points. 
For marginal model analysis, infants with mild, moderate, and severe BPD were clustered 
in a single BPD category. Antenatal betamethasone exposure was categorized according to 
time between exposure and birth (<24 h, 2–7 d, and >7 d). One of the advantages of the 
marginal model analysis is that all individual data are used for the parameters estimation, 
not only of those subjects with complete data 21. To check whether the occurrence of 
missing values depended on the predictors at stake, a logistic regression model was ap-
plied. Explanatory variables significantly associated with missingness were kept in the final 
marginal model.  
Multivariable analyses—logistic regression for prediction of BPD 
Backward logistic regression analysis was performed to evaluate which combination of 
growth factors in BALF best predicted the development of BPD at each postnatal day. 
Receiver operating characteristic (ROC) curves for BPD prediction were computed using 
individual predicted probabilities derived from the final logistic regression model. In all 
analyses, an alpha level of 0.05 was applied (two-tailed). All analyses were performed 
using SPSS 15.0 software. 
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Results 
General characteristics 
One hundred twenty-one BALF specimens were obtained from 62 patients. At 36-wk PMA, 
34 patients fulfilled the diagnostic criteria of BPD. In further analyses, the latter are com-
pared with patients alive without BPD at 36-wk PMA (n = 21). Seven patients had died and 
were excluded from further analyses. General characteristics, ventilatory settings, and 
oxygen requirement for patients with and without BPD are shown in Table 1. Infants who 
developed BPD were more often born to mothers with preeclampsia, had lower birth 
weight, and had higher oxygen requirement just before BALF collection on d 0 and 1. 
 
 
Table 1. General characteristics and ventilatory requirements of infants included in the study. * p < 0.001. † p < 
0.05. ‡ p < 0.01. FiO2, fraction of inspired oxygen; MAP, mean airway pressure. 
   No BPD (n=21) BPD (n=34) 
Gestational age (wks) 29.0 ± 1.8 28.0 ± 1.8 
Birth weight (g) 1212 ± 136 1005 ± 263* 
Histological chorioamnionitis (%) 19 17 
Preeclampsia (%) 10 38† 
< 24 hrs before birth 33 24 
1-7 days before birth 14 38 Antenatal steroids  
>7 days before birth 33 27 
day 0 28 ± 10 52 ± 25‡ 
day 1 25 ± 5 32 ± 10† 
day 3 25 ± 7 27 ± 6 
Mean FiO2  
0-6 hrs before BAL (%) 
day 7 24 ± 3 26 ± 6 
day 0 8.8 ± 2.4 8.6 ±2.4 
day 1 8.2 ± 2.7 8.3 ± 2.4 
day 3 7.9 ± 2.0 8.2 ± 2.4 
Mean MAP  
0-6 hrs before BAL (cm H2O) 
day 7 8.3 ± 2.0 9.2 ± 1.9 
day 0 11 14 
day 1 9 24 
day 3 13 20 
BALF specimens collected (n) 
day 7 3 13 
 
Univariable analyses 
Growth factor and total PL concentrations for infants who did and those who did not de-
velop BPD are shown in Table 2. In unadjusted analyses, patients developing BPD had 
lower VEGF on d 0 and 3, lower TGF-α on d 0, and latent TGF-β1 on d 0. Conversely, both 
GM-CSF and active TGF-β1 were more likely to be detected in infants developing BPD on d 
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7. Infants with BPD had a higher active versus latent TGF-β1 ratio on d 3 [mean (CI) = 0.06 
(0.02–0.27) vs 0.01 (0.01–0.03); not shown]. Significant positive correlations were ob-
served between BALF levels of several growth factors on each postnatal day (Table 3). 
Moreover, total PL correlated with levels of VEGF and both active and latent TGF-β1 on 
several days. 
Multivariable analyses—the marginal model 
Figure 1 shows BALF growth factor and total PL concentrations as predicted by the mar-
ginal model for infants with BPD and those without. For ease of graphical display, model 
predicted values were transformed back to represent growth factor levels in picograms 
per milliliter. Model parameter estimates for each growth factor are shown in Table 4. For 
all marginal models, a diagonal covariance matrix of the outcome responses was selected 
as the most appropriate.  
BPD was associated with increased GM-CSF but lower latent TGF-β1 and total PL dur-
ing the entire study period in these analyses (Fig. 1D, E, and H). For VEGF and TGF-α, the 
interaction term (BPD × time) was retained in the model because of its significant contri-
bution, thus allowing for time dependent effect of BPD status on growth factor concentra-
tion (Table 4). Pairwise comparisons for individual time points showed BPD to be associ-
ated with decreased levels of both VEGF and TGF-α on d 0 and 3 [VEGF: mean difference 
(95% CI)=–1.75 (–2.72, –0.77), p < 0.001; and –1.18 (–2.30, –0.06), p = 0.04, respectively 
(Fig. 1A); TGF-α: mean difference (95% CI) = –0.73 (–1.42, –0.04), p = 0.04; and –1.01 (–
1.64, –0.38), p = 0.003, respectively (Fig. 1E)]. Marginal model analysis showed no signifi-
cant association between BPD and BALF concentrations of KGF, PDGF-BB, and active TGF-
β1.  
From the marginal model analyses, several other variables emerged as significant in-
dependent predictors of bronchoalveolar growth factor concentrations (Table 4). KGF and 
VEGF concentrations were shown to increase with advancing gestational age. Conversely, 
preeclampsia was associated with decreased VEGF, KGF, and GM-CSF. Both antenatal 
steroid exposure >7 d before birth and exposure to high fraction of inspired oxygen were 
associated with increased levels of PDGF-BB. Importantly, no explanatory variable was 
associated with whether data were missing (BALF not obtained). 
Multivariate analyses—ROC curves 
Development of BPD was best predicted using a combination of VEGF and TGF-α levels on 
d 0 [area under the ROC curve (AUC) = 0.92 (0.82–1.03); p < 0.001]. A slightly lower predic-
tive value was obtained using VEGF, TGF-α, and latent TGF-β1 levels on d 3 [AUC = 0.88 
(0.74–1.01); p < 0.001]. The best single predictor was VEGF on d 0 (AUC = 0.87, p = 0.002). 
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Table 2. Growth factor and total phospholipids concentrations in bronchoalveolar lavage fluid from infants 
who did or did not develop bronchopulmonary dysplasia (BPD and no BPD, respectively). * p < 0.01 vs no BPD. 
† p < 0.05. 
Concentration (median (IQR)) Detectable (%) 
 
 
Day no BPD BPD no BPD BPD 
0 28 (12-73) 5 (1-15)* 100 79 
1 43 (16-60) 27 (10-61) 100 96 
3 205 (91-291) 47 (26-98)* 100 90 
 
VEGF 
(pg/ml) 
 
7 223 (30-469) 102 (59-212) 100 100 
0 5 (0-29) 4 (0-15) 64 57 
1 0 (0-8) 6 (0-18) 33 58 
3 8 (0-28) 9 (1-18) 69 75 
 
KGF 
(pg/ml) 
 
7 0 (0-6) 2 (0-9) 33 62 
0 0 (0-8) 2 (0-6) 46 64 
1 0 (0-7) 0 (0-4) 44 33 
3 10 (4-22) 5 (2-16) 100 95 
 
PDGF-BB 
(pg/ml) 
 
7 0 (0-7) 5 (3-11) 33 85 
0 2 (1-5) 2 (1-8) 82 93 
1 6 (2-8) 3 (1-13) 89 88 
3 53 (21-123) 65 (13-162) 100 95 
 
GM-CSF 
(pg/ml) 
 
7 15 (0-38) 29 (7-97) 67 100† 
0 7 (5-16) 4 (1-7) 100 100 
1 2 (1-7) 3 (2-5) 100 100 
3 5 (2-8) 2 (0-2)* 100 85 
 
TGF-α 
(pg/ml) 
 
7 3 (1-4) 2 (0-5) 100 85 
0 4 (1-6) 2 (0-4) 91 57 
1 5 (4-6) 4 (0-9) 100 71 
3 8 (5-8) 9 (4-16) 92 95 
 
active TGF-β1 
(pg/ml) 
 
7 0 (0-21) 11 (7-21) 33 100* 
0 132 (60-176) 17 (2-47)* 100 79 
1 95 (51-249) 72 (15-132) 100 92 
3 260 (53-566) 58 (11-213) 77 80 
 
latent TGF-β1 
(pg/ml) 
 
7 276 (44-348) 256 (128-475) 100 100 
0 161 (43-246) 22 (0-162) 91 71 
1 37 (19-195) 44 (18-89) 100 100 
3 85 (55-221) 73 (31-120) 100 96 
Total PL 
(μg/ml) 
 
7 92 (70-115) 55 (32-118) 100 100 
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Table 3. Significant correlations between bronchoalveolar lavage levels of individual growth factors and total 
phospholipids (PL) on different postnatal days. Numbers represent R2 values. * p < 0.001. † p < 0.01. ‡ p < 0.05. 
 Day 
latent 
TGF-β1 
active 
TGF-β1 TGF-α GM-CSF PDGF-BB KGF VEGF 
0 .34* .25† .19‡ - - - - 
1 - - - - - - - 
3 - - - - - - .13‡ 
Total PL 
7 .56† - - - - - .38‡ 
0 .36* .29† .13‡ - - .18‡  
1 .15‡ .14‡ .14‡ - - -  
3 .12‡ - .24† .24† .20† -  
VEGF 
7 .48† .25‡ - .62* - -  
0 .17‡ .22† .25† - .25†   
1 - - - - -   
3 - - - .27† .46*   
KGF 
7 - - - - .36‡   
0 - .14‡ .31† -    
1 .23† - .48* -    
3 - - - .38*    
PDGF-BB 
7 - .48† - -    
0 - - -     
1 - - -     
3 - - -     
GM-CSF 
7 .28‡ .43† -     
0 .62* .15†      
1 .60* .14‡      
3 .38* -      
TGF-α 
7 - -      
0 .32†       
1 .44*       
3 -       
active TGF-β1 
7 .39†       
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Table 4 (part 1). Parameter estimates and CIs from the marginal models for individual growth factors and total 
PL in bronchoalveolar lavage fluid. Figures represent β (95% CI) per unit increase for continuous factors or vs the 
reference group for nominal factors. * p < 0.05. † p < 0.01. FiO2, fraction of inspired oxygen. 
Parameter VEGF KGF PDGF-BB GM-CSF 
Intercept 
-0.82 
(-5.04; 3.41) 
-4.68 
(-9.98; 0.61) 
-1.55 
(-5.70; 2.57) 
-1.58 
(-5.61; 2.44) 
Day 1 (vs. day 0) 
-0.11 
(-1.21; 0.98) 
-0.03 
(-0.89; 0.84) 
0.01 
(-0.75; 0.75) 
0.40 
(-0.22; 1.02) 
Day 3 (vs. day 0) 
1.54 
(0.49; 2.60)† 
0.46 
(-0.41; 1.34) 
1.29 
(0.50; 2.08)† 
2.44 
(1.71; 3.17)† 
Day 7 (vs. day 0) 
1.18 
(-0.58; 2.94) 
-0.31 
(-1.19; 0.58) 
1.08 
(-0.16; 2.01) 
1.51 
(0.69; 2.33)† 
BPD 
-1.74 
(-2.72; -0.77)† 
0.53 
(-0.15; 1.21) 
-0.13 
(-0.70; 0.43) 
0.69 
(0.13; 1.25)* 
BPD x day 1 
1.89 
(0.51; 3.27)† 
- - - 
BPD x day 3 
0.57 
(-0.82; 1.95) 
- - - 
BPD x day 7 
2.01 
(0.01; 4.01)* 
- - - 
GA 
(per wk increase) 
0.15 
(0.01; 0.30)* 
0.23 
(0.04; 0.41)* 
0.05 
(-0.09; 0.26) 
0.10 
(-0.04; 0.23) 
Chorioamnionitis - 
-0.74 
(-1.52; 0.04) 
- - 
Preeclampsia 
-0.93 
(-1.52; -0.34)† 
-0.96 
(-1.66; -0.25)† 
-0.63 
(-1.27; 0.01) 
-1.09 
(-1.66; -0.53)† 
Antenatal steroids 
<24 hrs before birth 
- - 
0.43 
(-0.32; 1.17) 
- 
Antenatal steroids 
2-7 days before birth 
- - 
0.46 
(-0.43; 1.35) 
- 
Antenatal steroids 
>7 days before birth 
- - 
1.25 
(0.44; 1.35)† 
- 
FiO2 
(per 0.1 increase) 
- - 
0.25 
(0.04; 0.46)* 
- 
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Table 4 (part 2). Parameter estimates and CIs from the marginal models for individual growth factors and total 
PL in bronchoalveolar lavage fluid. Figures represent β (95% CI) per unit increase for continuous factors or vs the 
reference group for nominal factors. * p < 0.05. † p < 0.01. FiO2, fraction of inspired oxygen. 
Parameter TGF-α active TGF-β1 latent TGF-β1 total PL 
Intercept 
3.40 
(0.77; 6.03)* 
1.18 
(-2.84; 5.20) 
1.62 
(-4.00; 7.23) 
0.89 
(-3.52; 5.29) 
Day 1 (vs. day 0) 
-1.00 
(-1.68; -0.31)† 
0.15 
(-0.38; 0.69) 
0.90 
(0.03; 1.77)* 
0.21 
(-0.78; 1.19) 
Day 3 (vs. day 0) 
-0.34 
(-0.99; 0.32) 
0.97 
(0.43; 1.51)† 
0.61 
(-0.47; 1.69) 
0.46 
(-0.54; 1.46) 
Day 7 (vs. day 0) 
-1.15 
(-2.32; -0.01) 
1.03 
(0.30; 1.76)† 
2.21 
(1.17; 3.24)† 
0.66 
(-0.35; 1.66) 
BPD 
-0.73 
(-1.42; -0.04)* 
-0.05 
(-0.54; 0.43) 
-1.19 
(-1.87; -0.39)† 
-0.64 
(-1.23; -0.05)* 
BPD x day 1 
0.86 
(-0.02; 1.75) 
- - - 
BPD x day 3 
-0.29 
(-1.16; 0.59) 
- - - 
BPD x day 7 
0.36 
(-0.98; 1.69) 
- - - 
GA 
(per wk increase) 
-0.04 
(-0.13; 0.05) 
0.01 
(-0.12; 0.14) 
0.10 
(-0.10; 0.29) 
0.11 
(-0.04; 0.26) 
Chorioamnionitis - 
-0.58 
(-1.17; 0.01) 
- - 
Preeclampsia 
-0.33 
(-0.69; 0.03) 
- 
-1.33 
(-2.14; -0.51)† 
- 
Antenatal steroids 
<24 hrs before birth 
- 
0.08 
(-0.60; 0.76) 
- - 
Antenatal steroids 
2-7 days before birth 
- 
-0.55 
(-1.28; 0.17)  
- - 
Antenatal steroids 
>7 days before birth 
- 
0.54 
(-0.19; 1.27) 
- - 
FiO2 
(per 0.1 increase) 
- - - - 
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Figure 1. (A–H): Temporal growth factor and total PL patterns in bronchoalveolar lavage fluid for infants de-
veloping bronchopulmonary dysplasia (BPD; •,continuous line) and infants surviving without BPD (ο, dashed 
line) as predicted by the marginal models with adjustment for confounders. Points represent mean predictives, 
and p values relate to the model estimate for the BPD effect (Table 4; *p < 0.05 and **p < 0.01 for individual time 
points). 
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Discussion 
We describe the dynamic patterns of various growth factors and total PL in BALF during 
the first postnatal week in ventilated preterm infants. Distinct expression patterns were 
observed for different growth factors. Substantial differences in BALF growth factor con-
centrations were present during the first postnatal week between infants who developed 
BPD and those who did not. Moreover, it was shown that VEGF concentrations entail im-
portant predictive value for BPD development already within 24 h after birth.  
The most prominent differences in BALF concentrations between infants with and 
without BPD were observed for VEGF. In the lung, VEGF is produced by endothelial cells as 
well as bronchial and type II alveolar epithelial cells 3,8. Inhibition of VEGF during lung de-
velopment results in disruption of vascular and alveolar development and a pathologic 
picture similar to that of new BPD 8. Thus, the lower initial VEGF concentrations found in 
our study in infants eventually developing BPD could well reflect a mechanistic process of 
adverse lung development and are in agreement with previous human studies 22,23. BALF 
VEGF levels may be used to identify individuals at particular risk for BPD at an early stage, 
which could facilitate future implementation of individualized preventive strategies for 
BPD in preterm infants.  
Moreover, VEGF may be a marker of lung development, supported by the positive as-
sociation between VEGF and gestational age, and the correlation between VEGF and PL 
concentrations in BALF. The latter observation corresponds to animal experimental evi-
dence indicating a stimulatory effect of VEGF on pulmonary surfactant synthesis 24,25. The 
association between lower alveolar VEGF and total PL concentrations and subsequent BPD 
development supports the concept that a developmental arrest of the lung is a critical 
mechanism in the development of new BPD 2.  
Besides VEGF and PL, TGF-α was also decreased in infants developing BPD. We are 
unaware of earlier reports of TGF-α quantification in BALF from preterm infants. Given the 
low overall levels, reducing accuracy of the measurements, it is surprising that significant 
differences were detected. TGF-α is a known stimulant of angiogenesis and alveolar 
epithelial differentiation. Pulmonary overexpression of TGF-α disrupts lung morphology in 
mice 14, while paradoxically TGF-α knockout also results in a reduction of the terminal gas 
exchange area 26. The latter corresponds to our findings of reduced TGF-α being associ-
ated with the development of BPD. Together, the available data on the role of TGF-α 
within the lung indicate that tight regulation of its expression is vital for proper lung de-
velopment.  
GM-CSF is a stimulator of proliferation and differentiation of granulocytes and macro-
phages, and a regulator of surfactant homeostasis 12,13. GM-CSF overexpression leads to 
exaggerated macrophage proliferation and activation 27, while GM-CSF null mice experi-
ence excessive accumulation of surfactant constituents in the alveolar space 28. The sud-
den increase in BALF levels of GM-CSF by the third postnatal day as found in our study is in 
line with earlier reports 29. We hypothesize that the increase in GM-CSF in infants develop-
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ing BPD is a marker of increased influx and activation of inflammatory cells in the alveolar 
space.  
TGF-β1 is an ubiquitous regulator of embryonic development. It is secreted as an inac-
tive precursor protein consisting of mature TGF-β1 and the latency associated peptide 
(LAP) 16. Latent TGF-β1 can be activated in various ways, including by acidification as per-
formed in this study 16. Our study shows that in ventilated preterm newborns, the inactive 
precursor protein comprises the vast majority of TGF-β1 in the alveolar space. Why such 
an abundance of the latent TGF-β1 form is present in the lung remains unknown, although 
our data indicate that increased TGF-β1 activation may be implicated in the pathophysiol-
ogy of BPD. TGF-β1 overexpression decreases alveolarization in newborn murine models 
on the one hand 17, whereas TGF-β1 diminishes apoptosis and promotes repair in alveolar 
type II cells after hyperoxia 30. The ambivalent nature of TGF-β1 in pulmonary physiology 
complicates interpretation of its contribution to BPD development.  
Earlier reports indicate a role in the pathogenesis of BPD for TGF-β1 and other classic 
growth factors involved in fibrosis and lung repair such as PDGF-BB and KGF 3,6. In this 
study, we were unable to reproduce previous associations between BALF levels of these 
factors and development of BPD in multivariable analysis. Instead, significant associations 
were detected between BPD and levels of total PL and growth factors involved in lung 
maturation and development (e.g., VEGF and TGF-α). These findings are in agreement 
with the current concept of a shift in pathophysiology from old to new BPD 2,4. Secondary 
lung injury and fibrosis are replaced by a picture depicted as a developmental arrest of the 
lung. Although, to date, the pathophysiology of this change has primarily been studied in 
animals, this study provides an additional supportive evidence of a molecular basis for this 
shift in humans.  
Positive correlations were observed between individual levels of various growth fac-
tors on each day, in line with earlier studies in TAF 31, suggesting important interaction or 
costimulation. Moreover, it was striking to see a strong negative correlation between 
preeclampsia and almost any growth factor in BALF after multivariable adjustment. Inter-
pretation of this association is complicated, because preeclampsia may be a proxy for 
being small for gestational age as well as for absence of chorioamnionitis 5. Both factors 
are associated with changes in growth factor expression as well as BPD risk 5. Additional 
studies are needed to explore the effect of maternal preeclampsia on fetal lung develop-
ment and growth factor expression.  
Particular strengths of this study include the simultaneous quantification of several 
growth factors in one population and the application of a marginal model approach. The 
former enables a composite picture of the several growth factors to be obtained, to find 
possible differential expression patterns. The latter allows for temporal comparisons of 
mean changes in growth factor concentrations with adjustment for potential confounders. 
It is important to emphasize that the model parameters and associated conclusions are 
only valid under the condition that, given all relevant covariates, missingness occurred at 
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random. We had no apparent reason to dismiss this assumption, and as such we believe 
that the results are unbiased.  
The underlying mechanisms responsible for the demonstrated effects were not stud-
ied and remain open to speculation. Similarly, alterations in growth factor expression 
observed in patients developing BPD do not provide information on the causality of this 
association. Additional research is needed to evaluate whether these alterations have a 
causal role in BPD development or are merely markers of the process of adverse lung 
development leading to BPD. The developmental regulation and differential temporal 
expression of certain growth factors in relation to BPD observed in this study suggest that 
time-dependent effects need consideration when designing additional studies.  
In conclusion, we have described general postnatal dynamics of BALF levels of various 
growth factors important for lung development and studied simultaneously in ventilated 
preterm infants. Important differences in BALF growth factor expression over time were 
demonstrated between infants developing BPD and healthy infants already from d 0. Dis-
turbance of the normal growth factor response to injury may explain part of the adverse 
lung development seen in BPD patients. Increased understanding of time dependent 
growth factor regulation of lung development may open up new perspectives for related 
interventions to prevent or treat BPD in the future. 
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Abstract  
Background: Prenatal hypoxia is an important cause of intrauterine growth retardation 
that affects fetal lung maturation, although previous studies have rendered conflicting 
results. The fetal chicken model allows the study of the isolated effects of hypoxia during 
development.  
Objectives: We hypothesized that prenatal hypoxia would differentially affect surfac-
tant synthesis, depending on timing and duration of hypoxia. Pulmonary vascular endo-
thelial growth factor (VEGF) expression was analyzed as a possible link between oxygen 
sensing and surfactant production.  
Methods: Fertilized White Leghorn eggs were incubated in normoxia, hyperoxia (60% 
O2) from day 15 or hypoxia (15% O2) from either day 6 or day 15 of incubation. Whole lung 
disaturated phospholipids (DSPL) and mRNA expression of VEGF isoforms were quantified 
at day 16 and 19.  
Results: Lung DSPL content increased approximately threefold between day 16 and 19 
in control animals. Both hypoxia and hyperoxia from day 15 significantly increased DSPL 
content at day 19 versus control (103 ± 22 and 116 ± 18 vs. 81 ± 15 μg/mg protein, p < 
0.01 and p < 0.001, respectively), while long-term hypoxia tended to decrease DSPL con-
tent (65 ± 17 μg/mg protein, p = 0.056). No differences in DSPL content were observed at 
day 16. Short-term hypoxia transiently up-regulated VEGF146 1.5-fold at day 16 (p < 0.05). 
A similar trend was observed for VEGF122 (p = 0.058) and VEGF190 (p = 0.08), while no 
differences were present at day 19.  
Conclusions: Both prenatal hypoxia and hyperoxia induced during critical windows of 
lung development differentially modulate surfactant synthesis. Our data support the con-
cept that fetal oxygen tension is a key signal in the regulation of the surfactant system. 
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Introduction 
Pulmonary surfactant is a complex mixture of phospholipids and proteins; it lowers sur-
face tension at the air-water interface and prevents alveolar collapse. Surfactant defi-
ciency due to lung immaturity causes respiratory distress syndrome (RDS) in preterm neo-
nates that is rescued by exogenous surfactant administration 1.  
Intrauterine growth retardation is most frequently the consequence of placental in-
sufficiency resulting in decreased availability of nutrients and oxygen 2,3. As normal pul-
monary development takes place in the relatively hypoxic environment of the uterus, it 
has classically been suggested that increased hypoxic intrauterine stress may accelerate 
lung maturity and protect the preterm infant from RDS 4. However, there is conflicting 
evidence in the literature regarding this accelerated pulmonary maturation. Elevated am-
niotic fluid lecitin/sphingomyelin ratios have been reported in preterm infants with pla-
cental insufficiency, suggesting accelerated lung maturation 5. Accordingly, investigators 
have found decreased rates of RDS in infants with intrauterine growth retardation 6. How-
ever, others have found no difference 7,8 or even increased rates of RDS 9-11 in infants with 
intrauterine growth retardation.  
Vascular endothelial growth factor (VEGF) has been shown in numerous studies to 
play a critical role in lung development 12. VEGF is highly expressed in alveolar type II cells 
and stimulates surfactant synthesis 12-14. Indeed, high levels of VEGF in tracheal aspirate 
fluid from preterm infants have been associated with a decreased need for exogenous 
surfactant administration 15. VEGF is under hypoxic control through upstream regulation 
by hypoxia-inducible factor 2α 13 and hypoxia has been shown to increase alveolar VEGF 
content 16.  
The chicken fetus is an excellent model for the study of the developmental conse-
quences of hypoxia and other prenatal insults 17-21. Hypoxia is easily induced by incubating 
the egg in a low-oxygen environment, and its effects can be studied without interferences 
of maternal hormonal, metabolic, or hemodynamic alterations. In the present study, we 
hypothesized that exposure of chicken fetuses to hypoxia would have modulatory effects 
on pulmonary VEGF expression and surfactant production. The latter was quantified by 
analyzing disaturated phospholipids (DSPL), the most surface-active lipid fraction of sur-
factant and the main constituent of both mammalian and avian surfactant 22. We evalu-
ated the effects of two different regimes of hypoxia: 15% O2 during either the last two 
thirds or the last third of incubation. The effects of hyperoxia (60% O2 during the last third 
of the incubation) were also analyzed. 
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Methods 
Experimental protocol  
Experiments were performed in accordance with Dutch law for animal experimentation. 
Fertilized eggs of White Leghorn chickens were incubated at 37.8 °C and 45% humidity and 
turned over an angle of 90° once per hour (Incubator model 25HS; Masalles Comercial, 
Ripollet, Spain). Control eggs were incubated under normoxic conditions (21% O2). For the 
hypoxia protocol, eggs were incubated under normoxic conditions until day 6 (long term 
hypoxia) or day 15 (short-term hypoxia) of incubation, when they were transferred to an 
incubator where 15.0 ± 0.3% O2 was maintained. For the hyperoxia protocol, eggs were 
incubated under normoxia until day 15 and then transferred to an incubator where 60 ± 
1% O2 was maintained. The O2 concentrations in the incubators were monitored with a 
DrDAQ O2 sensor (Pico Technology, Eaton Socon, UK). Eggs were incubated for either 16 
(normoxia and hypoxia groups) or 19 days (all experimental groups). On the experimental 
day the fetuses were killed by decapitation and weighed; afterwards both lungs were 
excised. None of the fetuses had internally pipped 20,23. The right lung was weighed and 
homogenized in phosphate-buffered saline using a 2-ml dounce. The left lung was used for 
mRNA analysis (see below).  
Total protein quantification, DSPL isolation and quantification  
Total protein was quantified in the right lung homogenate using the Micro BCA protein 
assay kit (Thermo Fisher Scientific, Rockford, Ill., USA) according to the manufacturer’s 
instructions. Next, the lung homogenate was suspended 1:10 in 1-butanol and vortexed. 
The mixture was centrifuged at 800 g for 10 min after which the supernatant was evapo-
rated at 50 °C under continuous nitrogen gas flow. The pellet was redissolved in carbon 
tetrachloride + 100 mg/ml osmium tetroxide and DSPL were isolated according to Mason 
et al. 24. DSPL were dissolved in chloroform and quantified according to Stewart 25, with 
slight modifications. Briefly, ammonium ferrothiocyanate was added 1:2 to DSPL in chloro-
form and vortexed thoroughly for 30 s. The organic phase (containing the stained DSPL) 
was separated from the inorganic phase by centrifugation (10 min, 800 g). Then, 125 μl of 
the organic phase of each sample was transferred into a 96-well glass-coated microtiter 
plate (Instrument Solutions, Nieuwegein, The Netherlands) and extinction was measured 
at 488 nm in a Spectra Max M2 photospectrometer using a phosphatidylcholine standard 
curve (range: 0–200 μg/ml).  
RNA isolation and measurement of VEGF mRNA expression  
The chicken VEGF-A gene gives rise to four isoforms generated by alternative splicing of 
exons (VEGF122, VEGF146, VEGF166, and VEGF190, homologous to human VEGF121, 
VEGF145, VEGF165, and VEGF189, respectively) 26,27. We examined the expression of the 
VEGF-A isoforms by RT-PCR of total RNA isolated from fetal chicken lung. The left lung was 
cut into pieces and tissue RNAs were stabilized in RNAlater™ (Qiagen, Venlo, The Nether-
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lands) for 1 day at 4 °C, after which the samples were stored at –80 °C until use. After 
thawing, total RNA was isolated using the RNeasy® minikit (Qiagen) according to the 
manufacturer’s protocol, including a DNase treatment step (RNase-free DNase set for use 
with RNeasy columns; Qiagen). 
Total RNA was quantified using a Thermo Scientific NanoDrop™ 1000 Spectropho-
tometer. Part of the RNA was denatured at 65 °C for 10 min and immediately placed on 
ice. Then, 500 ng of RNA was translated to cDNA using Ready-To-Go™ You-Prime First-
Strand beads (GE Healthcare, Eindhoven, The Netherlands) and 200 pmol pd(N)6 random 
hexamer primers (GE Healthcare) in a total volume of 25 μl. RT-PCR was performed at 37 
°C for 1 h, after which the samples were heated to 95 °C for 3 min to stop the reaction. 
Subsequently, samples were cooled to 4 °C and stored at 4 °C until use.  
PCR was performed with chicken VEGF primers (FW 5’-caggccatcctgtgtgcctct-3’ , RV 5’-
ttccgctgctcaccgtctccgg-3’) designed to yield the four isoforms of chicken VEGF. PureTaq™ 
Ready-To-Go™ PCR beads (GE Healthcare) were used with 10 pmol of each primer and 1 
μl of cDNA per reaction with a total volume of 25 μl. PCR steps were as follows: denatura-
tion 3 min at 94 °C (denaturation at 94 °C 30 s, annealing at 60 °C 1 min, elongation at 72 
°C 1 min). Ribosomal 18S was used as an internal standard and analyzed by the same pro-
cedure (primer sequences: FW: 3’-ccatccaatcggtagtagcg-3’ and RV: 5’-
cgataacgaacgagactctgg-3’). PCR products in the exponential phase of the PCR reaction 
were yielded after 18 cycles. PCR products were visualized at a 2% agarose gel stained 
with ethidium bromide and band densities were measured using ImageQuant™ software 
(GE Healthcare). 
Statistics 
Data are expressed as mean and standard deviation (SD), while for clarity standard error 
of the mean (SEM) is used in figures. Differences between groups were tested using one-
way analysis of variance (ANOVA) with Dunnett’s post-hoc analysis. A test result of p < 
0.05 was considered significant (two-tailed). All analyses were performed using SPSS 15.0 
software (SPSS Inc., Chigaco, Ill., USA). 
Results 
Fetal body and lung masses  
Exposure to 15% O2 during middle (from day 6 onward) or late (from day 15 onward) in-
cubation resulted in decreased mass of the 19-day chicken fetus (table 1). However, this 
effect of hypoxia was not observed in the 16-day fetus. Exposure to 60% O2 during late 
incubation (day 15–19) did not significantly affect fetal body mass (table 1). Neither hy-
poxia nor hyperoxia significantly affected lung mass or the proportion lung mass:fetal 
mass.  
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Table 1. Morphometric parameters after incubation in normoxia, hyperoxia (60% O2 from day 15) or long-term 
(LT; from day 6) or short-term (ST; from day 15) hypoxia (15% O2) at days 16 and 19. Data are shown as mean ± 
SD. ***p < 0.001 vs. normoxia. 
Day 16 Day 19  
Normoxia 
(n=15) 
LT hypoxia 
(n=15) 
ST hypoxia 
(n=11) 
Normoxia 
(n=15) 
LT hypoxia 
(n=14) 
ST hypoxia 
(n=16) 
Hyperoxia 
(n=15) 
Body mass (g) 
17.0  
± 1.0 
16.3  
± 0.9 
16.3  
± 1.2 
29.9  
± 2.3 
25.8  
± 1.2*** 
26.4  
± 1.8*** 
29.6  
± 2.5 
Lung mass (mg) 80 ± 14 74 ± 13 76 ± 7 137 ± 18 123 ± 22 122 ± 16 130 ± 20 
Lung mass /body 
mass (‰) 
4.7  
± 0.8 
4.6  
± 0.8 
4.7  
± 0.5 
4.6  
± 0.5 
4.8  
± 0.9 
4.6  
± 0.6 
4.4  
± 0.7 
  
Lung DSPL  
There were no differences in whole lung total phospholipids and total protein content 
between experimental groups at any time point. As shown in figure 1, whole lung DSPL 
content increased between day 16 and day 19 in control animals, reflecting the physiol-
ogic increase in surfactant production during development. Incubation under hypoxic 
conditions did not affect whole lung DSPL content by day 16, irrespective of hypoxia dura-
tion. However, hypoxia from day 15 significantly increased whole lung surfactant content 
by day 19 (p < 0.01). Long-term hypoxia induced a nonsignificant decrease of DSPL content 
in the 19-day fetal lung (p = 0.058). Hyperoxic incubation from day 15 significantly in-
creased whole lung DSPL content at day 19 (p < 0.001).  
 
 
 
Fig. 1. Whole lung DSPL content after incubation in normoxia, hyperoxia (60% O2 from day 15) or long-term 
(LT; from day 6) or short-term (ST; from day 15) hypoxia (15% O2) at days 16 and 19. Bars represent mean + 
SEM ( **p < 0.01 and ***p < 0.001 vs. normoxia). 
 
Pulmonary VEGF mRNA expression  
When the pulmonary mRNA expression of the VEGF-A isoforms was examined by RT-PCR, 
we detected three bands corresponding to VEGF122, VEGF146, and VEGF190 isoforms (fig. 
2). No signal was detected for the VEGF166 isoform. As shown in figure 3, short-term hy-
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poxia induced a transient increase in the expression of the VEGF146 isoform (i.e., the 
expression was augmented at day 16 but not at day 19). A similar trend, although not 
statistically significant, was observed towards a transient increase in the expression of the 
VEGF122 and VEGF190 isofoms in the 16-day lungs exposed to short-term hypoxia (p = 
0.057 and p = 0.08, respectively). Neither long-term hypoxia nor hyperoxia significantly 
changed the pattern of development of VEGF mRNA expression (fig. 3). 
 
 
Fig. 2. mRNA expression of VEGF isoforms in the fetal chicken lung. VEGF isoforms 190 (442 bp), 146 (370 bp) 
and 122 (240 bp) were detected, but not isoform 166 (310 bp). 
Discussion 
This is the first study to examine how chronic hypoxic exposure started during middle or 
late incubation differentially affects surfactant synthesis in the chicken fetus. Hypoxia 
during late incubation (from day 15 onward) was found to increase surfactant synthesis in 
the 19-day fetus, while conversely, long-standing (from day 6 onward) hypoxia tended to 
decrease whole lung surfactant content. The increase in surfactant content induced by 
late hypoxic exposure was preceded by a transient upregulation of the VEGF isoform 
VEGF146. Interestingly, hyperoxia during late incubation also increased surfactant produc-
tion, but without a significant effect on VEGF expression. Our data support the concept 
that fetal oxygen tension is a key signal in the regulation of the surfactant system.  
Previous studies that focused on the effect of hypoxia on lung development and sur-
factant production using mammalian models have rendered conflicting results 28-33. In fetal 
sheep, both maternal hypoxia between gestation day 108 and 130 (term = 147 days) as 
well as embolization- induced fetal hypoxemia from day 134 to 136 up-regulated mRNA 
for surfactant protein (SP)-A and -B but not -C 28,29. Conversely, maternal hypoxia from 
gestation day 14 suppressed pulmonary SP-A, -B and -C mRNA expression in preterm fetal 
mice (day 17.5; term = 21 days) 32. In near-term fetal rats, intermittent maternal hypoxia 
reduced fetal lung disaturated phosphatidylcholine content when started at day 7 of ges-
tation (term = 21 days), while continuous hypoxia from day 14 had no effect on either lung 
morphology 33 or surfactant content 31. The results of the latter study point in the same 
direction as our data, suggesting the existence of ‘critical windows’ during which environ-
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mental perturbation would exert different effects. The main limitation of these mammal-
ian studies is the interference of maternal alterations induced by hypoxia. In addition, 
exposure to hypoxia generally induces a marked reduction in maternal food intake that 
may result in a cumulative substrate deficit and thus constituted a dual insult (i.e. hypoxia 
and malnutrition) for the offspring 34. In the last years, the use of the chicken fetus model 
has allowed the isolation of the effects of prenatal hypoxia and undernutrition 20,21. 
 
 
 
A 
 
B 
 
C 
 
Fig. 3. a–c VEGF isoform expression patterns after incubation in normoxia, hyperoxia (60% O2 from day 15) or 
long-term (LT; from day 6) or short-term (ST; from day 15) hypoxia (15% O2) at days 16 and 19. Bars represent 
mean + SEM ( *p < 0.05 vs. normoxia). 
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When interpreting the data presented, it is important to take into account the differences 
and similarities between human and avian lung development and structure. Surfactant has 
a crucial role in preventing alveolar collapse in the human lung during respiration 1. In 
contrast, the chicken lung consists of air capillaries rather than alveoli, that connect to 
tubular structures (parabronchi) with a unidirectional laminar airflow 35. These dissimilari-
ties have been suggested to imply functional differences of pulmonary surfactant between 
humans and chickens 22,35,36. It appears that SP-C and SP-D are absent in chicken lungs, 
while debate exists around SP-B 22,36-38. Despite these differences, the phospholipid com-
position and the fetal developmental pattern of surfactant in the chicken are very similar 
to those of mammals and other vertebrates 22,23,35. Type II cells develop within the atrial 
walls of the parabronchi between the 14th and 15th day of incubation 38, and lamellar 
bodies appear on day 16 and increase in number to a maximum at day 18 39. Concomi-
tantly, the amount of total phospholipids and DSPL increases in the final stages of incuba-
tion, and the DSPL:total phospholipid ratio becomes maximal at days 19–20 40. Around this 
time, the chicken fetus internally pips by piercing the air cell inner membrane with its beak 
and begins lung ventilation 23. Although during internal pipping, gas exchange is still partly 
dependent on the chorioallantoic membrane, the fetal lung is considered structurally and 
functionally mature 35,41. Whether changes in prenatal oxygen environment would affect 
the structural maturation of the developing chicken lung warrants further investigation.  
Our data show relatively low pulmonary surfactant content on day 16, while DSPL 
content approximately tripled by day 19. In addition, we demonstrated that the develop-
mental increase in surfactant production was differentially affected by hypoxia and that 
this effect was dependent on the timing and the duration of the stimulus. We are aware of 
one earlier report of surfactant measurements after hypoxic incubation in the chicken 
fetus. Blacker et al. 23 quantified surfactant lipids in bronchoalveolar lavage fluid from fetal 
chicks after incubation in 17% O2 from day 10. Hypoxia was shown to significantly increase 
phospholipid concentration by day 16 and of both phospholipids and DSPL by day 19. No 
significant differences were observed at days 20 and 21, suggesting that the effect was 
temporary. Only one hypoxic exposure period was used, therefore a timing-dependent 
differential effect could not be evaluated. Comparison to our data is difficult due to the 
differences in duration and severity of hypoxia. However, it should be noted that in con-
trast to 15% O2 
20,21, 17% O2 did not induce a significant delay in fetal growth in the study 
by Blacker et al. 23.  
The molecular mechanisms that regulate lung development differ to some extent be-
tween species, including humans and chickens 39,42. On the other hand, important similari-
ties are present, such as the stimulatory effect of corticosteroids on surfactant production 
23,42. Regarding the role of growth factors in the regulation of avian lung development, 
there is an important lack of data, as stressed by Maina 35. Our study thus contributes to 
an increased knowledge on pulmonary growth factor responses to hypoxia and hyperoxia 
in the chicken fetus. One of the most potent responses to tissue hypoxia is the induction 
of an angiogenic reaction that is partly mediated by expression of VEGF and its receptors 
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43. Recent evidence indicates that VEGF is not only involved in angiogenesis but also in 
epithelial cell growth and proliferation in the fetal lung 12. Moreover, type II cells express 
VEGF receptors and respond to VEGF by increasing surfactant production 13. We therefore 
examined the expression of VEGF mRNA in the developing chicken lung. Exposure to hy-
poxia from day 6 of incubation did not significantly affect VEGF expression, but when the 
fetuses were made hypoxic from day 15, an increase in the mRNA expression of the 
VEGF146 isoform was observed at day 16. However, this increase was transient and was 
no longer observed at day 19. Whether the increase in surfactant production induced by 
hypoxia is related to the transient increase of VEGF or to up-regulation of other stress-
induced stimulators of surfactant production such as corticosteroids 23,42 warrants further 
investigation.  
Since hyperoxia is one of the main contributors to neonatal chronic lung disease 44, 
numerous studies have analyzed the effects of postnatal alveolar hyperoxia on lung devel-
opment. In general, these studies demonstrate that hyperoxia stimulates surfactant syn-
thesis 45-47 but impairs surfactant function 48. Moreover, both VEGF and the expression of 
VEGF receptors are decreased by hyperoxia 49,50. We are aware of one earlier study evalu-
ating the effect of prenatal hyperoxia on surfactant, showing increased synthesis after 
intermittent maternal exposure to 100% O2 from day 7 of gestation in rats 
31. Our data 
show that continuous hyperoxic (60% O2) incubation of chicken fetuses during the physi-
ologic window of surfactant synthesis increases pulmonary surfactant content, but does 
not affect VEGF mRNA expression. Although we studied only one period of hyperoxia, Xu 
and Mortola 51 have shown that hyperoxia from day 14 to day 18 had more pronounced 
effects on lung mass and DNA content than did hyperoxia from day 7 to day 18. Moreover, 
van Golde et al. 52 demonstrated that exposure of the chicken fetus to 60% O2 induced a 
transient increase in the activity of superoxide dismutase, catalase and glutathione per-
oxidase in several organs, including the lungs. This effect was much more marked when 
hyperoxic exposure occurred on incubation days 10–11 than when it took place on incuba-
tion days 14–15 or 18–19, stressing again the relevance of stimulus timing 52.  
Critical time windows exist during development, and if environmental changes are ex-
perienced in the window of vulnerability, then the trajectory of development of the re-
sponding organ may be changed in ways that result in transient or persistent alterations 
53. The present study provides evidence for the high level of plasticity of the surfactant 
system within its maturation and for the critical role of fetal oxygenation in controlling this 
process. Both hypoxia and hyperoxia during the critical window of surfactant production 
trigger an increase in surfactant development that may represent an acceleration in the 
pattern of maturation 23. 
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Abstract  
In mechanically ventilated preterm infants, the combination of immaturity, volutrauma, 
oxidative stress, and inflammatory processes can lead to chronic lung injury. Mitochon-
drial DNA (mtDNA) is more susceptible to oxidative damage than nuclear DNA. We aimed 
to investigate the level of mtDNA damage (deletions, mutations and changes in copy 
number) in bronchoalveolar lavage (BAL) cells from 10 preterm infants (27-30 weeks). A 
first BAL (BAL1) was done within 24 h of endotracheal intubation and BAL2 was performed 
30-103 h thereafter. Deletions were analyzed by long range PCR, point mutations by het-
eroduplex analysis of the D-loop region, and copy number changes by real-time PCR. Using 
these methods, no deletions were found in any of the BAL samples. When BAL1 and BAL2 
samples were compared no new mutations were found. In contrast, a marked decrease in 
mtDNA copy number was observed in 5 patients.  
In conclusion, we found that exposure of preterm infants to short term mechanical 
ventilation did not lead to detrimental consequences for the mtDNA in the form of muta-
tions or deletions. 
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Introduction 
In mechanically ventilated preterm infants, immaturity in combination with oxidative 
stress, volutrauma, and inflammatory processes can lead to chronic lung injury 1-6. Oxida-
tive damage is found very early in infants subsequently developing chronic lung disease 
and knowledge is now accumulating on how reactive oxygen species (ROS) trigger cellular 
and molecular changes that may impair normal pulmonary growth and development 1,2.  
Mitochondrial DNA (mtDNA) is more susceptible to oxidative damage and conse-
quently acquires mutations at a higher rate than nuclear DNA 7. This is due to exposure to 
high levels of ROS generated during respiration, lack of protective histones, and limited 
capacity for repair of DNA damage 8. Significant damage to mtDNA will compromise cellu-
lar respiration, resulting in elevated levels of ROS that cause further injury to mitochon-
drial and nuclear DNA and, therefore, potentially contribute to chronic lung disease 8,9. In 
this study, we hypothesized that mechanical ventilation would induce mtDNA damage in 
the lung of preterm infants. To test our hypothesis, we conducted a pilot study evaluating 
mtDNA deletions, mutations and changes in copy number in bronchoalveolar lavage (BAL) 
cells from preterm infants following endotracheal intubation and within 2-4 days of me-
chanical ventilation. 
Patients and methods 
The study was approved by the Maastricht University Medical Centre Ethics Committee 
and fully informed, written consent was obtained from the parents of each infant. The 
study population consisted of ten intubated, mechanically-ventilated preterm infants, 
whose clinical information is summarized in table 1. The information about the character-
istics of the mechanical ventilation used during the study period is summarized in table 2. 
The ten children received surfactant (Curosurf 200 mg/kg; Chiesi Farmaceutica, Parma, 
Italy) within 2h after birth and at least 6 h before the first BAL. Patients 1, 8, 9, and 10 
received a second surfactant dose between the two BAL procedures. 
BAL cell collection and processing 
A first BAL (BAL1) was done within 24 h of endotracheal intubation and a second (BAL2) 
was performed 30-103 h (median 48.5 h) thereafter. BAL was performed as previously 
described 10. Briefly, with the infant lying supine and the head turned to the left, a 6 F 
suction catheter was gently inserted into the endotracheal tube until resistance was felt. 
Then, 1ml/kg birth weight of sterile isotonic saline was gently infused into the lung. After 5 
s, suctioning was performed while slowly retracting the catheter. The procedure was re-
peated once after which the collected fluid was pooled and placed on ice. From the 
pooled aspirate, aliquots were taken for total and differential cell count. Haemocytometer 
counting was used to obtain total cell counts per ml of BAL fluid and a differential cell 
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count was performed on cytospins of BAL cells using May-Grünwald-Giemsa stain. 500 
cells were counted on each cytospin. The remainder of the BAL fluid was centrifuged at 
300 x g for 10 minutes at 4 °C and the supernatant and the cells were stored at -80°C until 
analysis. All subsequent analyses were done by investigators who were blinded to the 
clinical features of the patients. 
 
 
Table 1. General characteristics of the patients. GA=gestational age; HC=histologic chorioamnionitis; 
AS=antenatal steroids; MV=mechanical ventilation; BPD=bronchopulmonary dysplasia; IVH=intraventricular 
haemorrhage; Cord pH = umbilical artery blood pH; NA=not available. * This child was born at home and trans-
ported to the hospital with cyanosis and hypothermia. Blood lactate was 7.9 mmol/l. 
 
Detection of deletions in the mitochondrial genome 
Total DNA was isolated according to the manufacturer’s procedure using the QIAmp® DNA 
mini kit from Qiagen. A deletion PCR was performed for the whole mitochondrial DNA. 
Two primer pairs were used, yielding two mtDNA fragments of 16.1 and 16.0 kb in size, 
respectively. Primer sequences for fragment one were 5’-
CCGCTTCTGGCCACAGCACTTAAACACATC-3’, at location 0314-0343, and 5‘-
GGAGGATGGTGGTCAAGGGACCCCTATCTG-3’, at location 16411-16382. For fragment 2 
primers 5’-CAAGGTGTAGCCCATGAGGTGGCAAG-3’, located at 01330-01355, and 5’-
GCTGCATTGCTGCGTGCTTGATG-3’, located at 00778-00756, were used. The PCR mix con-
sisted of Expand Long Template buffer (10x; 27.5 mM MgCl2), dNTP-mix containing 8.33 
mM of each base, 100 ng per microliter forward and reverse primer, 5 U per microliter 
Expand Long Polymerase and 50 ng of DNA in a total volume of 50 microliter.  
The PCR was performed using a PCR Perkin Elmer type 9700. First denaturation was 
achieved at 98 °C for 30 s, followed by 30 cycles of 10 s of denaturation at 98 °C and 8 min 
15 s annealing at 72 °C, followed by 10 min of elongation at 72 °C. The PCR products were 
stored at 4 °C until use. 25 microliter PCR-products were loaded on ethidium bromide 
stained 0.7% agarose gels in TAE-buffer and run for 16 hours at 32 V. After 16 hours a 
Nr Sex GA (wks) 
Birth 
weight (g) 
HC AS Cord pH O2 28 d O2 36 w 
Days on 
MV 
Died 
Cause of 
death 
1 M 28+5 1100 - + 7.29 - - 6 -  
2 M 30+2 880 - + 7.23 died died 12 day 11 Sepsis 
3 F 28+0 490 - + 7.28 + + 110 day 112 BPD 
4 M 29+2 1290 - + 7.35 - - 3 -  
5 M 27+3 1110 + - NA* - - 9 -  
6 F 27+4 940 - - 7.02 + died 37 day 50 IVH 
7 F 28+6 1240 NA + 7.06 - - 5 -  
8 M 29+3 1180 NA + 7.10 + - 6 -  
9 F 27+2 980 NA + 7.39 + + 10 -  
10 M 28+0 1135 - + 7.31 + + 8 -  
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picture was taken of the PCR products in the gel and the gel was run for another 16 hours 
at 32 V. Samples from the DNA bank of our institution were used as controls. The positive 
control was DNA obtained from muscle tissue of a 45-year-old female, whose mtDNA 
contained several deletions as a consequence of aging. The negative control was a DNA 
sample without mtDNA deletions. 
 
 
Table 2. Ventilatory requirements during admission and between BAL procedures. For HFV ventilation, peak 
pressures represent amplitude values. MAP=mean airway pressure; PIP=peak inspiratory pressure; HFV=high 
frequency ventilation; SIMV= intermittent mandatory ventilation 
 
Mutation detection in the mitochondrial D-loop 
Another set of PCRs was performed to yield three fragments (fragment 1, 2 and 3 from the 
MitoScreen™ Assay Kit, Transgenomic, Elancourt, France) spanning the mutation hot spot 
D-loop region of the mtDNA, that were subjected to denaturing HPLC (DHPLC) analysis. 
The first primer pair (5’-CTCCACCATTAGCACCCAAAGC-3’ and 5’-
GAGGATGGTGGTCAAGGGACC-3’) was used to amplify the region between 15974-
16409bp, the second primer pair (5’-TACAGTCAAATCCCTTCTCGTCC-3’ and 5’-
TCCAGCGTCTCGCAATGCTATC-3’) was used to amplify the region between 102-16341bp, 
and the third primer pair (5’-CTCACGGGAGCTCTCCATGCAT-3’ and 5’-
ATTAGTAGTATGGGAGTGGGAGG-3’) was used to amplify the region between 29-480 bp. 
The PCR mix contained 10* Optimase® reaction buffer with MgSO4, dNTP mix containing 
10 mM of each dNTP, Optimase Polymerase 2.5 U, 100 ng DNA, and 100 ng of both prim-
ers in a total volume of 50 μl.  
The PCR was performed using a Thermocycler (Perkin Elmer type 9700). Denaturation 
was achieved at 95 °C for 2 min, then the samples were subjected to 30 cycles of 30 s of 
denaturation at 95 °C, 30 s of annealing at 56 °C, 3 min of elongation at 72 °C, followed by 
 
Before 
1st BAL 
Between BAL procedures 
Nr 
Max  
FiO2 (%) 
Max 
FiO2 (%) 
FiO2>40% 
(% of time) 
NO 
(% of time)
Ventilator 
mode 
Mean MAP 
(cm H2O) 
Max MAP
(cm H2O) 
Mean PIP 
(cm H2O) 
Max PIP 
(cm H2O) 
1 100 25 0 70 HFV 12 14 16 20 
2 100 30 0 0 HFV 8 10 14 17 
3 100 65 20 0 SIMV 9 10 16 19 
4 50 30 0 0 SIMV 9 10 15 20 
5 100 35 0 100 HFV 8 9 16 21 
6 35 30 0 0 SIMV 9 10 16 20 
7 45 25 0 0 SIMV 10 11 18 20 
8 30 35 0 0 SIMV 11 14 19 25 
9 80 35 0 0 HFV 11 13 24 27 
10 65 45 10 0 HFV/SIMV 10 14 24 29 
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5 min of elongation at 72 °C. PCR products were stored at 4 °C until use. Heteroduplex 
formation was achieved by heating the PCR products at 95 °C for 5 min. Then the samples 
were cooled at a rate of 1.5 °C/min until a temperature of 25 °C was reached. Next, the 
samples were placed in the WAVE® nucleic acid fragment analysis system for analyses. The 
DNA was initially mixed with triethyl ammonium acetate, which functions as an ion pairing 
reagent. This enables size based binding of the hydrophilic DNA to the hydrophobic 
DNASep® Matrix.  
Heat was used as a denaturant, in conjunction with the hydrophobic eluant acetoni-
trile, which lead to elution of the DNA from the matrix according to helicity and size. DNA 
containing a heteroduplex (and thus a mutation) will elute earlier from the matrix than the 
homoduplex species. In this way the chromatogram pattern changes and the presence of a 
mutation can be detected. WAVE® Control Standards were used to ensure quality during 
the analysis. This includes the WAVE® DNA Sizing Control Sample, the Low Range Muta-
tion Control Standard, the Mid Range Mutation Control Sample and the High Range Muta-
tion Control Standard. The temperatures at which 8 μl of the PCR products was analyzed 
by DHPLC were optimized for each individual fragment: 50 °C and 58 °C for fragment 1, 50 
°C and 60 °C for fragment 2 and 50 °C, 57 °C and 59 °C for fragment 3. The resulting chro-
matograms from BAL1 and BAL2 were compared between each other and with standards. 
mtDNA copy number analysis 
To analyze potential changes in copy number of mtDNA as a consequence of mechanical 
ventilation, Real-Time PCR was performed for the nuclear RNase P gene and the mtDNA 
encoded 12S-RNA gene. The PCR mix contained Taqman® Universal PCR Master Mix, 
TaqMan® RNase P Control Reagents Kit (VIC™ Probe), primers 12S (3’-
CCCCAGGGTTGGTCAATTT-5’ and 3’-CTATTGACTTGGGTTAATCGTGTGA-5’) and Taqman® 
probe 12S (3’-TGCCAGCCACCGCG-5’) 6 pmol.  
The PCR was performed in an ABI Prism 7000 Sequence Detection System. Amplitaq 
Gold activation was obtained at 95 °C for 10 minutes, followed by 40 cycles of denatura-
tion for 15 s at 95 °C and annealing and extension at 60 °C for 1 min. A standard DNA dilu-
tion was made to plot a standard curve to determine the efficiency of the PCR. Every sam-
ple was analyzed in duplicate. The efficiency was calculated by the formula Eff = 10-
1/slope. Relative copy number (Rc) was calculated by expressing threshold cycle number 
differences of the nuclear gene and the mitochondrial gene PCR, as described by Ritov et 
al 11: Rc=2(Ct nDNA-Ct mtDNA), where Ct is the threshold cycle number. 
Results 
Total and differential BAL cell counts are presented in Table 3. More detailed BAL cytospin 
data from patient 3, who experienced severe pneumonia, have previously been reported 
12. When the mtDNA of the BAL cells was screened for deletions none of the samples 
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showed positive results. Figure 1 shows an example of the PCR products that were ex-
posed to gel electrophoresis for 32 h. The positive control shows several bands, which 
indicate deletions in the DNA of this sample (muscle tissue from a 45-year-old female, 
whose mtDNA contained several deletions as a consequence of aging). In contrast, no 
extra bands are observed in the mtDNA of BAL1 and BAL2 samples, as well as in the nega-
tive control.  
 
 
Table 3. Cell content in BAL-fluid. 
BAL1 BAL2  
median range median range 
Cell count (*10-6 cells/ml)  0.93 0.30-4.27 0.80 0.46-8.82 
Macrophages (%)  25 5-88 58 25-72 
Neutrophils (%) 73 11-95 38 10-73 
Lymphocytes (%) 0.7 0-2.0 0.8 0-19 
Eosinophils (%) 0 0-1.0 0 0-0 
 
 
When BAL1 and BAL2 samples were compared, no newly formed mutations in the D-loop 
of the mtDNA were observed. Figure 2 shows an example of the DHPLC output from BAL1 
and BAL2 DNA of two children. As can be seen in the figure, no new heteroduplexes were 
found in the analyzed products.  
The results of the mtDNA copy number analysis are presented in Table 4. One of the 
samples was not successfully amplified despite the availability of ample genetic material. 
Five of the BAL2 samples analyzed showed a decrease in the relative mtDNA copy number 
when compared to the corresponding BAL1. Two of the samples showed no change and 
two showed an increase in mtDNA copy number. The efficiency of this PCR was 1.97. 
Discussion 
Documentation of mtDNA damage in vivo after acute insults is sparse compared with the 
number of in vitro studies that have demonstrated oxidative injury to mtDNA 13. To the 
best of our knowledge, this is the first study addressing the putative mtDNA damage in-
duced by mechanical ventilation in humans. We observed, in a population of ten preterm 
infants, that 2-4 days of mechanical ventilation with oxygen concentrations up to 100%, 
and in some cases in combination with NO, did not induce any detectable mutation or 
deletion in the mtDNA isolated from BAL cells. However, in five of the samples a decrease 
in mtDNA copy number was detected.  
Our findings raise several points of discussion. First of all, whether the methods used 
are sensitive enough to detect mtDNA deletions and mutations. The deletion PCR we con-
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structed is considered as a sensitive method with a detection limit of 0.5-1% 14,15. Single 
base mutations in mtDNA can not be detected by deletion PCR. Therefore we performed 
heteroduplex analysis using the DHPLC method 16,17 to screen the D-loop region (a muta-
tion hot spot region in the mtDNA) 18. This method has a 97-100% efficiency of mutation 
detection (confirmed by sequencing the abnormal PCR-products) and a threshold of 1-5% 
for detection of a specific mutation 16,17. Mutations can randomly occur across the DNA 
fragments and it can be expected that each mutation would eventually lead to a hetero-
duplex and an altered migration pattern producing altered peak or peaks, which would 
contain mixtures of different mutations. Differences in these peak patterns were not ob-
served when BAL1 and BAL2 samples were compared, indicating that new mutations were 
not present. Other techniques, with very high sensitivity for mutation detection have been 
recently described. One mutation among 109 bases can be detected with the random 
mutation capture (RMC) method 19,20. Whether this method could detect mutations that 
we did not find with the DHPLC method remains to be investigated. 
 
 
 
 
Figure 1. Representative examples of deletion PCR products from patient 1 (lane 3 and 4) and 2 (lane 5 and 6). 
Positive and negative controls are shown in lane 7 and 8 respectively. A 1 kb DNA ladder (lane 1) as well as a 
HindIII ladder (lane 2) were used to identify the PCR product size. A size of about 16 kb is a PCR product from 
DNA without deletions. The positive control (muscle tissue from a 45-year-old female with known deletions from 
aging) shows several products (arrows), apart from the 16 kb fragment, indicating deletions in part of the 
mtDNA. BAL1: first BAL; BAL2: second BAL. 
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Figure 2. Representative examples of the DHPLC analysis for mutations in the mtDNA. The x-axis represents the 
retention time in minutes, which is dependent on the length of the product analyzed; the y-axis is a measure of 
absorbance (converted to mV). The two panels on the left show an example of a normal homoduplex pattern in 
both BAL1 and BAL2 of patient 7. The two panels on the right show the presence of similar heteroduplexes in 
both BAL1 and BAL2 of patient 9, indicating the presence of mutations that did not change between the two BAL 
procedures. 
 
Table 4. Relative mtDNA copy number. Relative copy number was calculated by the formula 2(Ct nDNA-Ct mtDNA) 
where Ct is the threshold cycle number of the nuclear gene and the mitochondrial gene PCR (see methods for 
details). 
# BAL1 BAL2 
1 - - 
2 248.24 466.45 
3 133.90 195.76 
4 1243.33 130.33 
5 311.32 190.71 
6 455.50 201.39 
7 251.75 275.03 
8 406.42 426.29 
9 208.69 74.96 
10 312.45 216.77 
 
 
Also the intensity and duration of the insult in the studied population could be related to 
our negative results. It can be argued that higher levels of or longer exposures to oxidative 
stress would be necessary to induce mtDNA deletions or mutations. The majority of the 
patients in our population were exposed to high concentrations of oxygen at birth, when 
resuscitation was performed. A preceding hypoxic period appeared to be present in four 
cases (Table 1). Afterwards, between the two moments of sampling, patients were gener-
144 
ally exposed to gentle mechanical ventilation and the majority did not need oxygen-rich 
gas.  
With the advent of surfactant therapy and the widespread use of antenatal steroids, 
the clinical picture of infant RDS changed considerably 1. Nowadays, preterm newborns 
often require little supplemental oxygen during their initial postnatal course, and it is 
uncommon for such infants to receive mechanical ventilation with high inflation pressures 
or large tidal volumes 1. Interestingly, it has been suggested that the inflammatory re-
sponse is more likely than hyperoxia to lead to pulmonary oxidative damage in mechani-
cally ventilated preterm infants 5. On the other hand, our understanding of the ill effects 
of brief oxygen exposure at birth has been increased significantly and it has been shown 
that hyperoxia, even for short periods and particularly following a previous hypoxic insult, 
contributes to the development of several neonatal morbidities 1,2,21-23. In this regard, 
oxygen administration in the delivery room has become a matter of discussion in the last 
years 21-24. Moreover, an association has been suggested between the DNA damage in-
duced by post-hypoxic neonatal exposure to high oxidative stress and childhood cancer 
23,25,26. In the present work, we analyzed mtDNA, which is more susceptible to oxidative 
damage than nuclear DNA 7. However, our data suggest that in a normal clinical setting of 
mechanical ventilation DNA deletions or mutations are not produced or, alternatively, 
they have been repaired, although repair systems are less efficient for the mtDNA than for 
the nuclear DNA 7,8.  
There is overwhelming evidence from in vitro studies that oxidative stress damages 
DNA 7,8,27. Also, in vivo experimental studies using exposure to hyperoxia in premature 
baboons 28, neonatal rats 29, adult rats 30,31, and adult mice 32 demonstrated pulmonary 
oxidative nuclear DNA damage. The urinary levels of 8-hydroxy-2’-deoxyguanosine, a 
marker of oxidative DNA damage, were significantly higher in preterm infants requiring 
supplemental oxygen and ventilator support than in nonmechanically ventilated preterm 
and healthy term neonates 33. To the best of our knowledge, only one study has analyzed 
pulmonary mtDNA integrity after in vivo hyperoxic exposure 13. In consonance with our 
results, Lightfoot et al. observed that hyperoxia (24-48 h of 95% oxygen in adult rats) 
failed to induce significant injury to mtDNA and only when combined with NO inhalation 
transient mtDNA damage was produced. They speculate that efficient removal of ROS by 
mitochondrial antioxidant systems or upregulation during hyperoxia of mtDNA repair 
systems may be the explanation for the lack of injury in the mtDNA 13.  
In five cases, we found a decrease in the relative mtDNA copy number between BAL1 
and BAL2. With our limited sample size, we can only speculate about this finding. As dif-
ferent cell types contain different amounts of mtDNA, our finding may simply reflect the 
differences in BAL cell composition between the two moments of sampling. The majority 
of the studies dealing with the effects of oxidant stress on mtDNA copy number have been 
focused on chronic exposure to the insult and they demonstrated an increase in the copy 
number (see 8 for a review). This has been suggested to be a compensatory mechanism 
for defective mitochondria bearing impaired respiratory chain or mutated mtDNA 8. Be-
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cause ROS generation by the mitochondrial respiratory chain is a continuous physiological 
occurrence, mitochondria have an efficient antioxidant system composed of superoxide 
dismutase, glutathione peroxidase, glutathione reductase, glutathione, NAD(P) transhy-
drogenase, NADPH, vitamins E and C, thiol peroxidases and mitochondrial respiration itself 
34,35. However, when the capacity of antioxidant system is compromised, the exposure to 
higher oxidative stress may result in an increase of defective mitochondria beyond a non-
compensable level and thus, a cyclic increase in ROS production leading to mitochondrial 
lipid peroxidation and a decrease in mtDNA copy number 8,27,36. This could drive the cell 
into an irreversible cell death process 8,37 that would lead to an increase in extracellular 
mtDNA with proinflammatory effects, thereby creating a vicious circle of inflammation 
and cell destruction 38. Although it is generally accepted that extracellular and cytosolic 
antioxidant defenses are reduced in preterm infants 2,4, this has not been demonstrated 
for the mitochondrial antioxidant system. Therefore, the putative maturational changes in 
the mitochondrial antioxidant and DNA reparation systems and their possible role in 
chronic lung disease require further investigation.  
Although the pathogenesis of chronic lung disease of the premature infant remains 
unclear, much evidence suggests that reflects abnormal growth and repair of the imma-
ture lung exposed to the continuous stress of repetitive inflation with oxygen -rich gas in a 
setting of chronic inflammation, often aggravated by recurrent infection 1. An important 
part of these pathogenetic insights has been obtained through the analysis of BAL fluid 
and cells 3-6,10,12,39. Our pilot study proposes a new approach for the evaluation of lung 
injury and shows that the analysis of BAL cell mtDNA is feasible tool for testing the puta-
tive effects of oxidative stress during mechanical ventilation. However, and against our 
initial hypothesis, we could not find any detectable mtDNA mutation or deletion. The 
validity of our findings is limited by several factors such as the sample size, the relative 
inhomogeneity of the sample, the lack of parallel measurement of other oxidative stress 
markers, or the relative short exposure to the oxidative stimulus. The idea of our study 
was based on three generally accepted paradigms: I) Preterm newborns are very suscepti-
ble to oxidative stress 2,4,21,23,24,33; II) Oxidative stress plays a significant role in the patho-
physiology of ventilator-induced injury 1,2,4; and III) mtDNA is highly vulnerable to oxidative 
stress 7-9. Further studies including larger samples, which include longer periods and dif-
ferent strategies of mechanical ventilation, as well as different methods to evaluate 
mtDNA damage and function will be needed to assess whether the above paradigms also 
apply to the real clinical situation of mechanically ventilated preterm infants. 
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Abstract 
Objective: The objective of the study was to study the effects of histologic chorioamnioni-
tis (HC) with or without fetal involvement and antenatal steroid (AS) exposure on neonatal 
outcome in a prospective cohort of preterm infants. 
Study design: The clinical characteristics and placental histology were prospectively 
collected in 301 infants born at a gestational age 32.0 weeks or less in the Erasmus Uni-
versity Medical Center. 
Results: In univariable analyses, HC without fetal involvement (n = 53) was associated 
with decreased severe respiratory distress syndrome (RDS) (11% vs 28%; P < .05), whereas 
HC with fetal involvement infants (n = 68) had more necrotizing enterocolitis (9% vs 2%; P 
< .05), intraventricular hemorrhage (IVH) (25% vs 12%; P < .05), and neonatal mortality 
(19% vs 9%; P < .05). In HC without fetal involvement infants, AS reduced the incidences of 
RDS (43% vs 85%; P < .05) and IVH (5% vs 39%; P < .01). In multivariable analyses, HC 
without fetal involvement was associated with decreased severe RDS (odds ratio, 0.22; 
95% confidence interval, 0.05–0.93; P < .05) and increased early-onset sepsis (odds ratio, 
2.22; 95% confidence interval, 1.02–4.83; P < .05). 
Conclusion: In a prospective cohort of preterm infants, multivariable analyses reveal 
only a modest association between histologic chorioamnionitis and neonatal outcome. 
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Introduction 
Chorioamnionitis is an important cause of preterm birth. Consequently, the majority of 
very preterm infants has been exposed to chorioamnionitis, as shown by placental histol-
ogy 1. Several reports have linked histologic chorioamnionitis to adverse neonatal out-
come.  
Adverse neonatal outcome parameters most frequently associated with histologic 
chorioamnionitis in preterm infants include intraventricular hemorrhage (IVH), cerebral 
white matter abnormalities, and bronchopulmonary dysplasia (BPD) 2-9. Conversely, his-
tologic chorioamnionitis has been reported to reduce the incidence of respiratory distress 
syndrome (RDS) 4,9-15. The additional presence of a fetal inflammatory response seems to 
enhance the detrimental effects of chorioamnionitis on neonatal outcome 6,9,11,16,17. More 
recently several studies have linked chorioamnionitis to diseases beyond the neonatal 
period, such as cerebral palsy 16, autism 18, recurrent otitis media with effusion 19, and 
asthma 20.  
The vast majority of studies investigating the associations between histologic 
chorioamnionitis and adverse outcome have been retrospective in nature. Differences in 
inclusion and exclusion criteria between studies, as well as methodological issues, raise 
questions of external validity of the obtained data 9. Moreover, in many reports the data 
were not adjusted for important confounding variables, the most prominent being gesta-
tional age 9. Very few studies evaluated the combined effects of antenatal steroids and 
chorioamnionitis and separated the effects of histologic chorioamnionitis with and with-
out fetal involvement on neonatal outcome 9. 
Our aim was to explore the association between histologic chorioamnionitis and neo-
natal outcome in a prospective cohort of preterm infants, with particular focus on the 
distinct effects of chorioamnionitis with and without fetal involvement and the modula-
tory role of antenatal steroids. Multivariable models are used to adjust for potential con-
founders. 
Materials and methods 
Design 
This was a prospective, observational, nontherapeutic study with the aim to examine the 
association of histologic chorioamnionitis in early preterm delivery with neonatal out-
come. Pregnant women, who delivered between May 2001–February 2003 in the Erasmus 
University Medical Center–Sophia Children’s Hospital in Rotterdam, The Netherlands, at a 
gestational age of 32.0 weeks or less, were eligible for the study. Routine health care 
workers (residents, research-nursing staff, and neonatologists) informed the women 
about the study.  
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Enrolment was immediately after delivery when the newborns were admitted to the 
neonatal intensive care unit. Antenatal, perinatal, and neonatal data were prospectively 
stored in a database. Neonates who were transferred to another hospital were followed 
up to complete the data. Women received antenatal steroids (betamethasone 12 mg in-
tramuscularly, repeated after 24 hours) in case of imminent premature delivery.  
We used the following clinical definitions. Clinical chorioamnionitis included maternal 
temperature greater than 38.0°C in the absence of another focus for infection, with 2 or 
more of the following criteria: uterine tenderness, malodorous vaginal discharge, mater-
nal leucocytosis (white blood cell count > 15,000 cells/μL), raised serum C-reactive protein 
(CRP), maternal tachycardia (> 100 beats/min), and fetal tachycardia (> 160 beats/min). 
Preeclampsia was comprised of new onset hypertension (blood pressure > 140/90 mm Hg 
or mean arterial pressure > 105 mm Hg) with proteinuria and/or edema. HELLP syndrome 
(clinical presentation of intravascular hemolysis, elevated liver enzymes, and a low platelet 
count). Fetal distress was considered present when indicated by the obstetrician based on 
cardiotocographic criteria.  
Small for gestational age (SGA) was defined as birth weight less than 2 SD of the mean 
for gestational age. RDS was a clinical presentation (expiratory grunting, sub- or intercos-
tal or sternal retractions, nasal flaring, tachypnea, cyanosis in room air with or without 
apnea) and characteristic radiographic appearance according to Giedion et al. 21. BPD was 
a dependency on oxygen supplementation at a postmenstrual age of 36 weeks. IVH and 
cystic periventricular leukomalacia (PVL) were defined according to Volpe 22. Clinical neo-
natal sepsis was a clinical presentation of sepsis with raised CRP. Culture-proven neonatal 
sepsis was any systemic bacterial infection documented by a positive blood or cerebrospi-
nal fluid culture in the first 2 months of life. Early-onset neonatal sepsis was neonatal 
sepsis occurring during the first 72 hours of life. Necrotizing enterocolitis (NEC) was de-
fined as stage 2 or higher according to Bell et al. 23. Patent ductus arteriosus (PDA) was 
persistence of the open ductus arteriosus postnatally, as demonstrated by ultrasono-
graphic examination. Ethnicity was self-classified in this study. Gestational age was esti-
mated by ultrasonography or by using the last menstrual period when reliable. 
Histopathology 
Placentae and membranes were fixed in formalin for at least 16 hours immediately after 
delivery. Sampling was performed according to a standard protocol with 2 membrane 
rolls, 2 cross-sections of the cord, and 3 representative blocks of the placental disk as a 
minimum. The tissues were embedded in paraffin until histopathologic examination.  
To prevent interexaminer variation, the same pathologist (R.R.d.K.) examined all pla-
centas for histologic evidence of infection. The pathologist was blinded to clinical informa-
tion. Placental infection was categorized according to the stages of maternal and fetal 
inflammatory response, as suggested by the Amniotic Fluid Infection Nosology Committee 
24. According to these guidelines, fetal involvement was diagnosed when any of the follow-
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ing was present: chorionic vasculitis, umbilical phlebitis or vasculitis, (subacute) necrotiz-
ing funisitis, or concentric umbilical perivasculitis. 
Ethical aspects 
The study was approved by the Medical Ethics Committee for Research on Human Sub-
jects of the Erasmus University Medical Center, Rotterdam, The Netherlands. 
Statistics 
Data are presented as mean ± SD for continuous data, and median and interquartile range 
for ordinal data. Dichotomous data are expressed as frequencies and associated percent-
ages. Depending on the variable at stake, groups’ comparisons were carried out with ei-
ther parametric or nonparametric tests (Student t test or 1-way analysis of variance 
[ANOVA] with Dunnett’s post hoc analysis for the former and Mann-Whitney U test or 
Kruskall-Wallis test for the latter). χ2 or Fisher exact test was used for categorical data.  
Logistic multiple regression analysis was conducted to estimate the adjusted effects of 
the main explanatory variables of interest (gestational age and histologic chorioamnionitis 
with or without fetal involvement), as well as other potential predictors on the dichoto-
mous outcomes (RDS, severe RDS, PDA [early-onset] sepsis, IVH, severe IVH, cystic PVL, 
NEC, BPD, and neonatal mortality). Other potential predictors were the following: birth 
weight, ethnicity, sex, antenatal steroids, HELLP syndrome, preeclampsia, umbilical artery 
pH, mechanical ventilation (for BPD and mortality), PDA (for BPD and mortality), sepsis 
(for BPD and mortality), early-onset sepsis (for PDA and IVH), severe IVH, and NEC (both 
for mortality). The specified variables were entered in the start model together with a few 
prespecified 2-way interaction terms deemed as clinically relevant. A topdown procedure 
for variables selection was handled. Statistical analyses were performed using SPSS 15.0 
software (SPSS, Inc, Chicago, IL). 
Results 
Maternal and delivery characteristics 
Three hundred one preterm infants were included in the study. Histologic chorioamnioni-
tis was present in 121 of these (40.2%), 68 (56.2%) of whom had signs of fetal involve-
ment. Of the latter, all but 4 had inflammatory signs of both the fetal and maternal com-
partment. Maternal and delivery characteristics for the groups are shown in Table 1.  
Both chorioamnionitis groups had lower gestational age and significantly higher rates 
of clinical chorioamnionitis and preterm premature rupture of membranes when com-
pared with infants without chorioamnionitis. Conversely, mothers of infants without 
chorioamnionitis were more likely to have HELLP syndrome and preeclampsia and deliver 
by cesarean section. Their infants more often were SGA and more frequently experienced 
fetal distress, also reflected in lower umbilical cord pH and base excess. 
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Table 1. Maternal and delivery characteristics. 
Maternal characteristics HC- (n=180) HC+F- (n=53) HC+F+ (n=68) 
 Maternal age (yrs) 30.8 ±5.3 30.8 ±4.9 30.6 ±5.3 
 Parity 1 (1-2) 1 (1-2) 1 (1-3) 
 Gravidity 2 (1-2) 2 (1-2) 2 (1-3) 
 Ethnicity    
    Western Europe 132 (73) 40 (76) 45 (66) 
    Eastern Europe / Asia 4 (2) 4 (8) 2 (3) 
    Mediterranean 16 (9) 5 (9) 8 (12) 
    Sub-Saharan Africa 11 (6) 3 (6) 9 (13) 
    South America / Caribbean 17 (9) 1 (2) 4 (6) 
 Pregnancy characteristics    
 PPROM 28 (16) 16 (30)§ 42 (62)† 
 Clinical chorioamnionitis 21 (12) 28 (53)‡ 46 (68)‡ 
    Temperature ≥38.0°C 10 (6) 18 (34)‡ 29 (43)‡ 
    CRP raised 10 (6) 20 (38)‡ 39 (57)‡ 
    Leucocytosis 1 (1) 8 (15)† 18 (27)‡ 
    Uterine tenderness 0 (0) 5 (9)‡ 3 (4) 
    Cervical discharge 0 (0) 7 (13)† 19 (28)‡ 
 HELLP 62 (34) 3 (6)‡ 0 (0)‡ 
 Preeclampsia 100 (56) 5 (9)‡ 2 (3)‡ 
 None 32 (18) 6 (11) 12 (18) 
 1 dose 23 (13) 7 (13) 7 (10) 
 Antenatal steroids  
 ≥2 doses 123 (68) 40 (76) 49 (72) 
 Delivery characteristics    
 Gestational age (wks) 29.6 ±1.7 28.7 ±1.9§ 28.0 ±2.1‡ 
 Caesarean section 138 (77) 19 (36)‡ 19 (28)‡ 
 Singleton pregnancy 132 (73) 33 (62) 51 (75) 
 Male sex 90 (50) 30 (57) 34 (50) 
 Placental weight (g) 296 ±183 354 ±164 290 ±91 
 Birth weight (g) 1112 ±339 1249 ±365§ 1142 ±353 
 Small for gestational age 70 (39) 5 (9)‡ 4 (6)‡ 
 Fetal distress 109 (61) 17 (32)‡ 12 (18)‡ 
 pH 7.23 ±0.12 7.25 ±0.11 7.30 ±0.08‡  Umbilical artery  
 BE (mmol/l) -5.7 ±4.9 -5.7 ±4.7 -3.4 ±2.9† 
 1 min 6 (4-8) 6 (4-8) 5 (3-7) 
 5 min 8 (7-9) 8 (7-9) 8 (7-9) 
 Apgar score   
 10 min 9 (8-10) 9 (8-10) 9 (8-10) 
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Table 1 (previous page). Maternal and delivery characteristics of infants without histologic chorioamnionitis (HC 
negative) and those with chorioamnionitis with (HC positive, F positive) or without fetal involvement (HC posi-
tive, F negative). Numbers represent number of infants or mothers (positive percentage) in which characteristic 
is present for dichotomous data, median, and interquartile range for ordinal data and mean ± SD for continuous 
data. BE, base excess; CRP, C-reactive protein; F, fetal involvement; HC, histologic chorioamnionitis; HELLP, 
clinical presentation of intravascular hemolysis, elevated liver enzymes, and a low platelet count; PPROM, pre-
term premature rupture of membranes; SGA, small for gestational age. § P < .05; † P < .01; ‡ P < .001 vs HC nega-
tive (ANOVA or χ2 test, with Dunnett’s post hoc analysis). 
 
Neonatal outcome 
Neonatal outcome parameters for infants with histologic chorioamnionitis vs those with-
out chorioamnionitis are shown in Table 2. Infants with chorioamnionitis with fetal in-
volvement had higher incidences of NEC, IVH, and neonatal mortality when compared 
with infants without chorioamnionitis. The incidence of severe RDS was significantly lower 
in infants without fetal involvement but not in those with fetal involvement. Clinical 
chorioamnionitis was associated with an increased incidence of NEC (8% vs 2%; P = .02) 
but no significant change in any other outcome parameter (not shown). 
Chorioamnionitis, antenatal steroids, and neonatal outcome 
Within the 3 groups, no differences in any of the general characteristics were present 
between infants who had or had not received a full course of antenatal steroids (not 
shown). Neonatal outcome parameters for the 3 groups subdivided by antenatal steroid 
exposure are shown in Table 3. A full course of antenatal steroids significantly improved 
neonatal outcome only for infants with chorioamnionitis without fetal involvement, reduc-
ing the need for surfactant replacement therapy and the incidence of RDS, IVH, and severe 
IVH within this group. In addition, administration of any antenatal steroids (≥ 1 doses) 
reduced the need for PDA ligation in these infants (2% vs 33%; P = .006).  
When all infants with chorioamnionitis were considered, administration of any ante-
natal steroids was associated with an overall decrease in neonatal mortality (11% vs 28%, 
respectively; P = .048). Finally, in infants with clinical chorioamnionitis, antenatal steroids 
decreased the need for mechanical ventilation (76% vs 100%; P = .049) and PDA ligation 
(4% vs 23%; P = .009) and tended to decrease mortality (11% vs 31%; P = .06), IVH (14% vs 
31%; P = .055) and severe IVH (2% vs 10%; P = .053). Importantly, antenatal steroid ad-
ministration was not associated with an increase in adverse outcome in any chorioamnio-
nitis group. 
Chorioamnionitis and outcome: multivariable analyses 
In multivariable models, the only outcome parameters significantly affected by chorioam-
nionitis were severe RDS (Table 4) and early-onset sepsis (Table 5). Chorioamnionitis with-
out fetal involvement significantly reduced the risk for severe RDS when adjusted for eth-
nicity, preeclampsia, and gestational age (Table 4). Interestingly, in infants with fetal in-
volvement, a similar effect was present in the very preterm infants, whereas in contrast, in 
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more mature infants, fetal involvement was associated with an increased risk for severe 
RDS (Table 4). When adjusted for gestational age and birth weight, chorioamnionitis with-
out fetal involvement increased the risk for early-onset sepsis (Table 5). 
 
 
Table 2. Neonatal outcome. Neonatal outcome parameters in infants without histologic chorioamnionitis (HC 
negative) and those with chorioamnionitis with (HC positive, F positive ) or without fetal involvement (HC posi-
tive, F negative). BPD, bronchopulmonary dysplasia; F, fetal involvement; HC, histologic chorioamnionitis; IVH, 
intraventricular hemorrhage; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular 
leukomalacia; RDS, respiratory distress syndrome. § P < .05 vs HC negative (χ2 test with Dunnett’s post hoc analy-
sis). 
Outcome parameter 
(n (%)) 
HC- 
(n=180) 
HC+F- 
(n=53) 
HC+F+ 
(n=68) 
any grade 102 (57) 28 (53) 40 (59) RDS 
severe 50 (28) 6 (11)§ 19 (28) 
Mechanical ventilation 134 (74) 36 (68) 59 (87) 
Surfactant administered 88 (49) 25 (47) 33 (49) 
BPD 25 (15) 9 (18) 11 (20) 
Dexamethasone 11 (6) 7 (13) 6 (9) 
BPD or death 38 (21) 11 (21) 23 (34) 
Death 16 (9) 3 (6) 13 (19)§ 
total 55 (31) 21 (40) 23 (34) 
indomethacin treated 51 (28) 20 (38) 21 (31) 
PDA 
 
ligated  6 (3) 3 (6) 4 (6) 
NEC 3 (2) 4 (8) 6 (9)§ 
early onset 35 (20) 18 (34) 15 (22) 
    culture proven 12 (7) 6 (11) 4 (6) 
any sepsis 91 (51) 33 (62) 32 (47) 
Sepsis 
    culture proven 66 (42) 22 (42) 27 (40) 
any grade 22 (12) 7 (13) 17 (25)§ IVH 
grade 3-4 8 (4) 2 (4) 3 (4) 
Cystic PVL 5 (3) 2 (4) 2 (3) 
Comment 
In this prospective cohort of preterm infants, chorioamnionitis with fetal involvement was 
associated with increased incidences of IVH, NEC, and neonatal mortality in univariable 
analyses. However, none of these associations remained after multivariable adjustment. 
Conversely, chorioamnionitis without fetal involvement was independently associated 
with a lower severe RDS risk, whereas the effect of chorioamnionitis with fetal involve-
ment on the incidence of severe RDS was gestational age dependent. In addition, 
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chorioamnionitis without fetal involvement was independently associated with early onset 
sepsis. No other significant effect of chorioamnionitis on any adverse outcome parameter 
remained after multivariable adjustment. Antenatal steroids were shown to decrease 
neonatal mortality and morbidity predominantly in infants with chorioamnionitis without 
fetal involvement.  
The current study is one of very few prospective studies on neonatal outcome after 
histologic chorioamnionitis. The observed reduction in RDS incidence after chorioamnioni-
tis is in line with previous, mainly retrospective, reports 4,9-15. Both human and animal 
experimental data show that antenatal exposure to inflammation results in increased fetal 
lung maturation, providing a pathophysiologic basis for this association 25,26.  
 
 
Table 3. Neonatal outcome stratified by antenatal steroid exposure. Neonatal outcome parameters in patients 
without histologic chorioamnionitis (HC negative) and those with chorioamnionitis with (HC positive, F positive) 
or without fetal involvement (HC positive, F negative), depending on whether they received a full course of 
antenatal steroids (AS). BPD, bronchopulmonary dysplasia; F, fetal involvement; HC, histologic chorioamnionitis; 
IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; PVL, periven-
tricular leukomalacia; RDS, respiratory distress syndrome. § P < .05; † P < .01 vs AS negative (χ2 test with Dun-
nett’s post hoc analysis). 
HC- (n=180) HC+F- (n=53) HC+F+ (n=68) Outcome parameter  
(no. of patients (%)) S- (n=55) S+ (n=123) S- (n=13) S+ (n=40) S- (n=19) S+ (n=49) 
any grade 29 (53) 72 (59) 11 (85) 17 (43)§ 12 (63) 28 (57) RDS 
severe 12 (22) 38 (31) 2 (15) 4 (10) 7 (37) 12 (25) 
Mechanical ventilation 39 (71) 93 (76) 11 (85) 25 (63) 18 (95) 41 (84) 
Surfactant administered 30 (55) 58 (47) 11 (85) 14 (35)† 10 (53) 23 (47) 
BPD 6 (12) 19 (17) 4 (31) 5 (13) 3 (20) 8 (20) 
Dexamethasone 6 (11) 5 (4) 2 (15) 5 (13) 1 (5) 5 (10) 
BPD or death 9 (16) 29 (24) 4 (31) 7 (18) 7 (37) 16 (33) 
Death 4 (7) 12 (10) 0 (0) 3 (8) 5 (26) 8 (16) 
total 13 (24) 42 (34) 8 (62) 13 (33) 7 (37) 16 (33) 
indomethacin treated 13 (24) 38 (31) 7 (54) 13 (33) 7 (37) 14 (27) 
PDA 
 
ligated  2 (4) 4 (3) 2 (15) 1 (3) 1 (5) 3 (6) 
NEC 1 (2) 2 (2) 1 (8) 3 (8) 1 (5) 5 (10) 
early onset 9 (16) 26 (21) 3 (23) 15 (38) 3 (16) 12 (25) 
    culture  proven 2 (4) 10 (8) 0 (0) 6 (15) 1 (5) 3 (6) 
any sepsis 25 (46) 66 (54) 8 (62) 25 (63) 8 (42) 24 (49) 
Sepsis 
    culture proven 23 (42) 53 (43) 5 (39) 17 (43) 8 (42) 19 (39) 
any grade 8 (15) 13 (11) 5 (39) 2 (5)† 4 (21) 13 (27) IVH 
grade 3-4 3 (6) 5 (4) 2 (15) 0 (0)§ 1 (5) 2 (4) 
Cystic PVL 3 (6) 1 (1) 1 (8) 1 (3) 1 (5) 1 (2) 
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 Table 4. Multivariable model for prediction of severe respiratory distress syndrome. Estimated odds ratios 
based on the multiple logistic regression model for prediction of severe respiratory distress syndrome. Arbitrary 
cutoff values for gestational age are used to explore the interaction with chorioamnionitis with fetal involve-
ment. CI, confidence interval; OR, odds ratio.  
Outcome = severe respiratory distress syndrome 
Factor OR (95% CI) P value 
Ethnicity (ref = Western Europe)   
    Eastern Europe / Asia 0.28 (0.03-2.40) .25 
    Mediterranean 0.30 (0.10-0.97) .04 
    Sub-Saharan Africa 0.07 (0.01-0.60) .02 
    South America / Caribbean 0.51 (0.17-1.53) .23 
Preeclampsia 2.45 (1.20-4.98) .01 
Chorioamnionitis (ref = no chorio)   
    Chorioamnionitis (maternal side only) 0.22 (0.05-0.93) .04 
    Chorioamnionitis + fetal involvement 1.41 (0.60-3.32) .43 
Gestational age (per wk increase) 0.55 (0.43-0.69) <.001 
Chorioamnionitis (maternal side only) x gestational age 0.98 (0.52-1.83) .94 
Chorioamnionitis + fetal involvement x gestational age 1.57 (1.10-2.25) .01 
    Gestational age = 26 wks 0.35 (0.11-1.08)  
    Gestational age = 28 wks 0.86 (0.39-1.91)  
    Gestational age = 30 wks 2.12 (0.76-5.87)  
 
 
Table 5. Multivariable model for prediction of early onset sepsis. Estimated odds ratios based on the multiple 
logistic regression model for prediction of early onset sepsis. CI, confidence interval; OR, odds ratio. 
Outcome = early onset sepsis 
Factor OR (95% CI) P value 
Chorioamnionitis (ref = no chorio)   
    Chorioamnionitis (maternal side only) 2.22 (1.02-4.83) .04 
    Chorioamnionitis + fetal involvement 0.86 (0.39-1.92) .72 
Gestational age (per wk increase) 0.82 (0.67-1.01) .07 
Birth weight (per kg increase) 0.29 (0.09-0.98) .047 
 
 
In our study, the effect was predominantly present in infants without signs of fetal in-
volvement. Paradoxically, Lahra et al 11 recently showed that chorioamnionitis was associ-
ated with decreased RDS risk in infants both without and with fetal involvement and that 
the effect was largest in the latter group. Our data revealed an interaction between 
chorioamnionitis with fetal involvement and gestational age in predicting RDS risk. Infants 
with fetal involvement had decreased RDS risk when their gestational age was low, 
whereas the risk increased with advancing gestational age. Because the study by Lahra et 
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al 11 included younger infants than the present study, a gestational age-dependent effect 
of fetal inflammation on RDS incidence may explain why they found an overall reduction 
of RDS in these infants. This interaction underlines the complexity of the association be-
tween chorioamnionitis, gestational age, and neonatal outcome 9.  
Perhaps the most striking finding is the nearly complete absence of associations be-
tween chorioamnionitis and adverse outcome parameters after multivariable adjustment. 
This is in agreement with more recent epidemiologic studies, reporting relatively little 
correlation between chorioamnionitis and adverse neonatal outcome in multivariable 
models 13. We hypothesize that changes in clinical practice in neonatal intensive care may 
have contributed to these seemingly diminishing associations 9.  
An example of such a practice change is the increased use of antenatal steroids. Pre-
vious studies have shown antenatal steroids to decrease RDS 27, PDA 27, neurologic mor-
bidity 10,27, neonatal mortality 10,27, and the systemic inflammatory response syndrome 28 
in chorioamnionitis-exposed infants. The current study is the first to investigate the dis-
tinct effects of antenatal steroids on neonatal outcome in infants with chorioamnionitis 
with or without additional fetal involvement. Antenatal steroids significantly improved 
outcome mainly for infants without fetal signs of inflammation, further supporting their 
beneficial role in diminishing the association of chorioamnionitis with adverse outcome. 
Antenatal steroids reduced adverse outcome in infants with clinical chorioamnionitis as 
well, and, importantly, no harmful effects were observed in any chorioamnionitis group. 
The observed reductions in RDS incidence, need for surfactant, IVH, and neonatal mortal-
ity after antenatal steroids are in line with earlier human reports and animal experimental 
data 9,10,27,29. Despite the fact that all observational data currently available regarding the 
efficacy of antenatal steroids in infants with intrauterine inflammation have been reassur-
ing, a hesitant attitude remains regarding the use of antenatal steroids in this group 30,31. 
The current study adds to the available evidence, suggesting both the safety and necessity 
of a randomized trial of antenatal steroids in infants with suspected intrauterine inflam-
mation 28,30.  
Despite earlier evidence of significant associations between chorioamnionitis and out-
come parameters, such as cystic PVL and NEC 5,13,16, these were not observed in the pre-
sent study. In spite of its considerable cohort size, this may relate to the low overall inci-
dence of these outcomes. However, it is worth mentioning that the incidence of NEC was 
higher in infants with fetal involvement in univariable analysis and clearly tended to be 
higher in both chorioamnionitis groups in adjusted analyses.  
Fetal signs of inflammation are considered to represent the more serious side of the 
chorioamnionitis continuum. In this light, the association of chorioamnionitis without fetal 
involvement with early-onset sepsis, as demonstrated in our cohort, is surprising. Unad-
justed data from some previous studies seem to point in the same direction 3,14,32, 
whereas others have not separated the effects of chorioamnionitis with or without fetal 
involvement 8,10,33.  
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Experimental data in preterm sheep suggest that antenatal inflammation results in 
programming of the fetal immune response. Depending on time after exposure, in-
traamniotic endotoxin resulted in either a decreased or increased inflammatory response 
of cord blood monocytes to subsequent endotoxin exposure 34. In addition, repeated an-
tenatal exposure seemed to depress the inflammatory response 34. Since fetal and mater-
nal histologic signs of inflammation are believed to represent both differences in severity 
and timing of inflammation, differential regulation of the preterm immune response may 
well underlie their distinct effects on susceptibility for early-onset sepsis. Moreover, ante-
natal steroids have been shown to modulate the fetal immune response following expo-
sure to inflammation in preterm sheep 35. However, in the current study, an additional 
effect of antenatal steroids on sepsis susceptibility could not be demonstrated.  
An important drawback in cohort studies investigating the effects of chorioamnionitis 
on outcome is the absence of a healthy control group. Most infants without chorioamnio-
nitis have been exposed to potential adverse effects of maternal preeclampsia, HELLP 
syndrome, or placental insufficiency. Because most infants with chorioamnionitis have not 
been exposed to these entities, adverse outcome after chorioamnionitis may just as well 
indicate improved outcome after HELLP syndrome or preeclampsia and vice versa 9. In our 
study, these distinct antenatal modulators have been included in multivariable models, 
increasing the precision of the conclusions. Moreover, this may partly explain the absence 
of a significant effect of chorioamnionitis on adverse neonatal outcome. Additional larger 
studies are needed to further disentangle the effects of various antecedents on outcome 
in preterm infants.  
In conclusion, chorioamnionitis was shown to have relatively little impact on neonatal 
outcome. Changes in clinical practice may account for this gradually diminishing associa-
tion over time. Complex interactions with antenatal steroid exposure and gestational age-
dependent effects seem to exist. Additional research is needed to study these interactions 
and their underlying mechanisms and further explore the long-term effects of chorioam-
nionitis on health and disease 36. 
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Appendix  
 
Antenatal corticosteroids to prevent  
preterm birth 
 
 
Been JV, Kramer BW, Zimmermann LJ 
 
Lancet 2009; 373: 894 
 
(Comment on: Murphy KE et al. Lancet 2008; 372: 2143-2151) 
 
 
Note: 
This letter was written in response to the publication of a randomised controlled trial of 
repeat courses of antenatal steroids for fetal lung maturation. The aim was to emphasize 
the importance of investigating the effects of antenatal steroids in patients with 
chorioamnionitis, a group excluded from this trial, as well as from most previous antenatal 
steroid trials. 
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To the editor, 
We welcome publication of the MACS trial report 1. What concerns us is that, in line with 
many earlier trials of single-course and with all trials of multiple-course antenatal steroids 
for preterm birth, infants with chorioamnionitis were excluded. In very preterm infants 
the incidence of clinical chorioamnionitis is around 10–30%. Thus, exclusion of these in-
fants leads to an important reduction in external validity. Moreover, a growing body of 
evidence suggests that an opportunity is being missed when withholding antenatal ster-
oids from infants with chorioamnionitis. In infants with signs of intrauterine inflammation, 
including clinical and histological chorioamnionitis, antenatal steroid administration is 
associated with reductions in respiratory distress syndrome, patent ductus arteriosus, 
systemic inflammatory response syndrome, severe cerebral lesions, cerebral palsy, and 
neonatal mortality 2-4. In a prospective cohort (n=301), we saw similar reductions in respi-
ratory distress syndrome, intraventricular haemorrhage, ductus ligation, and mortality 
after antenatal steroids in infants with chorioamnionitis (unpublished data). Additionally, 
a meta-analysis of single-course studies showed particular benefit in infants with preterm, 
prelabour rupture of membranes, without an adverse effect on maternal outcome 5.  
Thus, whereas a general concern exists around antenatal steroid administration when 
intrauterine infection is suspected, recent studies leave no grounds for this fear and even 
seem to support this practice. We are in need of randomised trials of antenatal steroids 
that either focus on infants with chorioamnionitis or provide specific subgroup analysis for 
this group. Only then will we be able to validate or decline the generally restricted use of 
antenatal steroids in the setting of suspected intrauterine infl ammation. 
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Abstract 
Background: There is debate concerning the safety and efficacy of antenatal steroids (AS) 
in preterm labour with suspected intrauterine infection (chorioamnionitis; CA). 
Objectives: We aimed to evaluate perinatologists’ views on the efficacy, potential haz-
ards and available evidence of AS in clinical CA. Secondly, we performed a systematic 
literature review and meta-analysis on the efficacy of AS in clinical and histological CA. 
Methods / search strategy: We performed a nationwide survey among Dutch perina-
tologists (n=116). Furthermore, MEDLINE and EMBASE were searched using the terms 
‘chorioamnionitis OR intrauterine infection’ and ‘steroids OR corticoids’.  
Selection criteria:  Studies reporting selected neonatal outcome measures in preterm 
infants with clinical or histological chorioamnionitis, according to AS exposure, were eligi-
ble. 
Data collection and analysis: Study selection, data extraction and data analysis were 
done by two independent investigators. Meta-analysis techniques used included Mantel-
Haenszel analysis, assessment of study heterogeneity using Q statistic, and Eggers regres-
sion test and Funnel plots to assess publication bias. 
Main results: Great diversity was present among perinatologists regarding the use of 
AS in CA. Most acknowledged the lack of evidence on the subject. Seven observational 
studies were included in the meta-analysis. In histological CA, AS were associated with 
reduced mortality (OR[95%CI]=0.45[0.30-0.68]; p<.0001), RDS (OR[95%CI]=0.52[0.40-
0.71]; p<.0001), PDA (OR[95%CI]=0.56[0.37-0.85]; p=.007), IVH (OR[95%CI]=0.35[0.19-
0.66]; p=.001), and severe IVH (OR[95%CI]=0.39[0.19-0.82]; p=.01). In clinical CA, AS were 
associated with reduced severe IVH (OR[95%CI]=0.28[0.09-0.87]; p=.03) and PVL 
(OR[95%CI]=0.31[0.12-0.76]; p=.01).  
Conclusions: AS may reduce adverse neonatal outcome after preterm birth associated 
with CA. There is a need for RCTs addressing this issue. 
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Introduction 
Maternal administration of corticosteroids is an effective therapy to reduce respiratory 
distress and improve neurological morbidity and mortality in the preterm newborn. This 
approach has become standard care in case of imminent or anticipated preterm delivery 1. 
However, general concern exists regarding the administration of antenatal steroids in case 
of suspected intrauterine infection. Available guidelines delineate chorioamnionitis as a 
contraindication for antenatal steroids, although the scientific basis for this recommenda-
tion remains obscure 2,3. Accordingly, pregnant women exhibiting signs suggestive of in-
trauterine infection (clinical chorioamnionitis) have often been excluded from randomised 
controlled trials (RCTs) investigating the effect of antenatal steroids on neonatal outcome 
4. As a consequence, there is an important lack of data regarding the effects of antenatal 
steroids on neonatal outcome in the setting of suspected intrauterine infection 4. 
Antenatal infection or inflammation can be diagnosed in various ways. The diagnosis 
of chorioamnionitis based on histological examination of the placenta and associated 
tissues is probably the most reliable and valid marker of intrauterine infec-
tion/inflammation 5. Although accurate, this histological diagnosis can only be made after 
birth, which is why clinical criteria are often used to try to identify patients with intrauter-
ine infection. However, numerous studies have shown the agreement between this so-
called clinical chorioamnionitis and the histological diagnosis to be poor 6. To the best of 
our knowledge, RCTs reporting the effect of antenatal steroids in the subgroup of patients 
with either clinical or histological chorioamnionitis are non-existent. Observational studies 
addressing this issue are available, which thus should represent the best evidence cur-
rently available on the efficacy of antenatal steroids in patients with chorioamnionitis. 
Contrary to the general reluctance, the positive findings of single studies have led investi-
gators to suggest justification of a more liberal use of antenatal steroids in patients with 
suspected intrauterine infection/inflammation 4,7,8.  
In this current report, we describe the results of a nationwide survey in the Nether-
lands to assess perinatologists’ views on giving antenatal steroids in the setting of sus-
pected intrauterine infection. Furthermore, we performed a systematic review and meta-
analysis on antenatal steroid administration and neonatal outcome in preterm infants 
with chorioamnionitis. These results are reported separately for clinical and histological 
chorioamnionitis because of important differences in diagnostic criteria between the two. 
Methods 
Survey 
An email-based nationwide questionnaire survey was performed among all Dutch perina-
tologists (n=116). The survey consisted of four multiple choice questions aimed at assess-
ing the respondent’s view on the efficacy, potential hazards and available evidence re-
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garding administration of antenatal steroids in the setting of suspected intrauterine infec-
tion (Table 1). A single reminder was sent to all non-responders one month after the first 
approach. 
Systematic review - sources 
A systematic literature search was performed independently by two investigators (JVB and 
PLD) using online databases for medical literature (MEDLINE and EMBASE (both from 1966 
onwards)). In order to maximise the probability of identifying potentially relevant articles, 
broad search terms were used ((chorioamnionitis OR intrauterine infection) AND (steroids 
OR corticoids)) without additional restrictions. Additional searches were made by screen-
ing references lists from articles of interest as well as citations to articles of interest, using 
ISI Web of Knowledge.  
Systematic review - study selection 
Articles in any language were eligible for inclusion in the meta-analysis if they reported 
one or more neonatal outcome measures of interest according to antenatal steroid status 
in preterm infants with either histological or clinical chorioamnionitis. Neonatal outcome 
measures of interest were the following: neonatal mortality, RDS, bronchopulmonary 
dysplasia (BPD), IVH, severe IVH (grade 3-4), periventricular leukomalacia (PVL), necrotis-
ing enterocolitis (NEC), patent ductus arteriosus (PDA), culture proven early onset sepsis 
(within 72 hrs after birth) and any culture proven sepsis during admission. Composite 
outcome measures were not included in the meta-analysis. Study characteristics and pa-
tient data were extracted separately by the two investigators and subsequently cross-
referenced. Any disagreement was resolved by consensus. The corresponding author of an 
article of interest was contacted in order to clarify any indistinctions, if present.  
Systematic review - analyses 
Aggregate odds ratios (OR) and 95% confidence intervals (CI) were calculated using Man-
tel-Haenszel analysis (fixed effects model). Study heterogeneity was examined using both 
qualitative and quantitative assessment (Q statistic). When important heterogeneity was 
present, a random effects model was applied. Given the absence of valid and relevant 
general quality scores for observational studies 9, study quality was assessed in a non-
quantitative manner. To further assess effects of potential heterogeneity, fixed effect and 
random effect models were compared for each outcome, and subgroup analyses were 
performed were possible. Eggers regression test and Funnel plots were used to assess 
publication bias. An alpha level of .05 was applied in all analyses except for testing of 
study heterogeneity, where p<.10 was considered significant. All calculations were per-
formed using MIX 1.7 software 10. Results are presented according to the MOOSE criteria 
for meta-analysis of observational studies 9. 
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Table 1. Survey. Translated from Dutch. Abbreviations: ROM=rupture of membranes; CRP=C-reactive protein; 
CTG=cardiotocography; RCT=randomised controlled trial. 
Question Response  
(n (%)) 
1. A woman is 30 weeks pregnant and presents with ROM, preterm labour and clinical chorioam-
nionitis (T 38.5°C, leucocytosis, elevated CRP, no other focus). CTG registration shows mild tachy-
cardia, but is otherwise uneventful.  
A. I give antibiotics ± paracetamol, and wait and see. 
B. A. plus I give antenatal steroids. 
C. I give antibiotics ± paracetamol, and start tocolysis. 
D. C. plus I give antenatal steroids. 
E. I give antibiotics and perform a C-section 
 
 
 
21 (36) 
28 (48) 
1 (2) 
4 (7) 
5 (9) 
2. Antenatal steroids improve neonatal outcome, also when intrauterine infection is clinically 
present 
A. Yes 
B. No 
C. Insufficient evidence is available on this issue 
 
 
7 (12) 
3 (5) 
48 (83) 
3. Antenatal steroids are potentially hazardous when intrauterine infection is clinically present 
A. No 
B. Yes, for the fetus 
C. Yes, for the mother 
D. Yes, for both mother and fetus 
E. Insufficient evidence is available on this issue 
 
7 (12) 
1 (2) 
7 (12) 
14 (24) 
29 (50) 
4. Performing an RCT assessing the safety and efficacy of antenatal steroids in imminent preterm 
birth with suspected intrauterine infection would be: 
A. Useful 
B. Pointless, sufficient evidence is available 
C. Unethical, antenatal steroids should be given regardless of whether intrauterine infection is 
present 
D. Risky for mother and/or the fetus 
 
 
35 (64) 
0 (0) 
5 (9) 
 
14 (26) 
Results 
Survey 
Four perinatologists (3.4%) could not be reached by email. Of the remaining 112 perina-
tologists, 59 responded (53%). The full results are displayed in Table 1. Briefly, in a preg-
nant woman of 30 weeks gestation with preterm labour and clinical chorioamnionitis, a 
minority would start tocolysis (9%) while another 9% would perform a caesarean section. 
Conversely, only two percent would start tocolysis. Fifty-four percent would give antenatal 
steroids, even though many feel there is a lack of evidence on their efficacy (83%) and 
safety (50%) in chorioamnionitis. Giving steroids to a mother with clinical chorioamnionitis 
is considered potentially harmful to either the baby, the mother, or both by 38%. Finally, 
64% of the respondents would favour an RCT on the efficacy and safety of antenatal ster-
oids in preterm labour with clinical chorioamnionitis, although another 26% fear the po-
tential risks for mother and child.  
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Systematic review - study selection and characteristics 
Eight studies were identified that reported one or more outcome measures of interest for 
infants exposed to chorioamnionitis who did or did not receive antenatal steroids (Table 2) 
6,7,11-16. All studies were observational cohort studies, no RCTs addressing the effect of 
antenatal steroids within chorioamnionitis-exposed infants were identified. Of the eight 
studies, one small study was excluded because it included a highly selected cohort and 
applied liberal exclusion criteria, complicating extrapolation of the findings 16. General 
characteristics of the studies included in the meta-analysis are shown in Table 2. 
 
 
Table 2. Study characteristics. AS+ indicates the number of antenatal steroid doses used as a cut-off to deter-
mine antenatal steroids administration as positive. – no exclusion criteria used; ? no data available; *rescue 
course in selected cases ≥1 wk after initial full course. Abbreviations: AS=antenatal steroids; US=United States; 
CC=clinical chorioamnionitis; Retro=retrospective; HC=histological chorioamnionitis; Beta=betamethasone; 
Fra=France; DM=diabetes mellitus; Dex=dexamethasone; Aus=Australia; Pro=prospective; NL=Netherlands.  
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Elimian 
2000 10 
1990-
1997 
US 500-1750 g CC Retro HC Beta 12 24 ≥2× Yes 169 
 
358 32% 
Baud 
2000 11 
1993-
1997 
Fra <33 wks 
Singletons 
Severe DM; 
multiple 
malforma-
tions 
Retro CC Beta 
/Dex 
12 
6 
24 
12 
≥1× Yes 60 110 35% 
Dempsey 
2005 12 
1989-
1999 
US <30 wks 
Singletons 
- Retro HC Beta 12 24 ≥2× ? 88 42 68% 
Foix-
L’Helias 
2005 13 
1993-
1996 
Fra 24-31 wks 
Singletons 
- Retro CC Beta 
/Dex 
12 
6 
24 
12 
≥1× Yes 45 52 46% 
Kent 
2005 14 
1996-
2001 
Aus <30 wks - Pro HC Dex 12 12 ≥2× Yes 58 14 81% 
Golden-
berg 
2006 7 
1996-
2001 
US 23-32 wks 
Singletons 
- Retro HC
CC 
Beta 12 24 ≥1× Yes* 182 36 80% 
Been 
2009 6 
2001-
2003 
NL <32 wks Congenital 
anomalies 
Pro HC
CC 
Beta 12 24 ≥2× No 89 32 74% 
 
 
Three studies report the effect of antenatal steroids in infants with histological chorioam-
nionitis only 11,13,15, two in infants with clinical chorioamnionitis only 12,14 and two in both 
groups 6,7. All studies accepted overlap between clinical and histological chorioamnionitis, 
except for one in which infants with clinical chorioamnionitis were excluded 11. Variation 
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exists in the diagnostic criteria used to define both clinical and histological chorioamnioni-
tis and the outcome measures of interest (Table 3). The overall study quality was compa-
rable between reports. In all of the studies, consecutively born preterm infants were stud-
ied and essential maternal, perinatal and neonatal characteristics were documented, al-
though data collection was retrospective in most studies. Only one study reported com-
parison of chorioamnionitis-exposed infants treated or not treated with antenatal steroids 
with regard to baseline characteristics, showing no differences 6. 
Corresponding authors were contacted to obtain crude data when percentages were 
used 7,13,14 and obtain additional information on antenatal steroid administration (prepara-
tion, dose, dosing scheme) 7,12,14,15. Several responded and supplied additional information 
7,12,14,15. A 10% cohort overlap between the studies by Foix-L’Helias et al and Baud et al 
was reported 12,14. This was not accounted for in the meta-analysis and thus may slightly 
affect the pooled estimate on RDS after clinical chorioamnionitis (Figure 2). 
Meta-analysis - histological chorioamnionitis 
Individual study data and the results of meta-analysis of the effects of antenatal steroids 
in infants with histological chorioamnionitis are shown in Figure 1. For this purpose, re-
sults reported separately for chorioamnionitis with and without fetal inflammatory re-
sponse were pooled 6,15. Administration of antenatal steroids was associated with signifi-
cant reductions in neonatal mortality, RDS, PDA, IVH and severe IVH after histological 
chorioamnionitis. No significantly increased risk for any adverse outcome was detected 
after antenatal steroids. For early onset sepsis a random effects model was applied be-
cause of study heterogeneity (p=.04). No statistical indications for publication bias were 
present for any outcome measure. 
Meta-analysis - clinical chorioamnionitis 
Figure 2 shows individual study data and results of meta-analysis of the effects of antena-
tal steroids in infants with clinical chorioamnionitis. In these infants, antenatal steroids 
were associated with significant reductions in severe IVH and PVL. Again, no significant 
association between antenatal steroid administration and any adverse outcome measure 
was observed. In meta-analyses that included at least three studies, no indications for 
publication bias were present. 
Meta-analysis - sensitivity analysis 
The low number of studies and almost complete absence of subgroup specific data reports 
did not allow for subgroup analyses to be performed. Application of a random effects 
model did not importantly affect the effect size or significance level for most outcome 
measures (not shown). However, regarding the effect of antenatal steroids on severe IVH 
and PVL in infants with clinical chorioamnionitis, the random effects model resulted in loss 
of significance, although the point estimate remained essentially the same (OR [95%CI] = 
0.32 [0.03-3.29], p=.32; and OR [95%CI] = 0.38 [0.07-2.02], p=.25, respectively). 
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Table 3. Diagnostic criteria from individual studies. – outcome not reported. Abbreviations: HC=histological 
chorioamnionitis; CC=clinical chorioamnionitis; PL=preterm labour; mat=maternal; CRP=C-reactive protein; 
WBC=white blood cell count; +ve=positive; AF=amniotic fluid; PMNs=polymorphonuclear leucocytes; 
PPROM=preterm premature rupture of membranes; EOS=early onset sepsis; RDS=respiratory distress syndrome; 
MV=mechanical ventilation; TAF=tracheal aspirate fluid; FiO2=fraction of inspired oxygen; CPAP=continuous 
positive airway pressure; BPD=bronchopulmonary dysplasia; PMA=postmenstrual age; IVH=intraventricular 
haemorrhage; PVL=periventricular leukomalacia; NEC=necrotising enterocolitis; PDA=patent ductus arteriosus; 
CSF=cerebrospinal fluid. 
Diagnosis Elimian  
2000 
Baud  
2000 
Dempsey  
2005 
Foix-L’Helias 
2005 
Kent  
2005 
Goldenberg  
2006 
Been  
2009 
Chorio- 
amnionitis 
    
HC: Salafia 17 CC: PL + ≥2 
of: ≥2x mat T 
>38°C; mat 
CRP>40mg/l  
or WBC 
>18e3/ml;  
+ve AF 
culture 
HC: Abun-
dant PMNs 
in chorion + 
amnion 
CC: PL without 
PPROM + ≥2 
of the follow-
ing: mat T 
>38°C; mat 
CRP>20mg/l; 
+ve AF cultu-
re; EOS 
HC: 
Naeye 18 
and 
Lewis 19 
HC: Bendon 20, 
Faye-Petersen 21, 
and Redline 22 
CC: diagnosed by 
obstetrician  
(usually fever +  
abdominal pain + 
elevated WBC) 
HC: Redline 23 
CC: mat T>38°C +  
no other focus + ≥2 of: 
uterine tenderness; 
malodorous vaginal 
discharge; mat WBC 
>15e3/ml, raised CRP, 
mat / fetal tachycardia
RDS MV + O2 
need for 
≥48h + 
typical X-ray 
at <24h ≥2 
of: clinical 
signs;  
typical X-ray;  
lung imma-
turity in TAF  
≥3 of: clinical 
signs; FiO2 
>30% at 12-
72h; CPAP/ 
MV; typical  
X-ray 
at <48h ≥2 of: 
MV+O2 need; 
surfactant;  
typical X-ray; 
lung immatur-
ity in TAF 
- O2 need at 6-24h 
or X-ray at <24h 
consistent with 
RDS or need for 
surfactant 
Clinical signs  
+ typical X-ray  
according to Giedion 24
BPD - - - O2 at 36 w 
PMA 
- O2 at 36 w PMA O2 at 36 w PMA 
IVH Papile 25 Papile 25 Papile 25 
 
- Papile 25 
and De 
Vries 26 
Volpe 27 Volpe 27 
PVL echolucency 
or persistent 
echogenicity
cystic echo-
lucency 
before death 
or 6w of age 
- - - Volpe 27 
 
 
Volpe 27 
NEC Clinical signs 
+ X-ray, 
surgery/ 
autopsy 
confirmed 
- Intramural 
gas on X-ray 
or perfora-
tion or 
necrosis at 
surgery 
/autopsy 
- 
 
 
- Bell stage ≥2 28 Bell stage ≥2 28 
PDA requiring 
medication 
or surgery 
- - - - - Ultrasound criteria + 
requiring medication 
or surgery 
Sepsis +ve blood or 
CSF culture 
- - - - +ve blood culture 
no contamination  
+ve blood or CSF 
culture + clinical signs 
Early on- 
set sepsis 
- - +ve blood 
culture ≤72h 
- 
 
- - sepsis ≤72 h 
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Figure 1 A-E. Histological chorioamnionitis: Meta-analysis of the effect of antenatal steroids on selected neo-
natal outcome measures.  
174 
 
 
Figure 1 F-J. Histological chorioamnionitis: Meta-analysis of the effect of antenatal steroids on selected neona-
tal outcome measures.  
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Figure 2 A-E. Clinical chorioamnionitis: Meta-analysis of the effect of antenatal steroids on selected neonatal 
outcome measures. Figures from Been et al are partly unpublished data. 
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Figure 2 F-J. Clinical chorioamnionitis: Meta-analysis of the effect of antenatal steroids on selected neonatal 
outcome measures. Figures from Been et al are partly unpublished data. 
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Discussion 
There is great diversity in perinatologists’ views on the efficacy and safety of antenatal 
steroids in suspected chorioamnionitis. Many fear adverse effects in mother or child, and 
acknowledge the lack of evidence available on the subject. Although the majority would 
support an RCT to resolve the issue, many fear potential harms for mother and child. By 
performing a systematic review and meta-analysis, we aimed to put together the current 
best evidence on the subject. Only observational studies were available, and when aggre-
gated these suggest that antenatal steroids are beneficial in both histological and clinical 
chorioamnionitis, without increasing adverse outcome. 
Clearly, there is debate regarding the efficacy and potential hazards of antenatal ster-
oids in chorioamnionitis. To the best of our knowledge, as yet no aggregated data were 
available on how treating physicians view this issue and cope with it in daily practice. Our 
data show that, at least in the Netherlands, great diversity exists in whether or not ante-
natal steroids are given in the setting of suspected intrauterine infection, as well as in the 
underlying rationale. This underlines the scarcity of evidence on the subject, also ac-
knowledged by the majority of respondents. By restricting the questionnaire to four mul-
tiple choice questions and making it email-based, we aimed to increase our response rate, 
which in the end was reasonable. 
To our knowledge, no previous attempt was made to systematically review the avail-
able evidence on the efficacy and safety of antenatal steroids in chorioamnionitis. Given 
the lack of RCTs on the issue, the current aggregation of observational studies provides 
the current best evidence on this subject.  
The MOOSE statement underlines the usefulness of meta-analyses of observational 
studies when assessing efficacy and effectiveness of therapies, as long as potential sources 
of bias are considered and discussed 9. We believe the relative uniformity of inclusion 
criteria and outcome parameters used, and the separation of analyses for histological and 
clinical chorioamnionitis, justify performing a meta-analysis by statistically aggregating the 
data. The absence of statistical indications for publication bias and study heterogeneity 
(except for early onset sepsis after clinical chorioamnionitis) further supports the validity 
of the results. However as noted, although a meta-analysis may substantiate the conclu-
sions drawn from the available evidence, several important limitations should be ac-
knowledged. 
Overall the number of studies suitable for inclusion was low. Although individual co-
horts were of considerable size, this may introduce bias mainly through differences in 
inclusion and exclusion criteria between studies. An important example is the exclusion of 
infants with clinical chorioamnionitis by Elimian and colleagues 11. Given the association 
between clinical chorioamnionitis and severity of histological chorioamnionitis, this may 
have led to exclusion of more severely affected infants with histological chorioamnionitis 
29. While antenatal steroids seem to improve outcome predominantly in infants with less 
severe chorioamnionitis 6, an overestimation of their positive effect on neonatal outcome 
178 
may result. Resultant bias could be important due to the large cohort size of this particular 
study. Another consequence of the small number of studies, is that results from a single 
study may sometimes largely explain the overall meta-analysis outcome. An example is 
the association between antenatal steroids and improved neurological outcome in infants 
with clinical chorioamnionitis, which is largely explained by results from the study by Baud 
et al 12. 
Aspects regarding the administration of antenatal steroids need additional considera-
tion. Differences between studies are present in the type of drug used, in drug dosing and 
timing, and whether or not multiple courses were allowed. The latter may be a con-
founder, since repeat courses are less likely to have been given to mothers with 
chorioamnionitis 4. In some instances, steroids may not have been given because delivery 
ensued very quickly after admission, leading to a potential source of bias. Moreover, an-
tenatal steroid administration was scored as positive by some authors only when a full 
course was administered, while others also included infants that received incomplete 
courses in the steroid group. Incomplete courses of antenatal steroids have been shown 
to have some effect on outcome. Thus, differences between studies may arise from 
whether infants who received an incomplete course were assigned to the treatment group 
or the control group. Another source of variation between studies is introduced by differ-
ences in diagnostic criteria related to both chorioamnionitis and outcome definitions. 
Comparison of random effects and fixed effects models suggests that the effect of hetero-
geneity is limited for most outcomes. However, in infants with clinical chorioamnionitis 
the random effects model resulted in loss of significance of the beneficial effect of antena-
tal steroids, suggesting that study heterogeneity could account for part of the observed 
effect. In summary, while the meta-analysis clearly suggests that antenatal steroids may 
be beneficial in both histological and clinical chorioamnionitis, the results should be inter-
preted with great care given these methodological considerations. 
Certain additional issues should be taken into account when interpreting the data. 
Most importantly, there is a lack of information on timing of steroid administration rela-
tive to the emergence of signs suggestive of intrauterine infection. As stressed by Golden-
berg et al, steroids may have been administered before the occurrence of clinical 
chorioamnionitis in the majority of cases 7. Outcome measures of these infants obviously 
are not very helpful in guiding the use of antenatal steroids when intrauterine infection is 
clinically apparent. Thus, although antenatal steroids are associated with improved short-
term neurological outcome in infants with clinical chorioamnionitis in the current meta-
analysis, one should be prudent in extrapolating these findings to the clinical situation 
directly. Also, identification of potential maternal adverse effects of steroid administration 
in the setting of suspected intrauterine infection was beyond the scope of this review, 
although none were reported in the studies included in this meta-analysis. In this respect 
it is important to note that antenatal steroid administration in itself has been shown not 
to increase the risk of developing clinical chorioamnionitis 1. 
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From one standpoint, the efficacy of antenatal steroids in histological chorioamnioni-
tis may not seem clinically relevant, since placental histology is not available to the obste-
trician when deciding whether or not to give antenatal steroids. On the other hand, the 
beneficial effect of antenatal steroids after histological chorioamnionitis indicates that 
treatment may indeed be safe and effective, regardless of whether subclinical inflamma-
tion is present. Moreover, a meta-analysis of RCTs showing particular benefit of antenatal 
steroids in pregnant women with PPROM supports their therapeutic potential when in-
trauterine infection is imminent 1.  
Despite these potential sources of bias, the absence of any association between ante-
natal steroid treatment and adverse outcome in chorioamnionitis-exposed infants is reas-
suring. Moreover, the highly significant differences in several outcome measures between 
treated and non-treated infants suggest that at least part of these effects is genuine. Ani-
mal experimental data further support some of these associations. Antenatal steroids 
enhance lung maturation after experimental chorioamnionitis in preterm sheep, corre-
sponding to the reduction in RDS observed in this meta-analysis 30-32. Data from the same 
model show that antenatal steroids and chorioamnionitis modulate the fetal innate im-
mune response, both solitary and combined 33-35. Immunological effects may well mediate 
some of the associations between chorioamnionitis, antenatal steroids and outcome after 
preterm birth 36.  
The current meta-analysis provides information on steroid effects regarding neonatal 
outcome only. Data concerning the effects of antenatal steroids on outcome beyond the 
neonatal period in infants exposed to chorioamnionitis are virtually absent. We are aware 
of only one small study that was unable to show any difference in neurodevelopmental 
outcome at the ages of one and three years 15. Moreover, although not specifically de-
signed to address this issue, no data were found on the association between antenatal 
steroids and maternal outcome in chorioamnionitis. Additional research is needed to 
evaluate the maternal and long term offspring effects of antenatal steroids in chorioam-
nionitis. 
Conclusion 
In conclusion, there is considerable diversity in perinatologists’ opinions regarding the use 
of antenatal steroids in suspected intrauterine infection. Most agree that insufficient evi-
dence is currently present to resolve this issue. A meta-analysis of observational studies 
suggests that antenatal steroids are safe and effective in preterm infants born before 33 
weeks gestation with subclinical chorioamnionitis. However, when chorioamnionitis is 
clinically apparent, the evidence is less obvious and more sensitive to bias. Retrospective 
subgroup analysis of observational studies and RCTs in which data on chorioamnionitis 
and antenatal steroid exposure are available, may further increase our knowledge on this 
important topic. We, as well as most clinicians responding to our survey, would favour an 
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RCT to assess the efficacy and safety of antenatal steroids in clinical chorioamnionitis. 
Both maternal and neonatal outcome need to be evaluated, and should include long term 
follow-up. Until such a trial has been carried out, one should be cautious to make any 
clinical recommendation regarding this issue. 
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Abstract 
Chorioamnionitis, sepsis and prolonged mechanical ventilation have been reported to 
have a joint predisposing effect on bronchopulmonary dysplasia (BPD) in preterm infants. 
Our aim was to re-evaluate these findings in a prospective cohort of preterm infants (ges-
tational age ≤ 32.0 weeks; n=301). Using multiple logistic regression analysis we were 
unable to reproduce a joint association or interaction between chorioamnionitis, sepsis 
and prolonged mechanical ventilation related to development of BPD. We hypothesise 
that changes in neonatal care contributed to the diminishing association between 
chorioamnionitis and bronchopulmonary dysplasia. 
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Introduction 
Considerable evidence links antenatal inflammation to adverse lung development in pre-
term infants 1,2. However, the underlying mechanisms and associations are both complex 
and poorly understood. In an elegant case-control study published in 2002, Van Marter 
and colleagues showed evidence for an interrelationship between chorioamnionitis, sepsis 
and prolonged mechanical ventilation in the development of bronchopulmonary dysplasia 
(BPD) in very-low-birth-weight infants 3. Whereas chorioamnionitis in itself was associated 
with lower BPD risk, BPD susceptibility was significantly increased after subsequent expo-
sure to sepsis or prolonged mechanical ventilation 3. Their results were suggestive of in-
creased susceptibility to ‘second hits’ in the neonatal period in infants with chorioamnio-
nitis. Although highly cited for these presumed associations, the results have never been 
reproduced.  
Our aim was to re-evaluate the hypothesis derived from this study that chorioamnio-
nitis, sepsis and prolonged mechanical ventilation have a combined effect on the devel-
opment of BPD, in a prospective cohort of preterm infants reported previously 4. To 
maximise comparability, the inclusion criteria and analyses used are equivalent to those 
applied by Van Marter and colleagues to maximum extent 3. 
Methods 
All infants born at gestational age ≤ 32 weeks who were admitted to the neonatal inten-
sive care unit of the Erasmus MC between May 2001 and February 2003, were prospec-
tively included in this study. Those with major congenital abnormalities were excluded. 
Histological examination of each infant’s placenta was performed according to the Amni-
otic Fluid Infection Nosology Committee guidelines to detect signs of chorioamnionitis 
with or without fetal involvement 5. Relevant clinical parameters were stored in a data-
base. Definitions of mechanical ventilation, sepsis and BPD were equivalent to those used 
by Van Marter and colleagues 3,4.  
Logistic regression analysis was performed to test associations between BPD and the 
presence of chorioamnionitis, sepsis and prolonged mechanical ventilation (>7 days), ei-
ther solitary or combined. All analyses were adjusted for gestational age and birth weight. 
In accordance with the Van Marter study, further analyses were additionally adjusted for 
ethnicity 3. The study was approved by the local Medical Ethics Committee for Research on 
Human Subjects. 
Results 
The cohort consisted of 301 preterm infants 4, 249 of whom had a birth weight ≤ 1500 g 
corresponding to the inclusion criterion of the Van Marter study 3. Chorioamnionitis was 
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present in 96 (38.6%) infants in the latter group. Infants with chorioamnionitis had a lower 
gestational age (27.8 ±1.8 vs. 29.3 ±1.7, p<.001) and less often were small for gestational 
age (9 vs 46%, p<.001). Their mothers had lower rates of preeclampsia (7 vs 58%, p<.001), 
HELLP (haemolysis, elevated liver enzymes and low platelets; 2 vs 37%, p<.001),  and cae-
sarean section (34 vs 80%, p<.001). Conversely, clinical chorioamnionitis (65 vs 9%, 
p<.001) and PPROM (preterm premature rupture of membranes; 48 vs. 12%, p<.001) oc-
curred more frequently in patients with histological chorioamnionitis. No significant dif-
ferences in other perinatal variables were present. Moreover, rates of respiratory distress 
syndrome (RDS), BPD and neonatal mortality were not different between the groups in 
univariable analyses. Detailed mechanical ventilation data for ≥ 7 days were unavailable 
from 20 infants. Twenty-seven died before reaching 36 weeks postmenstrual age. 
As shown in Table 1, most infants who developed BPD were exposed to sepsis, pro-
longed mechanical ventilation, or both. Chorioamnionitis tended to have an additional 
effect predominantly in those with either sepsis or mechanical ventilation, although these 
differences were not statistically significant.  
 
 
Table 1. Number of infants that developed bronchopulmonary dysplasia related to exposure to chorioamnioni-
tis, prolonged mechanical ventilation and postnatal sepsis. Odds ratios are given versus patients exposed to 
none of the factors. Abbreviations: CA=chorioamnionitis; MV=mechanical ventilation; BPD=bronchopulmonary 
dysplasia; OR=odds ratio; CI=confidence interval. 
  Sepsis No Sepsis 
CA MV >7 d BPD/total (%) OR (95%CI) P value BPD/total (%) OR (95%CI) P value 
Yes 11/25 (44) 19.8 (1.86-211) .01 4/6 (67) 55.8 (3.75-830) .004 
Yes 
No 3/23 (13) 5.05 (0.46-56.1) .19 0/22 (0) - - 
Yes 16/29 (55) 26.8 (3.06-235) .003 2/6 (33) 11.7 (0.81-168) .07 
No 
No 3/39 (8) 1.54 (0.13-17.9) .73 1/46 (2) Reference group - 
 
 
In additional multivariable models, the main characteristic associated with the develop-
ment of BPD was prolonged mechanical ventilation, while a trend was observed for sepsis 
(Table 2). No significant effect of chorioamnionitis or interaction between chorioamnioni-
tis and either sepsis or prolonged mechanical ventilation was present. Moreover, further 
analysis revealed no additional effect of chorioamnionitis with fetal involvement (not 
shown) 5. The results were similar when infants > 1500 g were also included (not shown). 
Discussion 
In a prospective cohort of preterm infants, we were unable to reproduce the joint associa-
tion of chorioamnionitis, sepsis and prolonged mechanical ventilation with development 
of BPD previously reported by Van Marter and colleagues 3. While prolonged mechanical 
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ventilation, and to a lesser extent sepsis, did increase the risk for BPD, an additional effect 
of chorioamnionitis could not be demonstrated. 
 
 
Table 2. Odds ratios for development of bronchopulmonary dysplasia in multivariable models, adjusted for 
BW, GA and ethnicity. Abbreviations: CA=chorioamnionitis; MV=mechanical ventilation. Model 1=including one 
predictor; Model 2=including all three predictors; Model 3=model 2 including interaction terms.  
 Model 1 P value Model 2 P value Model 3 P value 
CA 1.22 (0.52-2.87) .65 1.28 (0.46-3.59) .64 2.64 (0.27-25.6) .40 
Sepsis 2.25 (0.92-5.55) .08 2.14 (0.71-6.48) .18 2.94 (0.64-13.6) .17 
MV >7 d 17.8 (5.74-55.5) <.001 16.6 (5.28-52.0) <.001 17.8 (4.59-68.8) <.001 
CA x MV >7 d - - - - - .82 
CA x Sepsis - - - - - .53 
 
 
Although effort was made to maximise comparability with the Van Marter study, some 
dissimilarities were inevitable. Our study was a prospective cohort study, while the previ-
ous one had a case-control design, with matching for gestational age and birth weight. 
Although we adjusted our analyses for these parameters, some confounding may remain. 
Whereas in our study 20% of patients developed BPD, by design this portion was 50% in 
the Van Marter study. Furthermore, their data were adjusted for hypothyroxinemia, while 
this information was lacking in our study. However, these differences are unlikely to fully 
explain the total absence of an effect of chorioamnionitis in our cohort. 
Several other factors may contribute to the dissimilar findings. Importantly, there is a 
ten year difference in inclusion period between both studies. Over this decade, consider-
able changes in neonatal intensive care have taken place. A general tendency towards 
more gentle and less prolonged mechanical ventilation of preterm newborns is facilitated 
by increased use of surfactant, non-invasive modes of ventilatory support, and antenatal 
steroid administration. These modalities may diminish inflammation and thus be of par-
ticular benefit for chorioamnionitis-exposed infants 1. Indeed, mechanical ventilation has 
been shown to reduce alveolar surfactant content, and to exaggerate pulmonary injury 
and decrease ventilatory efficiency after prior exposure to inflammation 6. Moreover, 
whereas early studies often identified chorioamnionitis as a risk factor for BPD develop-
ment, more recent studies have repeatedly failed to identify this association 1.  
However, the absence of an association between chorioamnionitis and BPD needs to 
be considered in the light of a reduction in RDS after chorioamnionitis 1. That is, given the 
decreased incidence of acute respiratory distress and the conjoining reduced need for 
invasive respiratory support, one would expect an accompanying reduction in chronic lung 
disease 1. The fact that this is not observed suggests that there is still a trade-off for the 
accelerated lung maturation, also reflected by an arrest in lung development observed 
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after experimental chorioamnionitis in animals 2. Additional research is needed to evalu-
ate which factors contribute to and, more importantly, may reverse this process. 
In conclusion, our data are in line with recent reports suggesting a diminishing asso-
ciation between chorioamnionitis and BPD, even in the presence of secondary pro-
inflammatory hits. Advances in neonatal care are likely to explain most of the effect. De-
spite these changes, mechanical ventilation remains a critical predisposing factor for BPD. 
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Abstract 
Objective. To study the association between antenatal exposure to chorioamnionitis and 
the neonatal response to surfactant. 
Study design. Prospective observational cohort of 301 preterm infants of gestational 
age ≤ 32.0 weeks, 146 of whom received surfactant according to standardized criteria. 
Fraction of inspired oxygen (FiO2) requirement (using analysis of variance) and time to 
extubation (using Kaplan-Meier and Cox regression analyses) were compared between 
groups based on the presence of histological chorioamnionitis (HC) with or without fetal 
involvement (HC-, n = 88; HC+F-, n = 25; HC+F+, n = 33) and between infants who devel-
oped bronchopulmonary dysplasia (BPD) or died (n = 57) and BPD-free survivors (n = 89). 
Multiple logistic regression was performed to investigate the association between HC and 
BPD. 
Results. Compared with HC- infants, HC+F+ infants had significantly greater FiO2 re-
quirement and prolonged time to extubation postsurfactant, not accounted for by differ-
ences in gestational age and birth weight. Infants with BPD/death had a strikingly similar 
pattern of increased FiO2 requirement postsurfactant. Moreover, in infants who received 
surfactant, HC+F+ status was associated with increased risk for BPD (odds ratio [OR] = 
3.40; 95% confidence interval [CI] = 1.02-11.3; P = .047) and for BPD/death (OR = 2.72; 
95% CI = 1.00-7.42; P = .049). 
Conclusions. An impaired surfactant response was observed in preterm infants with 
severe chorioamnionitis and may be involved in the association between chorioamnioni-
tis, mechanical ventilation, and the development of BPD. 
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Introduction 
Surfactant deficiency is the hallmark of the respiratory distress syndrome (RDS) in preterm 
infants, and the introduction of surfactant replacement therapy has greatly improved 
survival in this population 1. An important cause of preterm birth is chorioamnionitis, 
which affects up to 60% of extremely preterm infants 2. Chorioamnionitis is an antenatal 
inflammatory state associated with bacterial invasion of the uterine environment and 
subsequent neutrophil invasion of the placenta 3. More severe cases may exhibit signs of a 
fetal inflammatory response 4.  
Antenatal inflammation enhances lung maturation and increases surfactant produc-
tion in preterm animal models 5,6. Correspondingly, chorioamnionitis is associated with 
decreased incidence of RDS in many human studies 7-15. Despite accelerating lung matura-
tion, antenatal inflammation is associated with adverse lung development 14,16. Human 
evidence suggests that secondary proinflammatory hits, such as sepsis and mechanical 
ventilation, highly augment this association 17. Likewise, mechanical ventilation exagger-
ates pulmonary inflammation after experimental chorioamnionitis in preterm sheep 18, 
and higher pressures are needed to adequately ventilate these animals 19, despite previ-
ous administration of surfactant. This suggests that the efficacy of exogenous surfactant 
may be reduced after antenatal inflammation. Indeed, considerable evidence links in-
flammation to decreased surfactant function 20,21. Human studies investigating the asso-
ciation between antenatal inflammation and the subsequent response to surfactant are 
lacking, however.  
The aim of the present study was to explore the relationship between histological 
chorioamnionitis (HC) with or without fetal involvement and the response to exogenous 
surfactant in a prospective cohort of preterm infants reported previously 13,22. We hy-
pothesised that chorioamnionitis would be associated with decreased surfactant  efficacy. 
Methods 
Inborn preterm infants (gestational age ≤ 32.0 weeks) admitted to the neonatal intensive 
care unit of the Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, the Neth-
erlands, between May 2001 and February 2003 were eligible for the study. Antenatal, 
perinatal, and neonatal data were prospectively stored in a database. Women received 
antenatal steroids (betamethasone 12 mg i.m., repeated after 24 hours) in case of immi-
nent preterm delivery. Gestational age was estimated by early ultrasonography or based 
on the last menstrual period when information was reliable. Bronchopulmonary dysplasia 
(BPD) was defined as dependency on oxygen supplementation at postmenstrual age 36 
weeks. Other clinical definitions used in the study were as described previously 13. The 
study was approved by Erasmus University Medical Center’s Medical Ethics Committee for 
Research on Human Subjects. 
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Histopathology 
Placentas and membranes were fixed in formalin and embedded in paraffin according to a 
standard protocol, and then examined by a single pathologist blinded for clinical informa-
tion 13. Chorioamnionitis was diagnosed as proposed by the Amniotic Fluid Infection 
Nosology Committee 4. Accordingly, fetal involvement was diagnosed when any of the 
following was present: chorionic vasculitis, umbilical phlebitis or vasculitis, (subacute) 
necrotising funisitis, or concentric umbilical perivasculitis.  
Criteria for surfactant administration  
Exogenous surfactant (beractant, 100 mg/kg) was administered endotracheally to me-
chanically ventilated infants if the following criteria were met: mean airway pressure 
(MAP) × fraction of inspired oxygen (FiO2) ≥ 2 for infants ≤ 1000 g or MAP × FiO2 ≥ 2.5 for 
infants > 1000 g. A second dose was given when the criteria were still met 6-8 hours after 
the first dose. Data after the first dose were kept in time-dependent analyses, irrespective 
of whether a second dose was given. Subsequent ventilatory management was at the 
discretion of the attending physician, who was unaware of the diagnosis of chorioamnioni-
tis. 
Statistics 
Differences between groups were tested by analysis of variance or the χ2 test for di-
chotomous data. Survival curves were compared between groups using the Mantel-Cox 
logrank test for simple comparisons and Cox regression analysis for multivariate analyses. 
Dunnett post hoc analysis was applied for multiple group comparisons. Logistic regression 
analysis was performed to identify risk factors for adverse outcome. Significance was ac-
cepted at P < .05 (2-sided). All analyses were performed using SPSS version 15.0 (SPSS Inc, 
Chicago, Illinois). 
Results 
A total of 323 infants were eligible for inclusion in the study. Nineteen infants were ex-
cluded because of insufficient data, and 3 were excluded due to severe congenital anoma-
lies. Of the remaining 301 infants, 146 (48.5%) received surfactant, 98 of whom received 2 
doses. Infants treated with surfactant had lower gestational age and birth weight, more 
often were male, and less often received antenatal steroids (Table). There were no signifi-
cant differences between the infants without HC (HC-) and those with HC with (HC+F+) or 
without fetal involvement (H+F-) in terms of the proportion receiving surfactant or receiv-
ing a second dose. Infants with HC had lower rates of cesarean section, HELLP (hemolysis, 
elevated liver enzymes, low platelets), and preeclampsia, and higher rates of preterm 
premature rupture of membranes (PPROM) and clinical chorioamnionitis. Moreover, the 
HC+F- infants had less severe RDS.  
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Table. Infant characteristics according to surfactant treatment and presence of HC with or without fetal in-
volvement. Data are presented as mean ± standard deviation for continuous data and n (%) for dichotomous 
data. §P < .05, †P < .01, ‡P < .001 versus HC (analysis of variance or χ2 test, with Dunnett post hoc analysis). 
 No surfactant Surfactant dose 1 Surfactant dose 2 
Characteristic HC- 
(n=92) 
HC+F- 
(n=28) 
HC+F+ 
(n=35) 
HC- 
(n=88) 
HC+F- 
(n=25) 
HC+F+ 
(n=33) 
HC- 
(n=61) 
HC+F- 
(n=13) 
HC+F+ 
(n=24) 
Age at surfactant (hrs) 
- - - 
4.2  
± 5.9 
2.6  
± 1.8 
5.2 
 ± 10.5 
11.5  
± 5.3 
11.6  
± 4.9 
12.3  
± 12.0 
Time after 1st dose (hrs) 
- - - - - - 
8.1  
± 3.5 
9.0  
± 4.3 
7.1  
± 2.3 
Antenatal characteristics          
  Maternal age 30.7  
± 5.4 
30.7  
± 5.1 
30.4  
± 5.3 
30.8  
± 5.2 
30.8  
± 4.7 
30.8  
± 5.4 
30.8  
± 5.1 
30.3  
± 5.6 
30.6  
± 6.2 
  Preeclampsia 51 (55) 4 (14)‡ 1 (3)‡ 49 (56) 1 (4)‡ 1 (3)‡ 36 (59) 0 (0)‡ 1 (4)‡ 
  HELLP 28 (30) 1 (4)† 0 (0)‡ 34 (39) 2 (8)† 0 (0)‡ 28 (46) 1 (8)† 0 (0)‡ 
  PPROM 18 (20) 9 (32) 24 (69)‡ 10 (11) 7 (28) 18 (55)‡ 6 (10) 3 (23) 14 (58)‡ 
  Clinical chorioamnionitis 8 (9) 13 (46) 21 (60) 13 (15) 15 (60)‡ 25 (76)‡ 8 (13) 7 (54)† 18 (75)‡ 
  Antenatal steroids 65 (72) 26 (93)§ 26 (74) 67 (77) 19 (76) 27 (82) 52 (85) 10 (77) 19 (79) 
Delivery characteristics          
  Caesarean section 73 (79) 9 (32)‡ 11 (31)‡ 65 (74) 10 (40)† 8 (24)‡ 45 (74) 5 (39)§ 6 (25)‡ 
  Gestational age 30.3  
± 1.3 
29.6  
± 1.5 
28.9  
± 2.1‡ 
28.7 
± 1.7 
27.8  
± 1.8§ 
27.2  
± 1.7‡ 
28.6  
± 1.7 
27.8  
± 1.9 
27.2  
± 1.9† 
  Birth weight 1165 
 ± 356 
1363  
± 365§ 
1275  
± 374 
1056  
± 313 
1121  
± 325 
1001  
± 269 
1053  
± 337 
1157  
± 380 
1009  
± 293 
  Small for gestational age 41 (45) 2 (7)‡ 1 (3)‡ 29 (33) 3 (12) 3 (9)§ 19 (31) 1 (8) 2 (8)§ 
  Male sex 40 (45) 16 (57) 14 (40) 50 (57) 14 (56) 20 (61) 32 (53) 7 (54) 15 (63) 
Neonatal outcome          
  RDS 20 (22) 6 (21) 9 (26) 82 (93) 22 (88) 31 (94) 59 (97) 12 (92) 23 (96) 
     grade 3-4 5 (5) 1 (4) 2 (6) 45 (51) 5 (20)§ 17 (52) 37 (61) 2 (15)† 15 (63) 
  Early onset sepsis 16 (18) 7 (25) 5 (14) 19 (22) 11 (44) 10 (30) 15 (25) 6 (46) 7 (29) 
     culture proven 6 (7) 3 (11) 0 (0) 6 (7) 3 (12) 4 (12) 6 (10) 2 (15) 3 (13) 
  BPD 6 (7) 2 (7) 2 (6) 19 (24) 7 (30) 9 (39) 14 (27) 5 (46) 6 (38) 
  In-hospital mortality 3 (3) 0 (0) 4 (11) 13 (15) 3 (12) 9 (27) 11 (18) 2 (15) 7 (29) 
 
 
After the first surfactant dose, a similar decrease in FiO2 was initially observed in all groups 
(Figure 1, A). However, a subsequent rise in FiO2 requirement was apparent in the HC+F+ 
infants, with significantly higher levels up to 12 hours postsurfactant. Conversely, FiO2 
requirement continued to decrease after surfactant in the other 2 groups. Results were 
similar after a second surfactant dose (Figure 1, B). Moreover, time to extubation was 
prolonged with increasing severity of chorioamnionitis after both surfactant doses (P = 
.047 and .009, respectively) (Figures 2, A and 3).  
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Figure 1. Change in FiO2 requirement in response to exogenous surfactant for groups based on placental his-
tology. A, First dose. B, Second dose. Points represent means for each group ± standard error of the mean. *P < 
.05; **P < .01; ***P < .001 versus HC. 
 
    
Figure 2. A, Kaplan-Meier analysis and B, Cox regression analysis adjusted for gestational age and birth weight 
of time until extubation after the first dose of exogenous surfactant for groups based on placental histology. 
 
 
To disentangle the relative contributions of gestational age and chorioamnionitis, we 
compared the effects of surfactant between different gestational age strata in the HC- 
infants (< 28.0 weeks, 28.0-30.0 weeks, and ≥ 30.0 weeks). There were no significant dif-
ferences among these strata in FiO2 requirement at any time after surfactant administra-
tion, although the likelihood of extubation within 48 hours postsurfactant increased with 
advancing gestational age (data not shown). To evaluate whether this might explain the 
decreased chance of extubation after chorioamnionitis, we performed Cox regression 
analysis with adjustment for gestational age and birth weight. HC+F- infants were less 
likely to be extubated in the first 48 hours after the second surfactant dose (hazard rate 
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[HR] = 0.12; 95% confidence interval [CI] = 0.01-0.96; P = .046), while similar trends re-
mained after both surfactant doses for HC+F+ infants (HR = 0.42; 95% CI = 0.17-1.05; P = 
.06 and HR = 0.26; 95% CI = 0.06-1.15; P = .08) (Figures 2, B and 4). 
 
 
 
Figure 3. Kaplan-Meier analysis of time until extubation after the second dose of exogenous surfactant for 
groups based on placental histology. 
 
 
 
 
Figure 4. Cox regression analysis of estimated time to extubation after the second dose of exogenous surfac-
tant, adjusted for gestational age and birth weight in groups according to placental histology. P < .05 HC+F- vs 
HC-. 
 
To evaluate the association between the response to surfactant and the composite ad-
verse outcome BPD/death, data were grouped according to this outcome. Infants who 
died or developed BPD demonstrated a less effective response to surfactant (Figures 5 and 
6), very similar to that in the H+F+ infants. The time-dependent likelihood of extubation 
was decreased in infants who either died or developed BPD after both the first and the 
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second surfactant dose, as analyzed by Cox regression analysis, with adjustment for gesta-
tional age and birth weight (P = .03 and .02, respectively).  
 
 
 
Figure 5. Change in FiO2 requirement in response to the first dose of exogenous surfactant for infants who 
developed BPD or died versus BPD-free survivors. Points represent means for each group ± standard error of 
the mean. *P < .05; **P < .01; ***P < .001. 
 
 
Figure 6. Change in FiO2 requirement in response to the second dose of exogenous surfactant for infants who 
developed BPD or died versus BPD-free survivors. Points represent means for each group ± standard error of 
the mean. *P < .05; **P < .01. 
 
 
We performed logistic regression analysis to investigate the association of chorioamnioni-
tis with BPD and mortality in infants requiring surfactant. In a model adjusting for sex, 
gestational age, birth weight, patent ductus arteriosus, and sepsis, HC+F+ infants had an 
increased risk for BPD (odds ratio [OR] = 3.40; 95% CI = 1.02-11.3; P = .047) and for 
BPD/death (OR = 2.73; 95% CI = 1.00-7.42; P = .049). 
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Discussion 
In this prospective cohort of preterm infants, antenatal exposure to inflammation altered 
the response to postnatal surfactant administration. HC+F+ status was associated with 
increased FiO2 requirement postsurfactant. A strikingly similar pattern was observed in 
infants who died or developed BPD. Moreover, the likelihood of extubation over the first 
48 hours postsurfactant decreased with increasing severity of chorioamnionitis. The lower  
gestational age in these infants only partially explains these differences, although the 
possibility of additional effects of differences in other baseline characteristics cannot be 
excluded. Finally, in infants requiring surfactant, HC+F+ status was associated with devel-
opment of BPD in multivariate analysis.  
Pulmonary inflammation is a recognized modulator of the subsequent response to 
treatment. Previous exposure to inflammation aggravates the pulmonary inflammatory 
response to mechanical ventilation in several animal models 23-25. A similar effect has been 
demonstrated after antenatal inflammation 18, despite enhanced pulmonary maturation 
and surfactant production 16. Likewise, chorioamnionitis in preterm infants is associated 
with decreased BPD risk in those ventilated for less than 7 days, while prolonged mechani-
cal ventilation significantly increases the risk of BPD 17. Our data suggest that an altered 
response to exogenous surfactant may be an important modulator of this association. 
Surfactant was less effective in decreasing the FiO2 requirement in HC+ infants, associated 
with a prolonged need for mechanical ventilation. These effects were most prominent in 
the HC+F+ infants, generally considered the most severely affected. The consequent in-
creased need for respiratory support may explain, at least in part, the predisposition to 
BPD in HC+ infants 14,17,26. Our observations of a similar reduced response to surfactant in 
infants with BPD, and an association between HC+F+ status and BPD in infants treated 
with surfactant, further support this.  
The concept of decreased surfactant efficacy in an inflammatory environment is sup-
ported by earlier reports 20. In preterm infants with sepsis, tracheal aspirate fluid surface 
tension is increased, indicating poorer surfactant function 27. Likewise, in patients with 
acute respiratory distress syndrome, surfactant phospholipid composition is disturbed, 
and both surfactant protein levels and the active surfactant fraction are reduced 28-30. In 
accordance with our findings, surfactant dysfunction was correlated with adverse out-
come in these patients 28. Both inactivation and increased clearance of surfactant may 
reduce its efficacy 20,21. Inactivation may result from leakage of serum proteins into the 
alveolar space, inhibition by C-reactive protein, and altered expression or structural altera-
tion of surfactant proteins and phospholipids 20,21,31,32. Recruited inflammatory cells may 
cause increased surfactant clearance, as demonstrated after lipopolysaccharide instillation 
in rats 33. Accordingly, infants with BPD have a smaller alveolar surfactant pool size, but a 
larger total pulmonary surfactant pool 34. 
Several alternative approaches may increase surfactant efficacy in infants with 
chorioamnionitis. These include higher surfactant dosing 35,36 and methods of surfactant 
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administration in nonintubated infants 1. The latter may preclude the need for mechanical 
ventilation, an important modulator of adverse pulmonary outcome after chorioamnioni-
tis 17,37. Moreover, surfactant enrichment with additives capable of reducing inactivation, 
such as nuclear factor-kB inhibitors, show great potential to improve surfactant function in 
lungs exposed to chorioamnionitis 1,21,38-40.  
Decreased efficacy of exogenous surfactant is present in preterm infants with 
chorioamnionitis. Previous reports of increased surfactant clearance and inactivation in an 
inflammatory setting support this concept. Additional analyses further suggest links 
among decreased surfactant efficacy, chorioamnionitis, and development of BPD. Inter-
ventions aimed at increasing surfactant efficacy may be of particular benefit for infants 
exposed to chorioamnionitis. 
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Part 4 
 
General discussion 
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Overview 
In the current thesis, particular associations are described between perinatal events and 
pulmonary outcome in preterm infants. The main focus was on chorioamnionitis, the an-
tenatal event most frequently associated with preterm birth. The key findings will be high-
lighted and put into perspective. Finally, potential therapeutic consequences of the re-
ported work and follow-on directions for future research will be discussed. 
Perinatal events and the lung: molecular and cellular effects 
Lung development is a complex and tightly regulated process. Physiologically, the uterine 
environment provides the ideal circumstances for lung growth. Preterm birth interferes 
with this physiological situation and thus affects normal lung development. Moreover, the 
various causes of preterm birth have different implications for both maternal and fetal 
health, and as such further modulate this relationship. Additional effects of adverse post-
natal events and of therapeutic interventions associated with preterm birth and its com-
plications, are present. In a cohort of preterm infants we investigated the effects of sev-
eral of these perinatal modulators on markers of lung development, injury and repair.  
Growth factors are important regulators of normal lung development 1,2. Numerous 
animal studies have shown that disruption of normal growth factor expression patterns 
may have devastating effects on development of the lung and its response to subsequent 
injury 3-6. In line with these observations, we found important associations between tem-
poral growth factor expression in BALF from ventilated preterm infants, and subsequent 
BPD development (Chapter 6). Preeclampsia emerged as an important modulator of pul-
monary growth factor expression from multivariable modeling. Fetal hypoxia is considered 
an important effect of preeclampsia, resulting in intrauterine growth retardation. In a 
chicken model for hypoxia-induced fetal growth restriction, we found a differential effect 
of hypoxia on VEGF expression, depending on hypoxia timing and duration (Chapter 7). 
This is in line with a key role for preeclampsia and less prevalent causes of prenatal hy-
poxia in the regulation of pulmonary growth factor expression 7,8. Earlier studies as well as 
ours suggest that alterations in VEGF expression affect surfactant production as well as 
several other key aspects of lung development, with important implications for postnatal 
respiratory health 8,9. 
Chorioamnionitis has been associated with adverse lung development and BPD in 
both human (Chapter 3) and animal studies 10,11. Chorioamnionitis adversely affected the 
expression of the growth factors KGF and VEGF, important regulators of lung development 
and repair (Chapter 5). Moreover, chorioamnionitis decreased alveolar epithelial repair 
potential in BALF from preterm infants. These processes may play a role in the association 
between chorioamnionitis and adverse lung development.  
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Furthermore, chorioamnionitis appeared the most important modulator of early 
postnatal lung inflammation, as measured by BALF cytokine and chemokine expression 
(Chapter 4). Intriguingly, increased pulmonary inflammation during the first postnatal 
week did not correlate with subsequent BPD development. This underlines the complexity 
of the association between inflammation, chorioamnionitis and BPD, in which postnatal 
events are increasingly recognised to play an important role 12-14, as discussed later. We 
hypothesised that one way in which postnatal events may affect lung development would 
be through induction of DNA damage. However, we were unable to detect mutations in 
mitochondrial DNA from lung-derived cells over time in infants exposed to mechanical 
ventilation and hyperoxia (Chapter 8). This may be due to the relatively short follow-up. 
Alternatively, it may reflect the potential of the current strategy of ‘gentle’ ventilation and 
restriction of hyperoxia to limit secondary injury as measured by mitochondrial DNA mu-
tation analysis. 
Changing pathophysiology of BPD 
Altogether, the data presented above are in line with the current concept of a changing 
pathophysiology of BPD 15,16. The picture of ‘old BPD’, characterised by lung injury, in-
flammation and fibrosis due to secondary lung injury 17, is proposed to have shifted to-
wards that of ‘new BPD’, reflecting a developmental arrest of the lung 16. Although this 
concept is now widely acknowledged, there is a paucity of supportive pathophysiological 
evidence from human studies 18. In this regard, investigation of pathophysiological aspects 
attributed to both ‘old’ and ‘new’ BPD in the same cohort as presented in this thesis, is 
unique and provides evidence indeed supporting this pathophysiological change.  
Early postnatal inflammation did not predict BPD development in our cohort (Chapter 
4). Furthermore, over the early course of mechanical ventilation no alterations were de-
tected in mitochondrial DNA, which is considered highly susceptible to injury 19 (Chapter 
8). On the other hand, BPD was preceded by alterations in the expression of growth fac-
tors known to play an important role in lung development (Chapter 6). In addition, de-
creased surfactant availability, as measured by phospholipid content, likely reflects lung 
immaturity and was associated with BPD (Chapter 6). Thus, early developmental changes 
rather than lung inflammation seem to precede progression to BPD, in line with the cur-
rent concept of ‘new BPD’ 16. The application of multivariable modeling to account for 
important confounders further strengthens our findings. We did not apply these models 
to the chemokine and cytokine data due to methodological issues related to the large 
number of markers quantified in a relatively small cohort.  
In our cohort, changes in molecular markers and cellular processes were evaluated 
over time. This is an important strength, since lung development, injury and repair are 
dynamic processes. We aimed to identify early processes that play a role in the patho-
physiology of BPD in order to potentiate development of early interventional and preven-
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tive strategies. Therefore we chose to focus on the first postnatal week. Our data support 
a major contribution of a lung developmental arrest in the pathophysiology of BPD, and 
indeed provide room for potential therapeutic intervention, as discussed later.  
Still, recent studies show that prolonged mechanical ventilation and pro-inflammatory 
hits such as sepsis remain important modulators of BPD development 12,13,20,21. These 
processes likely exert their effects mainly beyond the first week of life and thus our data 
do not allow for conclusions to be made regarding their contributions.  
Chorioamnionitis and pulmonary outcome 
Over the last decade, chorioamnionitis is increasingly recognised to be an important 
modulator of pulmonary outcome after preterm birth (Chapter 3). Evidence suggests that 
chorioamnionitis enhances lung maturation, but at the expense of pulmonary inflamma-
tion and subsequent developmental arrest of the lung 10,11. In a prospective cohort of 
preterm infants, we found an association between chorioamnionitis and decreased severe 
RDS (Chapter 9). Enhanced structural maturation of the lung as well as increased surfac-
tant production seem to account for this effect (Chapter 3).  
Through this accelerated lung maturation and through increased pulmonary inflam-
mation, subsequent lung development is believed to be adversely affected 10,11. Animal 
studies support this concept and are currently employed to study the underlying mecha-
nisms 10,11. Although in several early human cohorts a direct association between 
chorioamnionitis and BPD was described, subsequent studies have generally failed to 
reproduce this finding (Chapter 3). Likewise, in our cohort we were unable to find an asso-
ciation between chorioamnionitis and BPD in simple comparisons, despite a decreased risk 
of severe RDS (Chapter 9).  
Important recent work has shown that the association between chorioamnionitis and 
adverse pulmonary outcome after preterm birth is highly dependent upon exposure to 
postnatal hits such as (prolonged) mechanical ventilation and sepsis 12,13. However, in an 
attempt to reproduce the findings of the study by Van Marter et al 12 we found no interac-
tion between chorioamnionitis, postnatal sepsis, and prolonged mechanical ventilation in 
the prediction of BPD (Chapter 11). Methodological issues complicate comparison of the 
two studies. The Van Marter study was a case-control study with a relatively large BPD 
group 12, while ours was a cohort with a smaller proportion of BPD-affected infants. Thus, 
insufficient power may explain part of the discrepancy. Treatment changes over time, 
including more ‘gentle’ ventilation strategies and increased use of antenatal steroids and 
postnatal surfactant may have contributed additionally. 
We studied the aspect of surfactant therapy in this regard, using the same cohort 
(Chapter 12). It was found that prior exposure to chorioamnionitis was associated with a 
less favourable response to surfactant administration. This resulted in increased exposure 
to hyperoxia and prolonged need for mechanical ventilation. Consequently, chorioamnio-
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nitis was associated with development of BPD in those with severe chorioamnionitis (with 
fetal involvement) that needed surfactant treatment. This again underlines the complexity 
of the association between chorioamnionitis and adverse lung development (Chapter 3). 
Furthermore, it supports the concept of secondary postnatal hits modulating this associa-
tion 12,13,22.  
Earlier we showed how chorioamnionitis is associated with increased pulmonary in-
flammation shortly after birth (Chapter 4). Given the propensity of surfactant to inactiva-
tion by inflammatory mechanisms 23-25, this may well explain its observed decreased effi-
cacy in chorioamnionitis-exposed infants. Moreover, in these babies reduced potential for 
alveolar epithelial repair may be an important mechanisms underlying their increased 
susceptibility to secondary lung injury (Chapter 5). 
Chorioamnionitis and antenatal steroids 
Over the last two decades, maternal administration of steroids in case of imminent pre-
term delivery has become standard care in obstetrical practice 26. However, fears of po-
tential adverse effects have limited their use in preterm delivery with suspected intrauter-
ine infection 27,28. A nationwide survey among perinatologists underlines how the issue 
remains unsolved until today (Chapter 10). Hence, data on the efficacy of antenatal ster-
oids as well as their potential undesirable effects in infant with chorioamnionitis, are 
scarce (Appendix I). 
In our cohort of preterm infants, we found that administration of antenatal steroids 
was associated with improved outcome in infants with chorioamnionitis (Chapter 9). The 
effect was present regardless of whether chorioamnionitis was defined histologically or 
clinically, and of whether a full course of steroids or a single dose was administered (Chap-
ter 9+10). In a subsequent meta-analysis of observational studies, it was confirmed that 
antenatal steroids were associated with improved neonatal outcome in preterm infants 
with either histological or clinical chorioamnionitis (Chapter 10).  
This suggests that, contrary to what seems to be the ruling opinion, a more liberal use 
of antenatal steroids may improve survival and reduce morbidity in preterm infants with 
chorioamnionitis. However, several issues remain to be resolved. Most importantly, the 
systematic review identified only observational evidence. Clearly, there is a need for sub-
stantiation by a randomised controlled trial. Additional issues that need to be addressed in 
such a trial include potential adverse effects in both mother and child, and effects on long 
term outcome. 
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Therapeutic implications 
Clinicians will always be interested in clinical applicability of translational research; from 
bench-to-bedside. The discussion of a thesis provides the ideal platform for elaboration on 
this issue. As discussed above, one important therapeutic implication of the work reported 
in this thesis could be a shift towards a more liberal use of antenatal steroids in the setting 
of (suspected) intrauterine infection (Chapter 9+10). Again, a randomised controlled trial 
should ideally precede such a practice change.  
We have shown that surfactant efficacy is reduced in infants exposed to chorioamnio-
nitis, which predisposes them to development of chronic lung disease (Chapter 12). One 
way to potentially increase surfactant efficacy is to overcome its inactivation by pro-
inflammatory mechanisms. Promising reports are available showing the potential of vari-
ous additives to increase the resistance of surfactant to inactivation (Chapter 2). More-
over, anti-inflammatory agents added to surfactant preparations may prove to be useful in 
overcoming inactivation and decreasing local inflammation 29,30. While awaiting further 
development of such preparations, a potential way of increasing surfactant efficacy may 
simply be reached by increasing the dose. Increased surfactant dosing has previously been 
shown to improve outcome 31, and our research suggests that chorioamnionitis-exposed 
infants may particularly benefit.  
In order to develop such tailor-made treatment strategies for chorioamnionitis-
exposed infants, the early identification of chorioamnionitis needs to be improved. The 
current gold standard for diagnosing chorioamnionitis is through histological examination 
of the placenta 32. However, in general practice the final result of this ‘test’ may take sev-
eral weeks, limiting its usefulness as a diagnostic marker to guide early treatment strate-
gies. Additional research is needed to develop reproducible ways in which to early identify 
infants exposed to chorioamnionitis. 
Likewise, early identification is invaluable to guide early preventive and interventional 
strategies for infants developing BPD. Although currently the efficacy of these strategies is 
limited 33,34, several lines of research carry great potential for early intervention for BPD in 
the future. With regard to our data, BALF growth factor levels may be used to identify 
infants at risk for BPD as early as the first day after birth (Chapter 6). Inclusion of addi-
tional markers in a ‘risk profile’ may further improve the diagnostic properties for BPD risk 
identification. Clearly, the diagnostic ability of VEGF and possible other markers needs to 
be studied in other and larger cohorts to confirm their potential. As soon as a marker with 
good diagnostic properties is identified, its potential to guide early interventions may be 
investigated in the setting of a clinical trial. 
The fact that VEGF and other growth factors predict future development of BPD, sug-
gests a modulating role for these molecules in the pathophysiology of BPD. This is sup-
ported by several lines of animal research showing how disruption of growth factor ex-
pression affects lung development 3-6. Consequently, modulation of growth factor expres-
sion carries great potential to treat or prevent adverse lung development in the future. 
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Consider VEGF, the lack of which has been associated with BPD, in our study (Chapter 6) as 
well as in others 35,36. Increasing the pulmonary availability of VEGF is effective in stimulat-
ing surfactant production, enhancing lung maturation, and overcoming lung injury 4,8,37. 
Similar positive effects have been described of modulation of the expression of several 
other growth factors in animal models 38. Our results indicate that timing of growth factor 
expression is highly important with regard to pulmonary outcome (Chapter 6). Timing 
issues, as well as optimal dosing, identification of the right vehicle, and assessment of 
adverse (long term) effects are among the key questions that need to be resolved before 
such treatments can be adapted in clinical practice. Our findings furthermore indicate that 
potential treatment with VEGF 4,8,37 as well as with KGF 38 may be of particular benefit to 
chorioamnionitis-exposed infants (Chapter 5), another topic requiring further study. 
As for clinical factors related to adverse lung development, our results are in line with 
accumulating evidence indicating that postnatal sepsis and mechanical ventilation remain 
among the most important risk factors for BPD 12,13,20,21. Once again these results stress 
the importance of continuing effort to develop ways in which exposure to sepsis and (pro-
longed) mechanical ventilation may be avoided. In this regard, increased use of non-
invasive modes of ventilation such as nCPAP 39, and ways to safely and effectively adminis-
ter surfactant in non-intubated infants (Chapter 2), deserve special attention. 
(Further) future directions 
The main goal of this thesis was to identify in preterm infants perinatal factors that con-
tribute to adverse pulmonary outcome. As much as certain answers have been obtained, 
new questions did arise. Some prospects for future research concerning potential thera-
peutic options have been highlighted in the last paragraph. In addition, increased knowl-
edge of the underlying mechanisms of both normal and abnormal lung development is 
necessary to continue to develop new interventions. A drawback of our mechanistic stud-
ies using BALF is that as a consequence of the technique only ventilated infants were in-
cluded. Given the general trend towards less invasive ventilatory strategies, it is essential 
to develop new ways of sampling the newborn airspace. Initial reports have been made of 
collection of exhaled air sampling in newborn infants 40,41. This technique as well as others 
such as new lung imaging modalities require further development to ensure future analy-
sis of new aspects of (adverse) lung development in a reproducible manner. 
Research effort should be guided not only towards pathophysiological mechanisms 
and development of new interventions. We are in need of early diagnostic tools to ade-
quately identify infants at risk for adverse outcome. Several potential markers, including 
VEGF as in our study (Chapter 6), have been proposed and need evaluation in multiple 
larger cohorts to evaluate their usefulness. Newer diagnostic techniques are becoming 
available that are capable of simultaneously quantifying an increasing amount of markers 
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in a biological sample of decreasing size. These should be adapted to identify populations 
at risk and further individualise treatment strategies in neonatology.  
Finally, there is a huge need for adequate follow-up studies of preterm infants. Previ-
ous cohorts have provided us with major insight into the long-term consequences of pre-
term birth. However, many new questions have arisen, requiring new cohorts and alterna-
tive approaches to become answered. Furthermore, due to treatment changes and in-
creasing survival with time, outcome will change, necessitating continuous collection of 
new data. Simultaneous collection of biological specimens is indispensable to facilitate 
identification of (epi)genetic associations and underlying mechanisms. Given the indica-
tions from our studies and recent work by others, long-term outcome after preterm birth 
may well be modulated to a significant degree by perinatal factors 42. These include as-
pects associated with the distinct causes of prematurity, including preeclampsia and 
chorioamnionitis. Future follow-up studies should evaluate the effects of these and other 
perinatal factors to facilitate the development of tailor-made preventive and interven-
tional strategies. Given the increased recognition of early-life origins of adult health and 
disease, such strategies may prove to extend their effects well beyond the neonatal period 
(Appendix II).  
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In utero and early-life conditions and adult 
health and disease 
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(Comment on: Gluckman PD et al. N Engl J Med 2008; 359: 61-73) 
 
 
Note: 
This letter was written in response to a review article in which the effects of prenatal and 
early postnatal events on adult health and disease were discussed. The aim was to em-
phasise the potential impact of antenatal exposure to inflammation on health and disease 
later in life, a subject not discussed in the review. 
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To the editor, 
Gluckman et al. review evidence on the effects of fetal conditions on adult disease. How-
ever, an important potential player is being left out of their discussion. Prenatal inflamma-
tion, reflected by chorioamnionitis and the fetal inflammatory response syndrome, has 
been recognized as a fetal condition that contributes to disease in the perinatal period and 
beyond, mainly affecting the developing lung and brain 1,2. The evidence is increasing that 
prenatal exposure to inflammation in utero is related to disease, later in childhood, involv-
ing the affected organs and is associated with physician-diagnosed asthma 3, recurrent 
wheezing 3, autistic behavior 4, and adverse neurodevelopmental outcome 5. Experimental 
chorioamnionitis results in pathogenic programming of the fetal immune response, en-
dotoxin tolerance, and crucial developmental changes, suggesting an important program-
ming effect 1.  
Thus, accumulating evidence implies an important role of antenatal inflammation in 
fetal programming and subsequent disease development, the mechanism of which need 
further investigation. Considering the immature stage of the exploration of these effects, 
we may well currently be looking at the tip of the iceberg, anticipating potential links with 
adult pulmonary and neurologic diseases like chronic obstructive pulmonary disease and 
dementia. 
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Introduction 
Approximately ten percent of all babies is born preterm, at less than 37 weeks gestation. 
Preterm birth is associated with increased morbidity and lifelong complications. The most 
important complication early after birth is respiratory distress, due to the lungs being 
immature. There is a deficiency of surfactant, a complex mixture of lipids and proteins 
required to keep the lungs open. In these infants, breathing may be supported by me-
chanical ventilation and oxygen supplementation. In addition, exogenous surfactant may 
be administered to treat respiratory distress. 
Although such treatments are often necessary to ensure survival of preterm infants, 
they may cause harm to the immature lungs of these babies. Consequently, an important 
subset may develop chronic lung disease (bronchopulmonary dysplasia; BPD). BPD is asso-
ciated with long-term complications including impaired lung function, increased suscepti-
bility for infections, and neurodevelopmental delay. 
Chapter 1 provides an introduction on normal lung development. Its disruption by 
preterm birth is discussed and how this may lead to chronic lung disease. Chapter 2 de-
scribes the role of surfactant in both the aetiology and treatment of neonatal respiratory 
distress. In chapter 3 the role of antenatal exposure to inflammation in the development 
of neonatal lung disease is discussed. Preterm birth is highly associated with occurrence of 
chorioamnionitis, an inflammatory process within the uterus. The fetal lungs are exposed 
to this inflammation through direct contact with the amniotic fluid. Previous studies have 
shown that chorioamnionitis enhances lung maturation, thus preparing the fetus for po-
tential preterm delivery. On the other hand evidence suggests an adverse effect of 
chorioamnionitis on subsequent lung development (as opposed to lung maturation). Thus, 
while the fetal lungs seem to benefit from exposure to inflammation on the short term, 
the eventual outlook may well be less favourable. 
Overview 
The current thesis describes several processes that take place within the lung during the 
first postnatal week in preterm infants. We aimed to gain additional insight in the underly-
ing causes of chronic lung disease in this group. Special attention is given to the role of 
chorioamnionitis. In addition, the effect of maternal administration of steroids before 
delivery is studied. Steroids are adrenal gland hormones that are known to enhance fetal 
lung maturation. Antenatal administration of steroids thus prepares the fetus for immi-
nent preterm delivery. 
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Summary of the thesis 
Part of the thesis describes analyses done in bronchoalveolar lavage fluid (BALF). When 
infants are mechanically ventilated, the ventilator is attached to a small tube entering the 
trachea. Through this tube a catheter is advanced into a certain lung section. A small 
amount of saline is flushed into the lung, after which suction is applied while the catheter 
is withdrawn. In this way a sample of lung-derived fluid is obtained. BALF contains cells 
and molecules which reflect the state the lung is in at that time. 
In chapter 4, quantification of a large group of inflammatory mediators in BALF is re-
ported. Inflammatory mediators are molecules that regulate inflammation in the lung, for 
example by attracting or activating white blood cells. Using a new technique (luminex 
immunoassay) we show that it is feasible to quantify these mediators in a very small 
amount of BALF. Levels of these factors were linked to several clinical aspects of lung dis-
ease in preterm infants. Using this approach, we found that antenatal exposure to 
chorioamnionitis increases the presence of inflammatory mediators directly after birth. 
Previous reports have shown pulmonary inflammation to be linked to the development of 
chronic lung disease. However, in our study we were unable to reproduce these findings. 
We hypothesise that the increasing awareness of minimising lung injury through reduction 
of mechanical ventilation and oxygen supplementation may have contributed to this. 
As mentioned earlier, both chorioamnionitis and administration of antenatal steroids 
affect lung development already before birth. Chapter 5 describes the specific effects of 
these factors on lung injury repair. Alveolar type 2 cells were cultured in the laboratory. 
These cells are very important for the lung, since they produce surfactant and are neces-
sary for the formation of type 1 cells. When cultured, these cells form a thin layer. The cell 
layer was wounded by scratching the surface, resulting in a linear defect. This is a well 
recognised model for epithelial injury in general, and for alveolar epithelial injury in this 
case. BALF was added to the wounded cell layer, and the effects on epithelial repair were 
evaluated. BALF from infants exposed to chorioamnionitis was much less effective in in-
ducing wound repair. This may partly explain the increased risk for lung injury in ventilated 
infants exposed to chorioamnionitis. Conversely, epithelial repair was stimulated by BALF 
from infants in whom antenatal steroids had been given. We investigated whether these 
effects could be explained by altered expression of two growth factors known to be im-
portant for lung development (vascular endothelial growth factor; VEGF, and keratinocyte 
growth factor; KGF). However, we were unable to establish a significant effect of these 
factors. 
Several other growth factors with important roles in lung development besides VEGF 
and KGF were quantified in BALF. In chapter 6 we show that important differences are 
present in the levels of these factors between infants who do and do not develop chronic 
lung disease. Decreased BALF levels of VEGF directly after birth predict subsequent devel-
opment of chronic lung disease several weeks later. Together with the results reported in 
chapter 4, these data support the current concept in which disruption of lung develop-
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ment seems more important than other processes including inflammation in the aetiology 
of chronic lung disease. Quantification of growth factors may facilitate early identification 
of a risk profile for chronic lung disease which may be used to tailor postnatal respiratory 
management. 
Several causes of preterm birth other than chorioamnionitis are associated with fetal 
hypoxia due to impaired placental function. Previous reports on effects of prenatal hy-
poxia on lung development have yielded contradictory results. The chick embryo develops 
outside of the mother, thus allowing for the effects of hypoxia to be studied without inter-
ference maternal influences. In chapter 7 we show that short-term hypoxia stimulates 
surfactant production, while long-term hypoxia has no significant effect. Thus, the effects 
of hypoxia on lung development seem highly dependent on timing and duration of the 
stimulus. Additional experiments again suggest an important role for VEGF in this process. 
Exposure to hyperoxia and mechanical ventilation are known to injure lung. In chapter 
8 we investigated whether this would result in injury to the genetic material (DNA) within 
the lung. We focused on DNA from mitochondria, the energy producing organelles within 
the cell, while this DNA is known to be most susceptible to injury. Surprisingly, no DNA 
injury was found during mechanical ventilation for a mean duration of three days, albeit in 
a small group of infants. Increased awareness of the potentially injurious effects of me-
chanical ventilation and hyperoxia may have contributed to our findings. 
In chapter 9 we explored the association between chorioamnionitis and the occur-
rence of known complications of preterm birth in a cohort of preterm infants. We found 
that chorioamnionitis leads to a decrease in acute respiratory problems in this group, 
indicative of enhanced lung maturation. On the other hand, the incidence of severe infec-
tions after birth is increased after chorioamnionitis. In addition we investigated how ante-
natal administration of steroids affected the incidence of postnatal complications in in-
fants with chorioamnionitis. Administration of antenatal steroids was associated with a 
decrease in acute respiratory problems and intraventricular haemorrhage in this group. 
This is important, because to date antenatal steroids are believed to be harmful when 
chorioamnionitis is present (appendix I). 
To further evaluate this effect, our data were combined with those of similar studies 
previously published as described in chapter 10. The overall effect of antenatal steroids in 
all studies together can be evaluated by means of a statistical technique called meta-
analysis. The results indicated that besides a reduction in acute respiratory problems and 
intraventricular haemorrhage, antenatal steroids were associated with increased survival. 
However, several aspects complicate interpretation of these findings, and we cannot draw 
definite conclusions regarding the safety and efficacy of antenatal steroids in infants with 
chorioamnionitis. Additional research on this topic is needed to further improve the out-
come of preterm infants. 
While previous studies showed a direct association between chorioamnionitis and 
chronic lung disease, we were unable to reproduce this (chapter 9). The results of one 
particular study suggest that chorioamnionitis is associated with an increased risk for 
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chronic lung disease only when combined with prolonged mechanical ventilation or post-
natal sepsis. In chapter 11 we investigated whether these findings could be reproduced in 
our cohort described in chapter 9. While we could confirm an association between pro-
longed mechanical ventilation and chronic lung disease, we were unable to detect signifi-
cant associations between chorioamnionitis, sepsis, and chronic lung disease. Again, part 
of these inconsistencies may be explained by improvements in treatment of preterm in-
fants over time. 
The complex association between chorioamnionitis and chronic lung disease is further 
explored in chapter 12. We show that ventilated infants with chorioamnionitis have a less 
effective response to surfactant treatment. This necessitates prolonged use of mechanical 
ventilation and increased use of supplemental oxygen. These factors then contribute to an 
increased risk for chronic lung disease in these infants, particularly those with severe 
chorioamnionitis. Altogether the relationship between chorioamnionitis and chronic lung 
disease is a complex one, in which decreased surfactant efficacy seems to play a role. 
Additional research is needed to investigate whether chorioamnionitis-exposed infants 
could benefit from increased surfactant dosing or addition of anti-inflammatory agents to 
surfactant. 
Conclusion 
The results reported in this thesis provide new insights into the background of lung devel-
opment and lung damage in preterm infants. Our findings are in agreement with the con-
cept of the changing pathophysiology of chronic lung disease in this group. In addition, our 
data underline the intriguing and complex effects that chorioamnionitis may have with 
regard to the lung and other organs. Additional research is needed to evaluate the long-
term effects of preterm birth and chorioamnionitis in particular, in order to improve the 
prospects for future preterm babies (appendix II). Several results reported in this thesis 
provide new directions for future research to develop strategies to improve the treat-
ment, and more importantly, the early recognition and prevention of chronic lung disease 
after preterm birth. 
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Introductie 
Rond de tien procent van alle kinderen wordt te vroeg geboren (voor de 37e zwanger-
schapsweek). Vroeggeboorte gaat gepaard met een verhoogd risico op allerhande compli-
caties, die gevolgen kunnen hebben voor de rest van het leven. Ademhalingsproblemen 
vormen de belangrijkste complicatie direct na de geboorte. De longen zijn nog onderont-
wikkeld en er is een tekort aan surfactant, een mengsel van stoffen dat de longblaasjes 
openhoudt. De ademhaling kan worden ondersteund door middel van beademing en het 
geven van zuurstof. Ook kan surfactant als medicijn worden toegediend.  
Deze behandelingen zijn vaak noodzakelijk voor de overleving van de vroeggeboren 
baby, maar gaan ook gepaard met schade aan de onderontwikkelde longen. Hierdoor 
ontstaat bij een belangrijk deel van deze kinderen chronische longschade (bronchopulmo-
nale dysplasie; BPD). Deze ziekte gaat niet alleen gepaard met langdurige beperking van 
de longfunctie, maar ook met een verhoogde gevoeligheid voor infecties en slechtere 
neurologische ontwikkeling.  
In hoofdstuk 1 wordt de normale longontwikkeling beschreven. Tevens wordt uitge-
legd hoe deze bij vroeggeboorte wordt verstoord, waardoor chronische longschade kan 
ontstaan. In hoofdstuk 2 wordt de rol van surfactant in het ontstaan van ademhalingspro-
blemen na de geboorte besproken. Daarnaast wordt besproken hoe het geven van surfac-
tant als medicijn de acute ademhalingsproblemen na vroeggeboorte kan verminderen. 
Hoofdstuk 3 gaat in op de rol van blootstelling van de long aan ontsteking vóór de geboor-
te. Vroeggeboorte gaat vaak gepaard met chorioamnionitis, een ontsteking binnen de 
baarmoeder. De longen van de foetus staan via het vruchtwater in contact met deze ont-
steking. Eerder onderzoek heeft laten zien dat hierdoor de longrijping wordt versneld; de 
foetus wordt als het ware voorbereid op een mogelijke vroeggeboorte. Aan de andere 
kant zijn er aanwijzingen dat chorioamnionitis slecht is voor de latere ontwikkeling van de 
long. Waar de foetus dus op korte termijn voordeel lijkt te hebben van deze ontsteking, 
kan dit op lange termijn wel eens nadelig zijn.  
Overzicht 
In dit proefschrift worden verschillende processen bestudeerd die zich in de long afspelen 
in de eerste week na de geboorte bij beademde vroeggeboren baby’s. Het doel hiervan is 
meer inzicht te krijgen in de onderliggende oorzaken van chronische longschade in deze 
groep. Specifieke aandacht is er voor het effect hierop van blootstelling aan chorioamnio-
nitis. Daarnaast wordt de invloed van het toedienen van steroïden aan de moeder voor de 
geboorte bestudeerd. Steroïden zijn bijnierschorshormonen en hebben een stimulerend 
effect op de longrijping van de foetus. Wanneer deze worden gegeven bij dreigende 
vroeggeboorte, is de foetus daarmee beter voorbereid op het leven buiten de baarmoe-
der. 
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Samenvatting proefschrift 
In verschillende onderdelen van het proefschrift worden metingen gedaan in vloeistof 
verkregen via longspoeling (bronchoalveolaire lavage vloeistof; BALV). Kinderen die be-
ademd worden, zijn via een buisje in de luchtpijp aangesloten op een beademingsmachi-
ne. Via dit buisje wordt een dun slangetje ingebracht in een deel van de long en wordt een 
kleine hoeveelheid zoutwater ingespoten. Dit wordt bijna direct weer opgezogen, waar-
door materiaal uit de long wordt verzameld. BALV bevat onder andere cellen en molecu-
len en de samenstelling ervan zegt iets over de toestand van de long op dat moment. 
In hoofdstuk 4 wordt de meting van een grote groep ontstekingsfactoren in BALV be-
schreven. Ontstekingsfactoren zijn moleculen die een rol spelen in het reguleren van ont-
steking, bijvoorbeeld door witte bloedcellen aan te trekken of te activeren. Met een nieu-
we techniek (luminex immunoassay) laten we zien dat het goed mogelijk is deze stoffen te 
meten in een zeer kleine hoeveelheid BALV. Daarnaast hebben we een relatie gelegd tus-
sen deze ontstekingsfactoren en aspecten van longproblemen bij deze vroeggeborenen. 
Zo blijkt dat blootstelling aan chorioamnionitis voor de geboorte leidt tot een toename 
van ontstekingsfactoren in de long direct na de geboorte. Eerdere onderzoeken lieten ook 
een belangrijke samenhang zien tussen ontsteking en de ontwikkeling van chronische 
longschade. Deze samenhang wordt in ons onderzoek niet meer gevonden. Wij denken 
dat een toenemende aandacht voor het beperken van de schadelijke gevolgen van be-
ademing en zuurstoftoediening hieraan bijdraagt.  
Zoals genoemd beïnvloeden chorioamnionitis en toediening van steroïden de long-
ontwikkeling al voor de geboorte. In hoofdstuk 5 wordt het specifieke effect van deze 
factoren onderzocht op herstel van longschade na de geboorte. In het laboratorium 
kweekten we een bepaald type longcellen, alveolaire type 2 cellen. Dit zijn cellen die van 
groot belang zijn voor de long, onder meer doordat ze surfactant aanmaken en als voorlo-
per dienen voor type 1 cellen. Wanneer deze cellen worden gekweekt vormen ze een 
dunne laag. Hierin werd schade aangebracht door cellen over een bepaald traject weg te 
schrapen, waardoor een defect ontstaat. Dit is een veelgebruikt model voor slijmvlies-
schade en in dit geval voor longschade. Aan de beschadigde cellaag werd BALV toege-
voegd, waarna werd gemeten in hoeverre dit het herstel bevorderde. Dit herstel bleek 
veel minder effectief wanneer kinderen voor de geboorte waren blootgesteld aan chorio-
amnionitis. Mogelijk verklaart dit ten dele waarom chorioamnionitis een verhoogd risico 
geeft op longschade bij beademde vroeggeborenen. Anderzijds werd het herstel juist 
extra gestimuleerd wanneer steroïden waren gegeven voor de geboorte. We onderzoch-
ten of twee groeifactoren die belangrijk zijn voor longontwikkeling (vascular endothelial 
growth factor; VEGF, en keratinocyte growth factor; KGF) van invloed waren op deze pro-
cessen, maar konden geen duidelijk effect aantonen. 
Naast VEGF en KGF hebben we verschillende andere groeifactoren die van belang zijn 
voor longontwikkeling, gemeten in BALV. In hoofdstuk 6 laten we zien dat er belangrijke 
verschillen zijn in de aanwezigheid van groeifactoren tussen kinderen die wel of geen 
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chronische longschade ontwikkelen. Zo is een tekort aan VEGF in BALV op de eerste dag 
na de geboorte al voorspellend voor het ontstaan van chronische longschade meerdere 
weken later. Samen met de bevindingen in hoofdstuk 4 ondersteunt dit de theorie dat 
chronische longschade tegenwoordig meer een gevolg is van verstoorde longontwikkeling 
dan van processen als ontsteking. Mogelijk kan het meten van groeifactoren in de toe-
komst helpen om vroeg een risico-inschatting voor chronische longschade te maken en 
daarop de behandeling aan te passen. 
Naast chorioamnionitis gaan de meeste andere oorzaken van vroeggeboorte samen 
met een zuurstoftekort bij de foetus (hypoxie) door bijvoorbeeld verstoorde functie van 
de moederkoek (placenta). Eerdere onderzoeken laten tegenstrijdige effecten zien van 
hypoxie op de longontwikkeling. Kippenkuikens ontwikkelen zich buiten de moeder, waar-
door het effect van hypoxie kan worden bestudeerd zonder effecten van de moeder. In 
hoofdstuk 7 laten we zien dat kortdurende hypoxie de productie van surfactant in kippe-
nembryo’s stimuleert, terwijl langdurige hypoxie geen effect heeft. Het effect van hypoxie 
lijkt dus in belangrijke mate af te hangen van de duur van de blootstelling. Verdere expe-
rimenten suggereren dat VEGF ook hierbij een belangrijke rol speelt. 
Blootstelling aan beademing en een teveel aan zuurstof zijn schadelijk voor de long. In 
hoofdstuk 8 onderzochten we of er tijdens behandeling met beademing en zuurstof scha-
de optreedt in het erfelijk materiaal (DNA). We bekeken hierbij in BALV het DNA van mi-
tochondriën, de energieproducerende onderdelen van cellen, omdat dit DNA het meest 
gevoelig is voor schade. Opvallend genoeg werd geen schade aangetoond na een gemid-
delde beademingsduur van drie dagen in een weliswaar kleine groep kinderen. Mogelijk 
speelt ook hier de toegenomen aandacht voor minder schadelijke beademing en vermin-
derde blootstelling aan zuurstof een rol. 
In hoofdstuk 9 wordt de samenhang beschreven tussen chorioamnionitis en algeme-
ne complicaties van vroeggeboorte in een grote groep vroeggeborenen. We vonden dat 
chorioamnionitis minder ernstige acute ademhalingsproblemen geeft, passend bij een 
stimulatie van de longrijping in deze groep. Verder is het risico op ernstige infecties kort 
na de geboorte verhoogd na chorioamnionitis. Daarnaast bekeken we hoe toediening van 
steroïden voor de geboorte het optreden van complicaties beïnvloedt bij kinderen met 
chorioamnionitis. Kinderen met chorioamnionitis bleken minder acute ademhalingspro-
blemen en minder hersenbloedingen (intraventriculaire bloedingen; IVH) te hebben wan-
neer ze steroïden hadden gekregen. Dit is belangrijk, omdat in het algemeen wordt aan-
genomen dat steroïden gevaarlijk zijn bij chorioamnionitis (appendix I). 
Om dit effect verder te onderzoeken werden de resultaten van ons onderzoek in 
hoofdstuk 10 samengevoegd met die van vergelijkbare eerdere onderzoeken. Door een 
statistische techniek (meta-analyse) kan zo het totale effect van steroïden over alle onder-
zoeken samen worden onderzocht. Toediening van steroïden bleek niet alleen gerelateerd 
met minder acute ademhalingsproblemen en minder hersenbloedingen, maar ook met 
een betere overleving. Verschillende factoren bemoeilijken echter de uitleg van deze re-
sultaten, waardoor de veiligheid en werkzaamheid van steroïden bij chorioamnionitis nog 
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niet vaststaan. Wij maken ons hard voor aanvullend onderzoek in deze richting, om zo de 
uitkomst van vroeggeborenen verder te verbeteren. 
In tegenstelling tot eerdere onderzoeken, vonden wij geen directe relatie tussen cho-
rioamnionitis en chronische longschade (hoofdstuk 9). In een van die eerdere studies 
wordt gesuggereerd dat het risico op chronische longschade na chorioamnionitis alleen is 
toegenomen wanneer deze kinderen na de geboorte langdurig worden beademd of een 
ernstige infectie (sepsis) krijgen. In hoofdstuk 11 onderzochten wij of deze samenhang 
ook aanwezig was in de eerder beschreven groep vroeggeborenen van hoofdstuk 9. Hoe-
wel we duidelijk zagen dat langdurige beademing het risico op chronische longschade 
verhoogde, kon geen samenhang worden aangetoond met chorioamnionitis of sepsis. Ook 
hierbij is het goed mogelijk dat verbeteringen in de behandeling van vroeggeborenen 
bijdragen aan deze verandering over de tijd. 
In hoofdstuk 12 gaan we dieper in op de complexe samenhang tussen chorioamnioni-
tis en chronische longschade. We zien dat beademde vroeggeborenen die blootgesteld 
zijn aan chorioamnionitis minder goed reageren op behandeling met surfactant. Hierdoor 
zijn langere beademing en meer zuurstof nodig bij deze kinderen. Dit blijkt met name bij 
kinderen met ernstige chorioamnionitis te leiden tot een verhoogd risico op chronische 
longschade. Al met al is de relatie tussen chorioamnionitis en chronische longschade dus 
complex, en lijkt behandeling met surfactant minder effectief te zijn bij deze kinderen. 
Mogelijk kan deze behandeling verbeterd worden door meer surfactant te geven of ont-
stekingsremmende medicijnen toe te voegen aan de behandeling. 
Conclusie 
De onderzoeken beschreven in dit proefschrift geven nieuwe informatie over de achter-
grond van longontwikkeling en longschade bij vroeggeborenen. De resultaten ondersteu-
nen de recent geïntroduceerde theorie van een verandering in de ontstaanswijze van 
chronische longproblemen in deze groep kinderen. Daarnaast wordt onderstreept hoe 
chorioamnionitis een proces blijft met intrigerende effecten op ontwikkeling van de long 
en andere organen. Nader onderzoek is nodig naar de lange termijn effecten van vroegge-
boorte en chorioamnionitis in het bijzonder, om de vooruitzichten voor deze kwetsbare 
groep kinderen in de toekomst te verbeteren (appendix II). Verschillende bevindingen uit 
dit proefschrift kunnen richting geven aan toekomstig onderzoek naar strategieën om 
chronische longschade in de toekomst beter te behandelen, of nog liever: te voorspellen 
en te voorkómen. 

225 
Curriculum 
Vitae 
226 
Jasper Valentijn Been werd op 16 maart 1978 geboren te Utrecht. In 1996 voltooide hij 
het Gymnasium aan het Christelijk Lycaeum Veenendaal. Datzelfde jaar begon hij de op-
leiding Geneeskunde aan de Universiteit Maastricht (UM), welke hij eind 2002 ‘met ge-
noegen’ afrondde. Na een periode als arts-assistent kindergeneeskunde niet in opleiding 
in het Máxima Medisch Centrum Veldhoven en het Maastricht Universitair Medisch Cen-
trum (MUMC), startte hij eind 2004 met een combinatietraject van promotieonderzoek 
binnen de School for Oncology and Developmental Biology (GROW) en specialisatie tot 
kinderarts in het MUMC (opleider Prof. dr. L.J.I. Zimmermann) en het Atrium MC Heerlen 
(opleider dr. J. Dankert).  
Het promotieonderzoek onder begeleiding van dr. J.F. van Iwaarden en Prof. dr. L.J.I. 
Zimmermann richtte zich op aspecten van longontwikkeling en ontstaan van chronische 
longschade bij vroeggeborenen, zoals beschreven in dit proefschrift. De inhoud ervan 
werd onder andere onderscheiden met de Pelerinprijs 2009 voor beste onderzoek door 
een arts-assistent in het MUMC en de Bengt Robertson Award 2010 voor neonataal long-
onderzoek van de European Academy of Paediatric Sciences. Recent ontving Jasper van 
het MUMC een Kootstra Talent Fellowship voor voortzetting van onderzoek. Verder volgt 
hij momenteel de Masteropleiding Epidemiology aan de UM, welke hij eind 2010 hoopt af 
te ronden. Jasper is getrouwd met Dorcas en samen hebben ze twee lieve dochters. 
 
 
Jasper Valentijn Been was born March 16th 1978 in Utrecht. He graduated from high 
school at the Christelijk Lycaeum Veenendaal in 1996 and subsequently started Medical 
school at Maastricht University (UM). He graduated with distinction in 2002, and worked 
as a paediatric resident-not-in-training for some time at the Máxima Medical Centre in 
Veldhoven and the Maastricht University Medical Centre (MUMC). He alternated working 
as a PhD-student at the School for Oncology and Developmental Biology (GROW) and a 
resident in training at the departments of paediatrics of the MUMC (supervisor Prof. L.J.I. 
Zimmermann) and the Atrium Medical Centre in Heerlen (supervisor Dr. J. Dankert). 
In his PhD project supervised by dr. J.F. van Iwaarden and Prof. dr. L.J.I. Zimmermann, 
Jasper focused on aspects of lung development and chronic lung disease in preterm in-
fants, resulting in the current thesis. Part of its content was awarded the Pelerin prize 
2009 for best research by a MUMC resident and the Bengt Robertson Award 2010 for 
neonatal lung research from the European Academy of Paediatric Sciences. Recently Jas-
per received a Kootstra Talent Fellowship grant which will allow him to continue his re-
search. In addition, he aims to complete his Masters course in Epidemiology at Maastricht 
University before the end of 2010. Jasper is married to Dorcas, together they have two 
lovely daughters. 
227 
List of publications 
228 
Internationaal 
1. Been JV, Degraeuwe PL, Kramer BW, Zimmermann LJ. Antenatal steroids and 
neonatal outcome after chorioamnionitis: a meta-analysis. BJOG; provisionally 
accepted. 
2. Gantert M, Been JV, Gavilanes DA, Garnier Y, Zimmermann LJ, Kramer BW. 
Chorioamnionitis – a multiorgan disease of the fetus? J Perinatol; in press. 
3. Been JV, Zimmermann LJ, Jonkers F, Rours IG, Kornelisse RF, de Krijger RR. Reply 
to letter ‘Chorioamnionitis bites the lung’. J Pediatr 2010 [Epub ahead of print]. 
4. Been JV, Rours IG, Kornelisse RF, Jonkers F, de Krijger RR, Zimmermann LJ. 
Chorioamnionitis alters the response to surfactant in preterm infants. J Pediatr 
2010; 156: 10-5. 
5. Been JV, Debeer A, van Iwaarden JF, Kloosterboer N, Lima Passos V, Naulaers G, 
Zimmermann LJ. Early alterations in growth factor patterns in bronchoalveolar 
lavage fluid from preterm infants developing bronchopulmonary dysplasia. Pedi-
atr Res 2010; 67: 83-9. 
6. Been JV, Zimmermann LJ. Exploring the association between chorioamnionitis 
and respiratory outcome. BJOG 2010; 117: 497. 
7. Been JV, Zoer B, Kloosterboer N, Kessels CG, Zimmermann LJ, van Iwaarden JF, 
Villamor E. Pulmonary vascular endothelial growth factor expression and disatu-
rated phospholipid content in a chicken model of hypoxia-induced fetal growth 
restriction. Neonatology 2010; 97: 183-9. 
8. Schuurman MJ, Robben SG, Been JV. A congenital anomaly in a preterm new-
born. BMJ 2010; 340: b5241. 
9. Zoer B, Been JV, Jongen E, Debeer A, Hendrickx A, Smeets H, Zimmermann LJ, Vil-
lamor E. Mitochondrial DNA damage analysis in bronchoalveolar lavage cells of 
preterm infants. Front Biosci 2010; E2: 361-8. 
10. Bok LA, Been JV, Struys EA, Jakobs C, Rijper EA, Willemsen MA. Antenatal treat-
ment in two Dutch families with pyridoxine-dependent seizures. Eur J Pediatr 
2010; 169: 297-303. 
11. Kunzmann S, Glogger K, Been JV, Kallapur SG, Nitsos I, Moss TJ, Speer CP, Newn-
ham JP, Jobe AH, Kramer BW. Thymic changes after chorioamnionitis induced by 
intraamniotic lipopolysaccharide in fetal sheep. Am J Obstet Gynecol 2010; 202: 
476.e1-8. 
12. Been JV, Zimmermann LJ, Debeer A, Kloosterboer N, van Iwaarden JF. Bronchoal-
veolar lavage fluid from preterm infants with chorioamnionitis inhibits alveolar 
epithelial repair. Respir Res 2009; 10: 116. 
13. Been JV, Kramer BW, Zimmermann LJ. Antenatal corticosteroids to prevent pre-
term birth. Lancet 2009; 373: 894. 
14. Been JV, Rours IG, Kornelisse RF, Lima Passos V, Kramer BW, Schneider TA, de 
Krijger RR, Zimmermann LJ. Histologic chorioamnionitis, fetal involvement, and 
229 
antenatal steroids: effects on neonatal outcome in preterm infants. Am J Obstet 
Gynecol 2009; 201: 587.e1-8. 
15. Been JV, Kornelisse RF, Rours IG, Lima Passos V, de Krijger RR, Zimmermann LJ. 
Early postnatal blood pressure in preterm infants: effects of chorioamnionitis and 
timing of antenatal steroids. Pediatr Res 2009; 66: 571-6. 
16. Been JV, Zimmermann LJ. Histological chorioamnionitis and respiratory outcome 
in preterm infants. Arch Dis Child Fetal Neonatal Ed 2009; 94: F218-25. 
17. Been JV, Zimmermann LJ. Chorioamnionitis and chronic lung disease in preterm 
infants. Pediatrics 2009; http://pediatrics.aappublications.org/cgi/eletters/123/5/ 
1314. 
18. Been JV, Robben SG, Delhaas T, Theunissen P, Dompeling E, Jöbsis Q. A 3-year old 
female with cough, dyspnoea and low-grade fever. Eur Respir J 2009; 33: 690-3. 
19. Degraeuwe PL, Been JV. Letter by Degraeuwe and Been regarding article, “Evi-
dence of arteriolar narrowing in low-birth-weight children”. Circulation 2009; 
119: e537. 
20. Kramer BW, Ladenburger A, Kunzmann S, Speer CP, Been JV, van Iwaarden JF, 
Zimmermann LJ, Gantert M, Garnier Y. Intravenous lipopolysaccharide-induced 
pulmonary maturation and structural changes in preterm sheep. Am J Obstet Gy-
necol 2009; 200: 195.e1-10. 
21. Been JV, Kramer BW, Zimmermann LJ. In utero and early-life conditions and adult 
health and disease. N Engl J Med 2008; 359: 1523-4. 
22. Been JV, Degraeuwe PL. Pleural effusion due to intra-abdominal extravasation of 
parenteral nutrition. Pediatr Pulmonol 2008; 43: 1033-5. 
23. Been JV, Bok LA, Willemsen MA, Struys EA, Jakobs C. Mutations in the ALDH7A1 
gene cause pyridoxine-dependent seizures. Arq Neuropsiquiatr 2008; 66: 288-9. 
24. Been JV, Zimmermann LJ. What’s new in surfactant? – A clinical view on recent 
developments in neonatology and paediatrics. Eur J Pediatr 2007; 166: 889-9. 
25. Been JV, Linssen CF, van Iwaarden JF, Zimmermann LJ. Massive bacterial cell in-
vasion and reactive type II pneumocytes in bronchoalveolar lavage fluid from a 
preterm neonate. Arch Dis Child Fetal Neonatal Ed 2007; 92: F319. 
26. Been JV, Kramer BW, Mulder TL, Zimmermann LJ. Conservative treatment of 
symptomatic patent ductus arteriosus beyond the first week of life. Arch Dis Child 
Fetal Neonatal Ed 2007; http://fn.bmj.com/cgi/eletters/92/6/F498#1967. 
27. Bok LA, Struys E, Willemsen MA, Been JV, Jakobs C. Pyridoxine dependent sei-
zures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semial-
dehyde levels. Arch Dis Child 2007; 92: 687-9. 
28. Been JV, Bok LA, Andriessen P, Renier WO. Epidemiology of pyridoxine depend-
ent seizures in the Netherlands. Arch Dis Child 2005; 90: 1293-6. 
29. Been JV, Smits MG, Bok LA. Improvement of sleep disturbances and behaviour in 
Smith-Magenis syndrome with morning melatonin. J Med Genet 2003; 
http://jmg.bmj.com/cgi/eletters/40/1/74#30. 
230 
Nationaal 
30. Kramer BW, Lievense S, Been JV, Zimmermann LJ. Van klassieke naar nieuwe 
bronchopulmonale dysplasie. Ned Tijdschr Geneeskd 2010; 154: A1024. 
31. van Eldik N, Been JV, van Well GT. Een ongewone verwekker van mastoïditis. 
Tijdsch Infect 2009; 4: 148-52. 
32. Bok LA, Struys E, Jakobs C, Been JV, Willemsen MA. Pyridoxine afhankelijke epi-
lepsie. Tijdschr Neurol Neurochir 2007; 108: 51-6. 
33. Been JV, Bok LA, Buijs J, Andriessen P, Roos FG, Bambang Oetomo S. Pyridoxine 
afhankelijke epilepsie: casusbeschrijving en landelijke inventarisatie. Medisch 
Journaal MMC 2006; 35: 95-7. 
Submitted 
34. Been JV, van Iwaarden JF, de Jager W, Debeer A, Zimmermann LJ. Bronchoalveo-
lar lavage fluid cytokine and chemokine profiles in ventilated preterm infants. 
35. Been JV, Rours IG, Kornelisse RF, de Krijger RR, Zimmermann LJ. Chorioamnioni-
tis, secondary ‘hits’ and bronchopulmonary dysplasia. 
36. Lievense S, Kramer BW, Zimmermann LJ, Nijhuis JG, Been JV. Wel of geen antena-
tale steroïden bij dreigende vroeggeboorte met chorioamnionitis? De mening van 
Nederlandse perinatologen. 
37. van der Putten ME, Been JV, Robben SG, Zimmermann LJ. An unusual cause of 
hydronephrosis in a preterm infant. 
38. Debeer A, Mayer S, Been JV, Roubliova X, Lewi P, Naulaers G, Carmeliet P, De-
prest J. A placebo controlled study of intra-amniotic injection of VEGF on lung 
maturation in preterm rabbits. 
231 
Co-author affiliations 
 
 
Debeer A, Naulaers G. Dept of Neonatology, University Hospital Gasthuisberg, Leuven, 
Belgium 
 
Degraeuwe PL, van Iwaarden JF, Kessels CG, Kloosterboer N, Kramer BW, Lievense S, 
Villamor E, Zimmermann LJ, Zoer B. Dept of Paediatrics, Maastricht University Medical 
Centre, Maastricht 
 
Hendrickx A, Jongen E, Smeets H. Dept of Clinical Genetics, Maastricht University, Maas-
tricht 
 
de Jager W. Dept of Paediatric Immunology, University Medical Centre Utrecht, Utrecht 
 
Jonkers F. Dept of Internal Medicine, Maastricht University Medical Centre, Maastricht 
 
Kornelisse RF. Dept of Paediatrics, Erasmus University MC - Sophia Children’s Hospital, 
Rotterdam 
 
de Krijger RR. Dept of Pathology, Erasmus University MC, Rotterdam 
 
Lima Passos V. Dept of Methodology and Statistics, Maastricht University, Maastricht 
 
Nijhuis JG. Dept of Obstetrics and Gynaecology, Maastricht University Medical Centre, 
Maastricht 
 
Rours IG. Dept of Paediatrics, Maasstad Hospital, Rotterdam; Dept of Paediatric Infectious 
Diseases / Medical Microbiology, Erasmus University MC, Rotterdam 
 
Schneider TA. Dept of Obstetrics, Erasmus University MC, Rotterdam 
232 
233 
Dankwoord 
234 
Zeer veel dank gaat uit naar mijn promotor, Prof. Zimmermann en co-promotor, Dr. van 
Iwaarden. Luc, dank voor je inspirerende en positief kritische begeleiding, waarin je vaak 
snel tijd kon maken ondanks de drukte. Dank voor de leuke tijd tijdens en het mogelijk 
maken van congresbezoeken, en dank ook voor je steun in het opzetten van vervolgon-
derzoek. Freek, dank voor de inwijding in de basistechnieken van het lab en je begeleiding 
van het onderzoek in het lab. Veel heb ik ook gehad aan je kritische houding tijdens de 
wordingsfase van verschillende artikelen. 
 
Ouders van kinderen die deel uitmaakten van de studies, bedankt voor het in ons/mij 
gestelde vertrouwen door toestemming voor deelname te geven. Verpleegkundigen van 
de NICU, dank voor de praktische ondersteuning van het onderzoek en de leuke sfeer. 
 
Nico, bedankt voor je onmisbare bijdrage in de opzet en uitvoer van al het labwerk. Boris 
voor je enthousiasme en dat je me betrok bij verschillende andere projecten. Laten we 
vooral samen dingen blijven doen! Bea, Lilian en Eduardo, dank voor jullie aandeel en 
initiatief ten aanzien van de kippen en het mitochondrieel DNA. Coen, je wordt bedankt 
voor je ondersteuning in de aanvullende celkweekproeven, succes met je eigen afronding! 
Pieter, het blijft leuk met je van gedachten te wisselen over methodologische aspecten 
van onderzoek, zeker wanneer hier zo nu en dan weer iets over op te schrijven valt. Tama-
ra, ontzettend bedankt voor alle secretariële ondersteuning die onmisbaar was tijdens het 
promotietraject. 
 
Dr. Anne Debeer, dank voor de succesvolle samenwerking in het onderzoek met de bron-
cho-alveolaire lavages, je bijdrage was onmisbaar. Dank ook aan Prof. Gunnar Naulaers 
voor de betrokkenheid hierin. Voor de samenwerking in het chorioamnionitis onderzoek 
van het Erasmus MC veel dank aan Ingrid Rours, René Kornelisse, Femke Jonkers, en Ro-
nald de Krijger. 
 
Verschillende mensen wil ik bedanken voor de praktische ondersteuning toen ons lab nog 
in wording was: Mo, Joep, Jacco en Tim (nu ‘one of us’) van de algemene heelkunde, Harry 
en Ramon van de pulmonologie, de mensen van de anatomie voor het gebruik van de 
stereomicroscoop, Eduard en Menno en vooral ook Cees en Leon van de biochemie, 
enthousiaste begeleiders van mijn eerste onderzoekservaringen. Dank ook aan Kitty 
Linssen en anderen van de microbiologie voor de gastvrijheid en begeleiding bij de cyto-
spins en natuurlijk voor alle differentiaties. Valéria voor de kritische en zeer zinvolle sta-
tistische begeleiding, Wilco voor de cytokine en chemokine metingen. 
 
Mijn kamergenoten tijdens het onderzoek: Charlotte, Bianca en later ook Rob en Cécile. 
Lief, leed, sportiviteit en een enkele frustratie hebben we gedeeld, waarvoor dank. Rob, 
you’re next! 
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De mensen in Veldhoven, dank voor belangrijke begeleiding in de vroege fase van mijn 
kindergeneeskundige loopbaan. Martin de Kleine voor de stimulering van betrokkenheid 
in onderzoek. Peter Andriessen, veel heb ik geleerd van je intensieve begeiding van het 
schrijven van mijn eerste artikel, al werd het nooit gepubliceerd. Vinus Bok, leuk dat we 
zoveel samen hebben gedaan in het uiteindelijk boven verwachting succesvolle onderzoek 
naar de pyridoxine-afhankelijke epilepsie. Succes met de afronding van je eigen promotie 
hierin! 
 
Graag wil ik ook de leden van de beoordelingscommissie, Professoren Nijhuis, van 
Schayck, Buurman, Bambang Oetomo en Walther bedanken voor hun tijd en moeite. 
Onno, dank ook voor je belangrijke begeleiding in het opstarten van een vervolgtraject.  
 
Mijn paranimfen, Bjorn en Jeroen: dank dat jullie me terzijde willen/durven staan. Watch 
out for that statistical question ! 
 
Dr. Tim, kort na jouw dankwoord mag ik ook het mijne aan jou richten. Onze wederzijdse, 
deels onderzoeksgerelateerde weerspiegelingen zijn onmisbaar voor de relativering van 
wat we aan het doen zijn, waarvoor veel dank. 
 
Papa en mama: ik weet dat mijn dank en waardering voor wie jullie zijn niet alleen hoeft 
te blijken uit wat ik hier schrijf. Toch wil ik jullie hierbij enorm bedanken voor jullie liefde 
en betrokkenheid en jullie stimulering en onvoorwaardelijke steun tijdens mijn school, 
studie en huidige leven. Zonder jullie had dit nooit gekund! Ook mijn zusjes bedankt voor 
jullie betrokkenheid, en Maaike speciaal voor alle posters en de omslag voor het boekje. 
Oma Cis en ook opa, die dit jammergenoeg net niet meer mee mocht maken, voor het 
altijd meeleven en op de voet volgen van alle vorderingen. 
 
Dorcas, mijn lieve, mooie vrouw: dank voor de tijd en mogelijkheden die je me hebt 
gegeven om dit mogelijk te maken, je bent fantastisch! Lieve Éowyn en Lore, jullie geven 
het leven zoveel meer zin en vrolijkheid en helpen het belang van andere zaken te relati-
veren. Love you lots! 
 
God, ik prijs u voor uw onnavolgbare en ondoorgrondelijke schepping. 
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Faith is being sure 
of what we hope for 
and being certain 
of what we do not see 
 
Hebrews 11:1 
  
 
 
